<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:cc="http://web.resource.org/cc/"
 xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:admin="http://webns.net/mvcb/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel rdf:about="https://www.mdpi.com/rss/journal/dermatopathology">
		<title>Dermatopathology</title>
		<description>Latest open access articles published in Dermatopathology at https://www.mdpi.com/journal/dermatopathology</description>
		<link>https://www.mdpi.com/journal/dermatopathology</link>
		<admin:generatorAgent rdf:resource="https://www.mdpi.com/journal/dermatopathology"/>
		<admin:errorReportsTo rdf:resource="mailto:support@mdpi.com"/>
		<dc:publisher>MDPI</dc:publisher>
		<dc:language>en</dc:language>
		<dc:rights>Creative Commons Attribution (CC-BY)</dc:rights>
						<prism:copyright>MDPI</prism:copyright>
		<prism:rightsAgent>support@mdpi.com</prism:rightsAgent>
		<image rdf:resource="https://pub.mdpi-res.com/img/design/mdpi-pub-logo.png?13cf3b5bd783e021?1776344295"/>
				<items>
			<rdf:Seq>
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/2/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/2/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/2/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/13/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/43" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/42" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/41" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/40" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/39" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/38" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/37" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/36" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/34" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/35" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/4/33" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/32" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/31" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/30" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/29" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/28" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/27" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/26" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/25" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/24" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/23" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/22" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/21" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/20" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/3/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/12/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/41" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/40" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/39" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/38" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/37" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/36" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/35" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/34" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/33" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/32" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/31" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/30" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/29" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/28" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/4/27" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/26" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/25" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/24" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/23" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/22" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/21" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/20" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/3/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/2/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/2/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/2/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/2/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2296-3529/11/1/2" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="https://creativecommons.org/licenses/by/4.0/" />
	</channel>

        <item rdf:about="https://www.mdpi.com/2296-3529/13/2/17">

	<title>Dermatopathology, Vol. 13, Pages 17: Desmosomal-Type Acantholysis&amp;mdash;A New Histologic Pattern Related to Mutations of Genes for Desmosomal Proteins</title>
	<link>https://www.mdpi.com/2296-3529/13/2/17</link>
	<description>Desmosomes are specialized cell&amp;amp;ndash;cell junctions that play a crucial role in maintaining the structural integrity of both cornifying and non-cornifying epithelium. Disruption of desmosomal cohesion in autoimmune, infectious, and other diseases is typically associated with acantholysis, often leading to intraepidermal blisters and erosions. In recent decades, genetic mutations have been identified that impair desmosomal integrity to varying degrees, giving rise to a spectrum of genodermatoses. These conditions, which include palmoplantar keratoderma, epidermolysis bullosa, and ichthyoses, can range from mild to severe, with some forms being syndromic and life-threatening. We investigated dermatopathologic changes in patients with mutations in genes encoding desmosomal proteins seen in consultations at our genodermatoses unit. A series of cases, including keratosis palmoplantaris areata et striata (striated palmoplantar keratoderma type 1), Carvajal&amp;amp;ndash;Huerta syndrome, severe dermatitis&amp;amp;ndash;multiple allergies&amp;amp;ndash;metabolic wasting (SAM) syndrome, ectodermal dysplasia&amp;amp;ndash;skin fragility syndrome, and inflammatory peeling skin disease, was examined histologically and, when necessary, immunohistochemically. Findings from our cohort were compared with histopathological consultation cases from our dermatopathology laboratory and previously published cases in the literature. Through these observations, we defined a distinct form of acantholysis associated with desmosomal protein mutations, which we term &amp;amp;ldquo;desmosomal-type acantholysis.&amp;amp;rdquo; We outline the spectrum of this newly characterized pattern and highlight its differences from conventional forms of acantholysis. Furthermore, for the first time, we describe incidental cases where &amp;amp;ldquo;desmosomal-type acantholysis&amp;amp;rdquo; appears sporadically in solitary acanthoma and in association with a melanocytic nevus.</description>
	<pubDate>2026-04-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 17: Desmosomal-Type Acantholysis&amp;mdash;A New Histologic Pattern Related to Mutations of Genes for Desmosomal Proteins</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/2/17">doi: 10.3390/dermatopathology13020017</a></p>
	<p>Authors:
		Dieter Metze
		Kira Süßmuth
		Clemens Metze
		Vinzenz Oji
		Heiko Traupe
		</p>
	<p>Desmosomes are specialized cell&amp;amp;ndash;cell junctions that play a crucial role in maintaining the structural integrity of both cornifying and non-cornifying epithelium. Disruption of desmosomal cohesion in autoimmune, infectious, and other diseases is typically associated with acantholysis, often leading to intraepidermal blisters and erosions. In recent decades, genetic mutations have been identified that impair desmosomal integrity to varying degrees, giving rise to a spectrum of genodermatoses. These conditions, which include palmoplantar keratoderma, epidermolysis bullosa, and ichthyoses, can range from mild to severe, with some forms being syndromic and life-threatening. We investigated dermatopathologic changes in patients with mutations in genes encoding desmosomal proteins seen in consultations at our genodermatoses unit. A series of cases, including keratosis palmoplantaris areata et striata (striated palmoplantar keratoderma type 1), Carvajal&amp;amp;ndash;Huerta syndrome, severe dermatitis&amp;amp;ndash;multiple allergies&amp;amp;ndash;metabolic wasting (SAM) syndrome, ectodermal dysplasia&amp;amp;ndash;skin fragility syndrome, and inflammatory peeling skin disease, was examined histologically and, when necessary, immunohistochemically. Findings from our cohort were compared with histopathological consultation cases from our dermatopathology laboratory and previously published cases in the literature. Through these observations, we defined a distinct form of acantholysis associated with desmosomal protein mutations, which we term &amp;amp;ldquo;desmosomal-type acantholysis.&amp;amp;rdquo; We outline the spectrum of this newly characterized pattern and highlight its differences from conventional forms of acantholysis. Furthermore, for the first time, we describe incidental cases where &amp;amp;ldquo;desmosomal-type acantholysis&amp;amp;rdquo; appears sporadically in solitary acanthoma and in association with a melanocytic nevus.</p>
	]]></content:encoded>

	<dc:title>Desmosomal-Type Acantholysis&amp;amp;mdash;A New Histologic Pattern Related to Mutations of Genes for Desmosomal Proteins</dc:title>
			<dc:creator>Dieter Metze</dc:creator>
			<dc:creator>Kira Süßmuth</dc:creator>
			<dc:creator>Clemens Metze</dc:creator>
			<dc:creator>Vinzenz Oji</dc:creator>
			<dc:creator>Heiko Traupe</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13020017</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-04-03</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-04-03</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>17</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13020017</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/2/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/2/16">

	<title>Dermatopathology, Vol. 13, Pages 16: Bilateral Auricular Blastomycosis-like Pyoderma: A Rare Presentation Histologically Misinterpreted as Squamous Cell Carcinoma</title>
	<link>https://www.mdpi.com/2296-3529/13/2/16</link>
	<description>Blastomycosis-like pyoderma (BLP) is a rare chronic inflammatory dermatosis characterized by exuberant vegetative and verrucous plaques, most frequently associated with bacterial colonization, particularly Staphylococcus aureus. Owing to its striking clinical and histopathological resemblance to squamous cell carcinoma (SCC) and other granulomatous or hyperplastic dermatoses, BLP represents a well-recognized diagnostic pitfall, often leading to delayed diagnosis or unnecessary surgical management. We report an unusual case of bilateral auricular BLP in a 58-year-old apparently immunocompetent woman, initially misdiagnosed as SCC. Comprehensive clinicopathological reassessment revealed pseudoepitheliomatous hyperplasia, intraepidermal neutrophilic microabscesses, and a dense mixed inflammatory infiltrate, findings consistent with a reactive rather than neoplastic process. Microbiological cultures confirmed Staphylococcus aureus, supporting the final diagnosis of BLP and guiding effective antimicrobial therapy. To better contextualize this rare presentation, we reviewed all previously reported cases of BLP, summarizing available clinical, histopathological, microbiological, and therapeutic data. This case further raises the possibility of an association between BLP and systemic inflammatory conditions, as the patient subsequently developed severe colitis, highlighting the potential role of immune dysregulation and the gut&amp;amp;ndash;skin axis in disease pathogenesis or a possible temporal association, without allowing causal inference. Beyond inflammatory bowel disease, blastomycosis-like pyoderma has been reported in association with a variety of systemic and immune-mediated conditions, including diabetes mellitus, hematologic malignancies, HIV infection, chronic renal failure, autoimmune disorders, and prolonged immunosuppressive therapies. These associations support the concept that BLP represents a hyperinflammatory reaction pattern occurring in the setting of altered immune surveillance rather than a purely infectious disease. Accurate recognition and management of BLP require careful integration of clinical features, histological findings, and microbiological results. Increased awareness of its diverse presentations is essential to avoid misdiagnosis and to ensure appropriate, conservative treatment.</description>
	<pubDate>2026-04-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 16: Bilateral Auricular Blastomycosis-like Pyoderma: A Rare Presentation Histologically Misinterpreted as Squamous Cell Carcinoma</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/2/16">doi: 10.3390/dermatopathology13020016</a></p>
	<p>Authors:
		Nazario Pesce
		Giorgia Di Marco
		Giorgio Stabile
		Antonio Podo Brunetti
		Alessandro Russo
		Stefania Guida
		Rongioletti Franco
		</p>
	<p>Blastomycosis-like pyoderma (BLP) is a rare chronic inflammatory dermatosis characterized by exuberant vegetative and verrucous plaques, most frequently associated with bacterial colonization, particularly Staphylococcus aureus. Owing to its striking clinical and histopathological resemblance to squamous cell carcinoma (SCC) and other granulomatous or hyperplastic dermatoses, BLP represents a well-recognized diagnostic pitfall, often leading to delayed diagnosis or unnecessary surgical management. We report an unusual case of bilateral auricular BLP in a 58-year-old apparently immunocompetent woman, initially misdiagnosed as SCC. Comprehensive clinicopathological reassessment revealed pseudoepitheliomatous hyperplasia, intraepidermal neutrophilic microabscesses, and a dense mixed inflammatory infiltrate, findings consistent with a reactive rather than neoplastic process. Microbiological cultures confirmed Staphylococcus aureus, supporting the final diagnosis of BLP and guiding effective antimicrobial therapy. To better contextualize this rare presentation, we reviewed all previously reported cases of BLP, summarizing available clinical, histopathological, microbiological, and therapeutic data. This case further raises the possibility of an association between BLP and systemic inflammatory conditions, as the patient subsequently developed severe colitis, highlighting the potential role of immune dysregulation and the gut&amp;amp;ndash;skin axis in disease pathogenesis or a possible temporal association, without allowing causal inference. Beyond inflammatory bowel disease, blastomycosis-like pyoderma has been reported in association with a variety of systemic and immune-mediated conditions, including diabetes mellitus, hematologic malignancies, HIV infection, chronic renal failure, autoimmune disorders, and prolonged immunosuppressive therapies. These associations support the concept that BLP represents a hyperinflammatory reaction pattern occurring in the setting of altered immune surveillance rather than a purely infectious disease. Accurate recognition and management of BLP require careful integration of clinical features, histological findings, and microbiological results. Increased awareness of its diverse presentations is essential to avoid misdiagnosis and to ensure appropriate, conservative treatment.</p>
	]]></content:encoded>

	<dc:title>Bilateral Auricular Blastomycosis-like Pyoderma: A Rare Presentation Histologically Misinterpreted as Squamous Cell Carcinoma</dc:title>
			<dc:creator>Nazario Pesce</dc:creator>
			<dc:creator>Giorgia Di Marco</dc:creator>
			<dc:creator>Giorgio Stabile</dc:creator>
			<dc:creator>Antonio Podo Brunetti</dc:creator>
			<dc:creator>Alessandro Russo</dc:creator>
			<dc:creator>Stefania Guida</dc:creator>
			<dc:creator>Rongioletti Franco</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13020016</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-04-01</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-04-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>16</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13020016</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/2/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/2/15">

	<title>Dermatopathology, Vol. 13, Pages 15: Comprehensive Genomic Profiling of Cutaneous Adnexal Carcinomas: A Genomic Landscape Study</title>
	<link>https://www.mdpi.com/2296-3529/13/2/15</link>
	<description>Cutaneous adnexal carcinomas (CACs) comprise a diverse group of malignant tumors that show morphological differentiation toward one of the four main adnexal structures in normal skin: hair follicles, sebaceous glands, sweat-apocrine glands, and sweat-eccrine glands. These tumors can arise sporadically or may be associated with rare genetic syndromes. A total of 276 CACs cases underwent hybrid capture-based comprehensive genomic profiling (CGP) to assess all classes of genomic alterations (GA). Sequencing data were used to determine microsatellite instability (MSI) status, tumor mutational burden (TMB), genomic loss of heterozygosity (gLOH), genomic ancestry, and COSMIC mutational signatures. PD-L1 expression was evaluated by immunohistochemistry (TPS; Dako 22C3). Statistical analyses were performed using Fisher&amp;amp;rsquo;s exact test, with false discovery rate correction via the Benjamini&amp;amp;ndash;Hochberg method. Sequencing was performed on primary cutaneous tumors in 131 cases (47.4%) and on local recurrence or metastatic site biopsies in 145 cases (52.5%). Across all groups, there was a male predominance (64&amp;amp;ndash;81%) and similar mean ages (59&amp;amp;ndash;63 years), with apocrine (APO) tumors occurring in older patients than eccrine (ECC) tumors (72 vs. 62 years; p = 0.001). Histologically, 173 tumors (62.7%) were sweat gland-derived (SWT), 55 (19.9%) sebaceous gland-derived (SEB), 14 (5.1%) hair follicle-derived (HRF), and 34 (12.3%) unclassified (UNK). Among SWT tumors, 150 (86.7%) were eccrine and 23 (13.3%) apocrine. SWT tumors included digital papillary adenocarcinomas (DPA, 6.9%), mucinous carcinomas (MC, 6.3%), porocarcinomas (POR, 11.0%), spiradenocarcinomas (SPR, 8.1%), syringoadenocarcinomas (SRNG, 5.8%), and 77 (44.5%) unclassified cases. The number of GA per tumor was highest in SEB compared with SWT tumors (7.9 vs. 4.9; p = 0.005) and lowest in DPA (2.1 vs. 5.0 in non-DPA; p = 0.03). No differences in ancestry distribution were observed. Compared with SWT tumors, SEB tumors exhibited higher frequencies of RB1 (38.2% vs. 8.1%; p &amp;amp;lt; 0.0001) and TP53 alterations (76.4% vs. 43.4%; p = 0.0002), suggesting potential neuroendocrine differentiation. MC tumors showed significantly higher PTCH1 alterations than non-MC tumors (36.4% vs. 1.8%; p = 0.044). MSI-high status was most frequent in SEB tumors compared with all other groups (15.7% vs. 1.2%; p = 0.005), and gLOH &amp;amp;gt; 16% was also more common in SEB than SWT tumors (19.6% vs. 7.2%; p = 0.081). The MMR signature occurred more frequently in SEB than SWT tumors (32.0% vs. 2.1%; p = 0.005). Mean TMB was elevated across most CACs types, ranging from 10.4 mutations/Mb in HRF to 38.8 mutations/Mb in MC, with the exceptions of APO (2.7 mut/Mb; p = 0.001) and DPA (1.4 mut/Mb; p = 0.003). PD-L1 expression was generally low and did not differ significantly between SWT and SEB tumors (37.0% vs. 33.3%; NS). Given the limited data on CAC treatment, this study provides a catalog of commonly observed GA. SEB tumors exhibited the highest frequency of genomic alterations. Prospective clinical trials are needed to determine the prognostic and predictive value of CAC-specific biomarkers for immune checkpoint inhibitor (ICI) response, which is essential for integrating novel therapies into the evolving treatment landscape.</description>
	<pubDate>2026-03-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 15: Comprehensive Genomic Profiling of Cutaneous Adnexal Carcinomas: A Genomic Landscape Study</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/2/15">doi: 10.3390/dermatopathology13020015</a></p>
	<p>Authors:
		Maroun Bou Zerdan
		Kevin T. Jamouss
		Alexandre Maalouf
		Rita Moukarzel
		Tanishq Chhabra
		Daniel J. Zaccarini
		Dean Pavlick
		Natalie Danziger
		Jeffrey Ross
		</p>
	<p>Cutaneous adnexal carcinomas (CACs) comprise a diverse group of malignant tumors that show morphological differentiation toward one of the four main adnexal structures in normal skin: hair follicles, sebaceous glands, sweat-apocrine glands, and sweat-eccrine glands. These tumors can arise sporadically or may be associated with rare genetic syndromes. A total of 276 CACs cases underwent hybrid capture-based comprehensive genomic profiling (CGP) to assess all classes of genomic alterations (GA). Sequencing data were used to determine microsatellite instability (MSI) status, tumor mutational burden (TMB), genomic loss of heterozygosity (gLOH), genomic ancestry, and COSMIC mutational signatures. PD-L1 expression was evaluated by immunohistochemistry (TPS; Dako 22C3). Statistical analyses were performed using Fisher&amp;amp;rsquo;s exact test, with false discovery rate correction via the Benjamini&amp;amp;ndash;Hochberg method. Sequencing was performed on primary cutaneous tumors in 131 cases (47.4%) and on local recurrence or metastatic site biopsies in 145 cases (52.5%). Across all groups, there was a male predominance (64&amp;amp;ndash;81%) and similar mean ages (59&amp;amp;ndash;63 years), with apocrine (APO) tumors occurring in older patients than eccrine (ECC) tumors (72 vs. 62 years; p = 0.001). Histologically, 173 tumors (62.7%) were sweat gland-derived (SWT), 55 (19.9%) sebaceous gland-derived (SEB), 14 (5.1%) hair follicle-derived (HRF), and 34 (12.3%) unclassified (UNK). Among SWT tumors, 150 (86.7%) were eccrine and 23 (13.3%) apocrine. SWT tumors included digital papillary adenocarcinomas (DPA, 6.9%), mucinous carcinomas (MC, 6.3%), porocarcinomas (POR, 11.0%), spiradenocarcinomas (SPR, 8.1%), syringoadenocarcinomas (SRNG, 5.8%), and 77 (44.5%) unclassified cases. The number of GA per tumor was highest in SEB compared with SWT tumors (7.9 vs. 4.9; p = 0.005) and lowest in DPA (2.1 vs. 5.0 in non-DPA; p = 0.03). No differences in ancestry distribution were observed. Compared with SWT tumors, SEB tumors exhibited higher frequencies of RB1 (38.2% vs. 8.1%; p &amp;amp;lt; 0.0001) and TP53 alterations (76.4% vs. 43.4%; p = 0.0002), suggesting potential neuroendocrine differentiation. MC tumors showed significantly higher PTCH1 alterations than non-MC tumors (36.4% vs. 1.8%; p = 0.044). MSI-high status was most frequent in SEB tumors compared with all other groups (15.7% vs. 1.2%; p = 0.005), and gLOH &amp;amp;gt; 16% was also more common in SEB than SWT tumors (19.6% vs. 7.2%; p = 0.081). The MMR signature occurred more frequently in SEB than SWT tumors (32.0% vs. 2.1%; p = 0.005). Mean TMB was elevated across most CACs types, ranging from 10.4 mutations/Mb in HRF to 38.8 mutations/Mb in MC, with the exceptions of APO (2.7 mut/Mb; p = 0.001) and DPA (1.4 mut/Mb; p = 0.003). PD-L1 expression was generally low and did not differ significantly between SWT and SEB tumors (37.0% vs. 33.3%; NS). Given the limited data on CAC treatment, this study provides a catalog of commonly observed GA. SEB tumors exhibited the highest frequency of genomic alterations. Prospective clinical trials are needed to determine the prognostic and predictive value of CAC-specific biomarkers for immune checkpoint inhibitor (ICI) response, which is essential for integrating novel therapies into the evolving treatment landscape.</p>
	]]></content:encoded>

	<dc:title>Comprehensive Genomic Profiling of Cutaneous Adnexal Carcinomas: A Genomic Landscape Study</dc:title>
			<dc:creator>Maroun Bou Zerdan</dc:creator>
			<dc:creator>Kevin T. Jamouss</dc:creator>
			<dc:creator>Alexandre Maalouf</dc:creator>
			<dc:creator>Rita Moukarzel</dc:creator>
			<dc:creator>Tanishq Chhabra</dc:creator>
			<dc:creator>Daniel J. Zaccarini</dc:creator>
			<dc:creator>Dean Pavlick</dc:creator>
			<dc:creator>Natalie Danziger</dc:creator>
			<dc:creator>Jeffrey Ross</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13020015</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-03-30</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-03-30</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>15</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13020015</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/2/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/13">

	<title>Dermatopathology, Vol. 13, Pages 13: Longitudinal Melanonychia in Children: Clinical and Histopathologic Features and Management with Literature Update</title>
	<link>https://www.mdpi.com/2296-3529/13/1/13</link>
	<description>Longitudinal melanonychia (LM) results from the deposition of pigment in the nail plate due to increased melanocytic activity within the nail matrix. Recent publications on this topic have helped clarify the main clinical, histological, and evolutionary characteristics of pediatric LM and provide guidance for its appropriate management. In this review, we will examine the literature on the subject. LM is far less common in children than in adults and is most often caused by benign nail matrix lesions. Pediatric LM has specific clinical and histopathologic features, and many of the clinical warning signs used in adults are not applicable to children. Pediatric lesions may show atypical cytologic and even architectural features yet still follow a benign clinical course. Spontaneous regression of LM is common in children, with fading and narrowing of the pigmented band, or even complete disappearance. The vast majority of pediatric LM cases can be managed conservatively with regular follow-up, including clinical photography and onychoscopy.</description>
	<pubDate>2026-03-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 13: Longitudinal Melanonychia in Children: Clinical and Histopathologic Features and Management with Literature Update</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/13">doi: 10.3390/dermatopathology13010013</a></p>
	<p>Authors:
		Isabelle Moulonguet
		Marie Caucanas
		Sophie Goettmann
		</p>
	<p>Longitudinal melanonychia (LM) results from the deposition of pigment in the nail plate due to increased melanocytic activity within the nail matrix. Recent publications on this topic have helped clarify the main clinical, histological, and evolutionary characteristics of pediatric LM and provide guidance for its appropriate management. In this review, we will examine the literature on the subject. LM is far less common in children than in adults and is most often caused by benign nail matrix lesions. Pediatric LM has specific clinical and histopathologic features, and many of the clinical warning signs used in adults are not applicable to children. Pediatric lesions may show atypical cytologic and even architectural features yet still follow a benign clinical course. Spontaneous regression of LM is common in children, with fading and narrowing of the pigmented band, or even complete disappearance. The vast majority of pediatric LM cases can be managed conservatively with regular follow-up, including clinical photography and onychoscopy.</p>
	]]></content:encoded>

	<dc:title>Longitudinal Melanonychia in Children: Clinical and Histopathologic Features and Management with Literature Update</dc:title>
			<dc:creator>Isabelle Moulonguet</dc:creator>
			<dc:creator>Marie Caucanas</dc:creator>
			<dc:creator>Sophie Goettmann</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010013</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-03-23</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-03-23</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010013</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/14">

	<title>Dermatopathology, Vol. 13, Pages 14: PRAME Expression in Melanoacanthomas: Expanding the Spectrum of Positive Melanocytes in Sun-Exposed Skin</title>
	<link>https://www.mdpi.com/2296-3529/13/1/14</link>
	<description>PRAME (Preferentially Expressed Antigen in Melanoma) is increasingly used as an immunohistochemical marker in the evaluation of melanocytic lesions; however, its expression in benign melanocytic proliferations remains incompletely characterized. This study investigated PRAME expression in melanoacanthomas, with particular emphasis on its relationship with ultraviolet exposure and chronic solar damage. A consecutive series of melanoacanthomas was retrospectively analyzed. Melanocytes were identified and quantified using SOX10 immunohistochemistry, while PRAME-positive melanocytes were counted and graded semiquantitatively according to nuclear staining intensity. PRAME expression was correlated with lesion site (photoexposed versus non-photoexposed skin) and with the degree of solar elastosis. Eighty-four cases were evaluated, of which 25 (29.8%) showed at least focal PRAME positivity in melanocytes. Overall melanocytic density assessed by SOX10 did not differ significantly between photoexposed and non-photoexposed lesions. Similarly, stratification based on total PRAME-positive melanocyte counts, irrespective of staining intensity, revealed no significant association with photoexposure. In contrast, analysis restricted to melanocytes with strong nuclear PRAME expression demonstrated a significant enrichment in photoexposed lesions compared with non-photoexposed sites (p &amp;amp;lt; 0.01). Moreover, high-intensity PRAME expression showed a positive association with increasing grades of solar elastosis. These findings indicate that strong PRAME expression in melanoacanthoma could be associated with chronic sun damage and may reflect non-specific, ultraviolet-related modulation rather than malignant transformation, underscoring the importance of contextual interpretation of PRAME immunohistochemistry in diagnostic practice.</description>
	<pubDate>2026-03-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 14: PRAME Expression in Melanoacanthomas: Expanding the Spectrum of Positive Melanocytes in Sun-Exposed Skin</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/14">doi: 10.3390/dermatopathology13010014</a></p>
	<p>Authors:
		Francesco Fortarezza
		Anna Poputchikova
		Federica Pezzuto
		Christian Ciolfi
		Vincenza Guzzardo
		Paolo Del Fiore
		Gerardo Cazzato
		Franco Bassetto
		Mauro Alaibac
		Angelo Paolo Dei Tos
		</p>
	<p>PRAME (Preferentially Expressed Antigen in Melanoma) is increasingly used as an immunohistochemical marker in the evaluation of melanocytic lesions; however, its expression in benign melanocytic proliferations remains incompletely characterized. This study investigated PRAME expression in melanoacanthomas, with particular emphasis on its relationship with ultraviolet exposure and chronic solar damage. A consecutive series of melanoacanthomas was retrospectively analyzed. Melanocytes were identified and quantified using SOX10 immunohistochemistry, while PRAME-positive melanocytes were counted and graded semiquantitatively according to nuclear staining intensity. PRAME expression was correlated with lesion site (photoexposed versus non-photoexposed skin) and with the degree of solar elastosis. Eighty-four cases were evaluated, of which 25 (29.8%) showed at least focal PRAME positivity in melanocytes. Overall melanocytic density assessed by SOX10 did not differ significantly between photoexposed and non-photoexposed lesions. Similarly, stratification based on total PRAME-positive melanocyte counts, irrespective of staining intensity, revealed no significant association with photoexposure. In contrast, analysis restricted to melanocytes with strong nuclear PRAME expression demonstrated a significant enrichment in photoexposed lesions compared with non-photoexposed sites (p &amp;amp;lt; 0.01). Moreover, high-intensity PRAME expression showed a positive association with increasing grades of solar elastosis. These findings indicate that strong PRAME expression in melanoacanthoma could be associated with chronic sun damage and may reflect non-specific, ultraviolet-related modulation rather than malignant transformation, underscoring the importance of contextual interpretation of PRAME immunohistochemistry in diagnostic practice.</p>
	]]></content:encoded>

	<dc:title>PRAME Expression in Melanoacanthomas: Expanding the Spectrum of Positive Melanocytes in Sun-Exposed Skin</dc:title>
			<dc:creator>Francesco Fortarezza</dc:creator>
			<dc:creator>Anna Poputchikova</dc:creator>
			<dc:creator>Federica Pezzuto</dc:creator>
			<dc:creator>Christian Ciolfi</dc:creator>
			<dc:creator>Vincenza Guzzardo</dc:creator>
			<dc:creator>Paolo Del Fiore</dc:creator>
			<dc:creator>Gerardo Cazzato</dc:creator>
			<dc:creator>Franco Bassetto</dc:creator>
			<dc:creator>Mauro Alaibac</dc:creator>
			<dc:creator>Angelo Paolo Dei Tos</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010014</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-03-23</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-03-23</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>14</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010014</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/12">

	<title>Dermatopathology, Vol. 13, Pages 12: Genital Disorders in Children: What Does a Biopsy Bring?</title>
	<link>https://www.mdpi.com/2296-3529/13/1/12</link>
	<description>Biopsies are only performed in less than 1% of all consultations dedicated to paediatric genital dermatology. The objectives of this paper are to review and clarify the histopathological features of the conditions most often biopsied: first, lichen sclerosus, which has a peak incidence in childhood and progresses over years; secondly, pigmented lesions, including atypical genital naevi and common naevi in the context of lichen sclerosus, both histologically differential diagnoses of melanoma, which probably does not present in childhood. And finally, Crohn&amp;amp;rsquo;s disease, which is a cause of vulval oedema or genital ulceration.</description>
	<pubDate>2026-03-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 12: Genital Disorders in Children: What Does a Biopsy Bring?</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/12">doi: 10.3390/dermatopathology13010012</a></p>
	<p>Authors:
		Francoise Plantier
		Fiona Lewis
		</p>
	<p>Biopsies are only performed in less than 1% of all consultations dedicated to paediatric genital dermatology. The objectives of this paper are to review and clarify the histopathological features of the conditions most often biopsied: first, lichen sclerosus, which has a peak incidence in childhood and progresses over years; secondly, pigmented lesions, including atypical genital naevi and common naevi in the context of lichen sclerosus, both histologically differential diagnoses of melanoma, which probably does not present in childhood. And finally, Crohn&amp;amp;rsquo;s disease, which is a cause of vulval oedema or genital ulceration.</p>
	]]></content:encoded>

	<dc:title>Genital Disorders in Children: What Does a Biopsy Bring?</dc:title>
			<dc:creator>Francoise Plantier</dc:creator>
			<dc:creator>Fiona Lewis</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010012</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-03-23</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-03-23</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>12</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010012</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/11">

	<title>Dermatopathology, Vol. 13, Pages 11: Cutaneous Granular Cell Tumor with Overlying Hypertrichosis in an Adult: A Rare Case Report</title>
	<link>https://www.mdpi.com/2296-3529/13/1/11</link>
	<description>Granular cell tumors are uncommon neoplasms of neural origin that may involve the skin and often present with nonspecific clinical features, making diagnosis challenging. Cutaneous granular cell tumors rarely exhibit overlying hypertrichosis, a finding that may obscure their clinical recognition. In this report, we describe a rare case of a primary cutaneous granular cell tumor with prominent overlying terminal hair growth in an adult patient. A 27-year-old woman presented with a slowly enlarging, firm, pigmented plaque on the upper back associated with pruritus and increased hair growth. Histopathologic examination revealed sheets of large polygonal cells with abundant granular eosinophilic cytoplasm, and immunohistochemical staining was positive for S100, SOX10, CD68, and calretinin, confirming the diagnosis. The lesion was completely excised with no evidence of malignancy. To our knowledge, this represents the second reported instance of a cutaneous granular cell tumor associated with hypertrichosis and the first described in an adult. It underscores the importance of clinicopathologic correlation in evaluating unusual cutaneous lesions and expands the spectrum of recognized presentations of cutaneous granular cell tumors.</description>
	<pubDate>2026-03-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 11: Cutaneous Granular Cell Tumor with Overlying Hypertrichosis in an Adult: A Rare Case Report</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/11">doi: 10.3390/dermatopathology13010011</a></p>
	<p>Authors:
		Yara Alhusaini
		Abdulaziz Almufadhi
		Naif Alzahrani
		Nawaf Alqahtani
		Ohoud Aljarbou
		</p>
	<p>Granular cell tumors are uncommon neoplasms of neural origin that may involve the skin and often present with nonspecific clinical features, making diagnosis challenging. Cutaneous granular cell tumors rarely exhibit overlying hypertrichosis, a finding that may obscure their clinical recognition. In this report, we describe a rare case of a primary cutaneous granular cell tumor with prominent overlying terminal hair growth in an adult patient. A 27-year-old woman presented with a slowly enlarging, firm, pigmented plaque on the upper back associated with pruritus and increased hair growth. Histopathologic examination revealed sheets of large polygonal cells with abundant granular eosinophilic cytoplasm, and immunohistochemical staining was positive for S100, SOX10, CD68, and calretinin, confirming the diagnosis. The lesion was completely excised with no evidence of malignancy. To our knowledge, this represents the second reported instance of a cutaneous granular cell tumor associated with hypertrichosis and the first described in an adult. It underscores the importance of clinicopathologic correlation in evaluating unusual cutaneous lesions and expands the spectrum of recognized presentations of cutaneous granular cell tumors.</p>
	]]></content:encoded>

	<dc:title>Cutaneous Granular Cell Tumor with Overlying Hypertrichosis in an Adult: A Rare Case Report</dc:title>
			<dc:creator>Yara Alhusaini</dc:creator>
			<dc:creator>Abdulaziz Almufadhi</dc:creator>
			<dc:creator>Naif Alzahrani</dc:creator>
			<dc:creator>Nawaf Alqahtani</dc:creator>
			<dc:creator>Ohoud Aljarbou</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010011</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-03-20</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-03-20</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010011</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/10">

	<title>Dermatopathology, Vol. 13, Pages 10: A Case of Recurrent Chromoblastomycosis Treated with Multiple Surgical Management Options</title>
	<link>https://www.mdpi.com/2296-3529/13/1/10</link>
	<description>Chromoblastomycosis is a chronic mycosis of the skin and subcutaneous tissue typically caused by traumatic inoculation of dematiaceous fungi of the Herpotrichiellaceae. A 59-year-old male presented with a 12-month history of an asymmetrical, scaly plaque on the left forearm that has been slowly increasing in size. Past medical history included atrial fibrillation on apixaban, hypertension and a cardiac stent. A 4 mm punch biopsy of the left forearm revealed superficial dermal fibrosis with mild pseudoepitheliomatous hyperplasia and granulomatous inflammation with scattered multinucleate histiocytes. There were giant cells with dark brown, somewhat round, yeast-like structures, some with internal septation exhibiting moderate staining for PAS, compatible with Medlar bodies suggestive of chromoblastomycosis. The patient was on rosuvastatin, rendering itraconazole not a possible treatment option, and instead the patient underwent curettage and cautery with two bouts of cryotherapy freeze and thaw cycles. A twelve-month follow-up noted a crusted area on the distal aspect of the scar. A shave biopsy of this area revealed pigmented organisms suggesting a recurrence of chromoblastomycosis. A further excisional biopsy was performed, with no evidence of chromoblastomycosis. This case highlights multiple surgical options for the management of chromoblastomycosis in patients where medical management is contraindicated. It highlights the therapeutic challenge of this disease due to frequent recurrence of lesions and that repeat biopsy may be efficacious in monitoring for recurrence.</description>
	<pubDate>2026-03-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 10: A Case of Recurrent Chromoblastomycosis Treated with Multiple Surgical Management Options</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/10">doi: 10.3390/dermatopathology13010010</a></p>
	<p>Authors:
		Madeleine Kelly
		Crystal Williams
		Robert Miller
		</p>
	<p>Chromoblastomycosis is a chronic mycosis of the skin and subcutaneous tissue typically caused by traumatic inoculation of dematiaceous fungi of the Herpotrichiellaceae. A 59-year-old male presented with a 12-month history of an asymmetrical, scaly plaque on the left forearm that has been slowly increasing in size. Past medical history included atrial fibrillation on apixaban, hypertension and a cardiac stent. A 4 mm punch biopsy of the left forearm revealed superficial dermal fibrosis with mild pseudoepitheliomatous hyperplasia and granulomatous inflammation with scattered multinucleate histiocytes. There were giant cells with dark brown, somewhat round, yeast-like structures, some with internal septation exhibiting moderate staining for PAS, compatible with Medlar bodies suggestive of chromoblastomycosis. The patient was on rosuvastatin, rendering itraconazole not a possible treatment option, and instead the patient underwent curettage and cautery with two bouts of cryotherapy freeze and thaw cycles. A twelve-month follow-up noted a crusted area on the distal aspect of the scar. A shave biopsy of this area revealed pigmented organisms suggesting a recurrence of chromoblastomycosis. A further excisional biopsy was performed, with no evidence of chromoblastomycosis. This case highlights multiple surgical options for the management of chromoblastomycosis in patients where medical management is contraindicated. It highlights the therapeutic challenge of this disease due to frequent recurrence of lesions and that repeat biopsy may be efficacious in monitoring for recurrence.</p>
	]]></content:encoded>

	<dc:title>A Case of Recurrent Chromoblastomycosis Treated with Multiple Surgical Management Options</dc:title>
			<dc:creator>Madeleine Kelly</dc:creator>
			<dc:creator>Crystal Williams</dc:creator>
			<dc:creator>Robert Miller</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010010</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-03-18</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-03-18</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010010</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/9">

	<title>Dermatopathology, Vol. 13, Pages 9: Defining Histological Patterns in Inherited Ichthyoses: Toward a Diagnostic Algorithm Based on 66 Confirmed Cases</title>
	<link>https://www.mdpi.com/2296-3529/13/1/9</link>
	<description>Background: Inherited ichthyoses are a heterogeneous group of disorders of cornification caused by mutations in genes encoding epidermal proteins. Clinically, patients with ichthyosis present with erythema, scaling, and occasionally blistering; some subtypes are syndromic. Accurate and timely diagnosis is essential for appropriate management and genetic counseling. Objectives: Diagnosis of ichthyosis typically relies on a combination of clinical features, histopathological and ultrastructural findings, immunohistochemistry, and molecular genetic testing. Dermatopathology can be particularly valuable in three diagnostic scenarios: (i) when the clinical diagnosis of ichthyosis is evident, but the specific subtype remains unclear; (ii) when differential diagnoses such as inflammatory dermatoses need to be excluded; and (iii) when molecular testing is unavailable or yields variants of uncertain significance. However, definitive classification according to current nomenclature requires molecular confirmation. Methods: Despite being a routine diagnostic tool in dermatology, histopathological criteria for ichthyoses remain ill-defined and diagnostically challenging. In this retrospective study, we systematically assessed histological features in 66 patients with confirmed ichthyosis. Results: Our analysis revealed six distinct histological patterns. Based on these, we propose a pattern-based diagnostic algorithm to support the histological classification of ichthyosis subtypes. Limitations: Although some rare subtypes were underrepresented, this cohort represents the largest and most heterogeneous group of molecularly confirmed ichthyosis cases analyzed histologically to date. Conclusions: Our findings highlight the diagnostic value of skin biopsies in inherited ichthyoses. The delineation of characteristic histological patterns and the development of a diagnostic algorithm may facilitate more accurate subtype identification, particularly in settings where genetic testing is limited or inconclusive.</description>
	<pubDate>2026-02-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 9: Defining Histological Patterns in Inherited Ichthyoses: Toward a Diagnostic Algorithm Based on 66 Confirmed Cases</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/9">doi: 10.3390/dermatopathology13010009</a></p>
	<p>Authors:
		Kira Süßmuth
		Vinzenz Oji
		Jacqueline Bodes
		Isabelle Jochum
		Florian Muhs
		Katalin Komlosi
		Ingrid Hausser
		Matthias Schmuth
		Heiko Traupe
		Judith Fischer
		Dieter Metze
		</p>
	<p>Background: Inherited ichthyoses are a heterogeneous group of disorders of cornification caused by mutations in genes encoding epidermal proteins. Clinically, patients with ichthyosis present with erythema, scaling, and occasionally blistering; some subtypes are syndromic. Accurate and timely diagnosis is essential for appropriate management and genetic counseling. Objectives: Diagnosis of ichthyosis typically relies on a combination of clinical features, histopathological and ultrastructural findings, immunohistochemistry, and molecular genetic testing. Dermatopathology can be particularly valuable in three diagnostic scenarios: (i) when the clinical diagnosis of ichthyosis is evident, but the specific subtype remains unclear; (ii) when differential diagnoses such as inflammatory dermatoses need to be excluded; and (iii) when molecular testing is unavailable or yields variants of uncertain significance. However, definitive classification according to current nomenclature requires molecular confirmation. Methods: Despite being a routine diagnostic tool in dermatology, histopathological criteria for ichthyoses remain ill-defined and diagnostically challenging. In this retrospective study, we systematically assessed histological features in 66 patients with confirmed ichthyosis. Results: Our analysis revealed six distinct histological patterns. Based on these, we propose a pattern-based diagnostic algorithm to support the histological classification of ichthyosis subtypes. Limitations: Although some rare subtypes were underrepresented, this cohort represents the largest and most heterogeneous group of molecularly confirmed ichthyosis cases analyzed histologically to date. Conclusions: Our findings highlight the diagnostic value of skin biopsies in inherited ichthyoses. The delineation of characteristic histological patterns and the development of a diagnostic algorithm may facilitate more accurate subtype identification, particularly in settings where genetic testing is limited or inconclusive.</p>
	]]></content:encoded>

	<dc:title>Defining Histological Patterns in Inherited Ichthyoses: Toward a Diagnostic Algorithm Based on 66 Confirmed Cases</dc:title>
			<dc:creator>Kira Süßmuth</dc:creator>
			<dc:creator>Vinzenz Oji</dc:creator>
			<dc:creator>Jacqueline Bodes</dc:creator>
			<dc:creator>Isabelle Jochum</dc:creator>
			<dc:creator>Florian Muhs</dc:creator>
			<dc:creator>Katalin Komlosi</dc:creator>
			<dc:creator>Ingrid Hausser</dc:creator>
			<dc:creator>Matthias Schmuth</dc:creator>
			<dc:creator>Heiko Traupe</dc:creator>
			<dc:creator>Judith Fischer</dc:creator>
			<dc:creator>Dieter Metze</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010009</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-02-28</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-02-28</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010009</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/8">

	<title>Dermatopathology, Vol. 13, Pages 8: The Unusual Invader in a Patient with Long-Standing Rheumatoid Arthritis: A Case of Leishmania major Colonization of Rheumatoid Nodules</title>
	<link>https://www.mdpi.com/2296-3529/13/1/8</link>
	<description>Rheumatoid nodules are the most common extra-articular manifestation of rheumatoid arthritis. Long-term immunomodulatory therapies, including corticosteroids, used in the management of rheumatoid arthritis are associated with a higher risk of infections. Leishmaniasis is a neglected protozoal infection that may arise in these patients. Cutaneous presentation is the most common and is characterized by a wide spectrum of clinical manifestations and courses, depending on the interplay between species involved and the host&amp;amp;rsquo;s immune response. Here, we report the rare and intriguing case of a patient with long-standing rheumatoid arthritis, chronically treated with systemic prednisone, whose rheumatoid nodules were colonized by Leishmania major. In this context, therapeutic strategies must be tailored to species and patient factors. This report expands the differential diagnosis of rheumatoid nodule, highlighting the importance of considering opportunistic infections in exuberant presentations, particularly in immunosuppressed patients coming from or travelling in endemic regions. Intracellular pathogens may exploit the localized immunological niche represented by the rheumatoid nodule of an immunocompromised host to survive and replicate undisturbed. It also underscores the value of the clinico-pathological correlation and the importance of integrating molecular analyses to identify unexpected microorganisms that can be hidden by concomitant disease, avoiding misdiagnosis, ensuring timely treatment, and improving patients outcomes.</description>
	<pubDate>2026-01-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 8: The Unusual Invader in a Patient with Long-Standing Rheumatoid Arthritis: A Case of Leishmania major Colonization of Rheumatoid Nodules</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/8">doi: 10.3390/dermatopathology13010008</a></p>
	<p>Authors:
		Monia Di Prete
		Viviana Lora
		Arianna Lamberti
		Alessandra Latini
		Carlo Cota
		</p>
	<p>Rheumatoid nodules are the most common extra-articular manifestation of rheumatoid arthritis. Long-term immunomodulatory therapies, including corticosteroids, used in the management of rheumatoid arthritis are associated with a higher risk of infections. Leishmaniasis is a neglected protozoal infection that may arise in these patients. Cutaneous presentation is the most common and is characterized by a wide spectrum of clinical manifestations and courses, depending on the interplay between species involved and the host&amp;amp;rsquo;s immune response. Here, we report the rare and intriguing case of a patient with long-standing rheumatoid arthritis, chronically treated with systemic prednisone, whose rheumatoid nodules were colonized by Leishmania major. In this context, therapeutic strategies must be tailored to species and patient factors. This report expands the differential diagnosis of rheumatoid nodule, highlighting the importance of considering opportunistic infections in exuberant presentations, particularly in immunosuppressed patients coming from or travelling in endemic regions. Intracellular pathogens may exploit the localized immunological niche represented by the rheumatoid nodule of an immunocompromised host to survive and replicate undisturbed. It also underscores the value of the clinico-pathological correlation and the importance of integrating molecular analyses to identify unexpected microorganisms that can be hidden by concomitant disease, avoiding misdiagnosis, ensuring timely treatment, and improving patients outcomes.</p>
	]]></content:encoded>

	<dc:title>The Unusual Invader in a Patient with Long-Standing Rheumatoid Arthritis: A Case of Leishmania major Colonization of Rheumatoid Nodules</dc:title>
			<dc:creator>Monia Di Prete</dc:creator>
			<dc:creator>Viviana Lora</dc:creator>
			<dc:creator>Arianna Lamberti</dc:creator>
			<dc:creator>Alessandra Latini</dc:creator>
			<dc:creator>Carlo Cota</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010008</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-01-27</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-01-27</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010008</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/7">

	<title>Dermatopathology, Vol. 13, Pages 7: Beh&amp;ccedil;et-like Syndromes: A Comprehensive Review</title>
	<link>https://www.mdpi.com/2296-3529/13/1/7</link>
	<description>Background: Beh&amp;amp;ccedil;et-like syndrome (BLS) refers to the presence of Beh&amp;amp;ccedil;et&amp;amp;rsquo;s disease (BD) features occurring in association with distinct clinical&amp;amp;ndash;pathological conditions such as inborn errors of immunity, myeloproliferative disorders, infections, or drug exposure. BLS may differ clinically from BD and is increasingly recognized as a separate entity. Distinguishing BLS from primary BD is essential for appropriate management, and studying BLS may provide insights into BD pathogenesis. Objectives: To summarize clinical features, treatments, and genetic abnormalities reported in BLS, we reviewed all published cases up to January 2024. Methods: A systematic search of PubMed, Scopus, and Embase was performed using the terms &amp;amp;ldquo;Beh&amp;amp;ccedil;et-like syndrome&amp;amp;rdquo;, &amp;amp;ldquo;Beh&amp;amp;ccedil;et-like disease&amp;amp;rdquo;, and &amp;amp;ldquo;Pseudo-Beh&amp;amp;ccedil;et disease&amp;amp;rdquo;. We included English-language reports of patients &amp;amp;gt; 12 years old with a defined underlying etiology and Beh&amp;amp;ccedil;et-like manifestations, defined by &amp;amp;ge;2 ICBD criteria and/or gastrointestinal involvement, mucosal ulcers, thrombosis, or non-recurrent disease. Epidemiological, clinical, laboratory, histological, and treatment data were extracted and analyzed descriptively. Results: Of 679 publications, 53 met inclusion criteria, comprising 100 patients with BLS. The median age was 44 years (IQR 22&amp;amp;ndash;52), with a female predominance (1:2). Fifty-three percent were from non-European countries. A genetic disorder was identified in 70% of cases, while HLA-B51 was present in 10%. Frequent manifestations included skin lesions (68%), fever (56%), intestinal involvement (43%), and joint symptoms (43%). Treatments included glucocorticoids (65%), conventional DMARDs (32%), and biologics (22%), mainly anti-TNF agents. Antiviral/antibiotic therapy was used in 9% and chemotherapy in 15%. Two patients with trisomy-8 MDS underwent allogeneic stem cell transplantation. Conclusions: Diverse conditions&amp;amp;mdash;including monogenic diseases, immune defects, myeloproliferative disorders, infections, and drug-related reactions&amp;amp;mdash;can produce Beh&amp;amp;ccedil;et-like features. Our findings highlight differences in clinical expression and treatment response across BLS etiologies. Recognizing BLS is essential for appropriate management and may contribute to a deeper understanding of BD pathogenesis and future targeted therapies.</description>
	<pubDate>2026-01-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 7: Beh&amp;ccedil;et-like Syndromes: A Comprehensive Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/7">doi: 10.3390/dermatopathology13010007</a></p>
	<p>Authors:
		Gaia Mancuso
		Igor Salvadè
		Adam Ogna
		Brenno Balestra
		Helmut Beltraminelli
		</p>
	<p>Background: Beh&amp;amp;ccedil;et-like syndrome (BLS) refers to the presence of Beh&amp;amp;ccedil;et&amp;amp;rsquo;s disease (BD) features occurring in association with distinct clinical&amp;amp;ndash;pathological conditions such as inborn errors of immunity, myeloproliferative disorders, infections, or drug exposure. BLS may differ clinically from BD and is increasingly recognized as a separate entity. Distinguishing BLS from primary BD is essential for appropriate management, and studying BLS may provide insights into BD pathogenesis. Objectives: To summarize clinical features, treatments, and genetic abnormalities reported in BLS, we reviewed all published cases up to January 2024. Methods: A systematic search of PubMed, Scopus, and Embase was performed using the terms &amp;amp;ldquo;Beh&amp;amp;ccedil;et-like syndrome&amp;amp;rdquo;, &amp;amp;ldquo;Beh&amp;amp;ccedil;et-like disease&amp;amp;rdquo;, and &amp;amp;ldquo;Pseudo-Beh&amp;amp;ccedil;et disease&amp;amp;rdquo;. We included English-language reports of patients &amp;amp;gt; 12 years old with a defined underlying etiology and Beh&amp;amp;ccedil;et-like manifestations, defined by &amp;amp;ge;2 ICBD criteria and/or gastrointestinal involvement, mucosal ulcers, thrombosis, or non-recurrent disease. Epidemiological, clinical, laboratory, histological, and treatment data were extracted and analyzed descriptively. Results: Of 679 publications, 53 met inclusion criteria, comprising 100 patients with BLS. The median age was 44 years (IQR 22&amp;amp;ndash;52), with a female predominance (1:2). Fifty-three percent were from non-European countries. A genetic disorder was identified in 70% of cases, while HLA-B51 was present in 10%. Frequent manifestations included skin lesions (68%), fever (56%), intestinal involvement (43%), and joint symptoms (43%). Treatments included glucocorticoids (65%), conventional DMARDs (32%), and biologics (22%), mainly anti-TNF agents. Antiviral/antibiotic therapy was used in 9% and chemotherapy in 15%. Two patients with trisomy-8 MDS underwent allogeneic stem cell transplantation. Conclusions: Diverse conditions&amp;amp;mdash;including monogenic diseases, immune defects, myeloproliferative disorders, infections, and drug-related reactions&amp;amp;mdash;can produce Beh&amp;amp;ccedil;et-like features. Our findings highlight differences in clinical expression and treatment response across BLS etiologies. Recognizing BLS is essential for appropriate management and may contribute to a deeper understanding of BD pathogenesis and future targeted therapies.</p>
	]]></content:encoded>

	<dc:title>Beh&amp;amp;ccedil;et-like Syndromes: A Comprehensive Review</dc:title>
			<dc:creator>Gaia Mancuso</dc:creator>
			<dc:creator>Igor Salvadè</dc:creator>
			<dc:creator>Adam Ogna</dc:creator>
			<dc:creator>Brenno Balestra</dc:creator>
			<dc:creator>Helmut Beltraminelli</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010007</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-01-16</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-01-16</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010007</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/6">

	<title>Dermatopathology, Vol. 13, Pages 6: Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma&amp;mdash;A Systematic Review</title>
	<link>https://www.mdpi.com/2296-3529/13/1/6</link>
	<description>Cutaneous squamous cell carcinoma (cSCC) is an immunogenic malignancy with variable immune infiltration and inconsistent responses to checkpoint blockade. Tumor-infiltrating lymphocytes (TILs) influence tumor progression and therapeutic outcome, yet their phenotypic and functional diversity across disease contexts remains incompletely understood. This review systematically characterizes the TIL landscape in human cSCC. Following PRISMA 2020 guidelines, PubMed and Embase were searched up to May 2025 and restricted to studies evaluating tumor-infiltrating lymphocytes in human cSCC, using the modified Newcatle&amp;amp;ndash;Ottawa score to assess risk of bias. Data were synthesized qualitatively given methodological heterogeneity. 48 studies met inclusion criteria. cSCCs exhibited dense CD3+ infiltrates composed of cytotoxic (CD8+GzmB+, Ki-67+, CD69+) and regulatory (FOXP3+, CCR4+) subsets. Higher CD8+ activity correlated with smaller tumors and longer disease-free survival, whereas FOXP3+ enrichment and TGF-&amp;amp;beta;2 signaling promoted immune evasion. Immunosuppressed patients demonstrated diminished CD8+ density and clonality. Immune modulation with PD-1/PD-L1 blockade, imiquimod, HPV vaccination, or OX40 stimulation enhanced effector function. The cSCC immune microenvironment reflects a balance between cytotoxic and suppressive factors. Harmonizing multimodal immune profiling and integrating spatial context with systemic immune status may advance both prognostic stratification and therapeutic design.</description>
	<pubDate>2026-01-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 6: Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma&amp;mdash;A Systematic Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/6">doi: 10.3390/dermatopathology13010006</a></p>
	<p>Authors:
		Li Yang Loo
		Shi Huan Tay
		Choon Chiat Oh
		</p>
	<p>Cutaneous squamous cell carcinoma (cSCC) is an immunogenic malignancy with variable immune infiltration and inconsistent responses to checkpoint blockade. Tumor-infiltrating lymphocytes (TILs) influence tumor progression and therapeutic outcome, yet their phenotypic and functional diversity across disease contexts remains incompletely understood. This review systematically characterizes the TIL landscape in human cSCC. Following PRISMA 2020 guidelines, PubMed and Embase were searched up to May 2025 and restricted to studies evaluating tumor-infiltrating lymphocytes in human cSCC, using the modified Newcatle&amp;amp;ndash;Ottawa score to assess risk of bias. Data were synthesized qualitatively given methodological heterogeneity. 48 studies met inclusion criteria. cSCCs exhibited dense CD3+ infiltrates composed of cytotoxic (CD8+GzmB+, Ki-67+, CD69+) and regulatory (FOXP3+, CCR4+) subsets. Higher CD8+ activity correlated with smaller tumors and longer disease-free survival, whereas FOXP3+ enrichment and TGF-&amp;amp;beta;2 signaling promoted immune evasion. Immunosuppressed patients demonstrated diminished CD8+ density and clonality. Immune modulation with PD-1/PD-L1 blockade, imiquimod, HPV vaccination, or OX40 stimulation enhanced effector function. The cSCC immune microenvironment reflects a balance between cytotoxic and suppressive factors. Harmonizing multimodal immune profiling and integrating spatial context with systemic immune status may advance both prognostic stratification and therapeutic design.</p>
	]]></content:encoded>

	<dc:title>Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma&amp;amp;mdash;A Systematic Review</dc:title>
			<dc:creator>Li Yang Loo</dc:creator>
			<dc:creator>Shi Huan Tay</dc:creator>
			<dc:creator>Choon Chiat Oh</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010006</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2026-01-13</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2026-01-13</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010006</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/5">

	<title>Dermatopathology, Vol. 13, Pages 5: The Need for Standardization of PRAME Immunohistochemistry in Melanocytic Neoplasms</title>
	<link>https://www.mdpi.com/2296-3529/13/1/5</link>
	<description>Accurate diagnosis of melanomas is crucial for proper evaluation and treatment. One immunohistochemical stain frequently utilized is PRAME (PReferentially expressed Antigen in MElanoma), a tumor-associated antigen expressed in most melanomas. This study aims to evaluate the reproducibility of PRAME scoring performed by dermatopathologists at an academic tertiary referral medical center. A blinded survey was designed featuring 21 melanocytic neoplasms stained with PRAME and H&amp;amp;amp;E. For each case, five dermatopathologists provided a PRAME score from 0&amp;amp;ndash;4+, percent PRAME positivity, values for H-score, and a descriptive interpretation. Absolute agreement across raters was assessed using a Kappa statistic for PRAME score and intraclass correlations (ICCs) for H-score and PRAME percentage. Statistical analysis indicated poor inter-rater reliability for PRAME score (Kappa = 0.16), percent PRAME positivity (ICC = 0.31), and H-score (ICC = 0.40). Reporting language varied among pathologists. Our study demonstrated that the interpretation of PRAME immunohistochemistry lacks reproducibility, especially for challenging lesions. This suggests that a more rigorous, defined, and reproducible scoring method should be investigated for equivocal cases. Future studies may explore the utility of artificial intelligence software in the interpretation of PRAME for borderline lesions to improve reliability and standardize scoring.</description>
	<pubDate>2025-12-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 5: The Need for Standardization of PRAME Immunohistochemistry in Melanocytic Neoplasms</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/5">doi: 10.3390/dermatopathology13010005</a></p>
	<p>Authors:
		Calla M. Sullivan
		Dominick DiMaio
		Scott Lauer
		Dinesh Pradhan
		Julie Youngs
		Kaeli Samson
		Corey J. Georgesen
		</p>
	<p>Accurate diagnosis of melanomas is crucial for proper evaluation and treatment. One immunohistochemical stain frequently utilized is PRAME (PReferentially expressed Antigen in MElanoma), a tumor-associated antigen expressed in most melanomas. This study aims to evaluate the reproducibility of PRAME scoring performed by dermatopathologists at an academic tertiary referral medical center. A blinded survey was designed featuring 21 melanocytic neoplasms stained with PRAME and H&amp;amp;amp;E. For each case, five dermatopathologists provided a PRAME score from 0&amp;amp;ndash;4+, percent PRAME positivity, values for H-score, and a descriptive interpretation. Absolute agreement across raters was assessed using a Kappa statistic for PRAME score and intraclass correlations (ICCs) for H-score and PRAME percentage. Statistical analysis indicated poor inter-rater reliability for PRAME score (Kappa = 0.16), percent PRAME positivity (ICC = 0.31), and H-score (ICC = 0.40). Reporting language varied among pathologists. Our study demonstrated that the interpretation of PRAME immunohistochemistry lacks reproducibility, especially for challenging lesions. This suggests that a more rigorous, defined, and reproducible scoring method should be investigated for equivocal cases. Future studies may explore the utility of artificial intelligence software in the interpretation of PRAME for borderline lesions to improve reliability and standardize scoring.</p>
	]]></content:encoded>

	<dc:title>The Need for Standardization of PRAME Immunohistochemistry in Melanocytic Neoplasms</dc:title>
			<dc:creator>Calla M. Sullivan</dc:creator>
			<dc:creator>Dominick DiMaio</dc:creator>
			<dc:creator>Scott Lauer</dc:creator>
			<dc:creator>Dinesh Pradhan</dc:creator>
			<dc:creator>Julie Youngs</dc:creator>
			<dc:creator>Kaeli Samson</dc:creator>
			<dc:creator>Corey J. Georgesen</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010005</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-12-31</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-12-31</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010005</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/4">

	<title>Dermatopathology, Vol. 13, Pages 4: Deeply Pigmented Reticulated Acanthoma with Sebaceous Differentiation Mimicking Cutaneous Malignancy: A Case Report and Review of the Literature</title>
	<link>https://www.mdpi.com/2296-3529/13/1/4</link>
	<description>Reticulated acanthoma with sebaceous differentiation (RASD) is a rare, benign cutaneous neoplasm. Its variable clinical presentation frequently mimics both benign and malignant entities, posing a significant diagnostic challenge. We report a case of pigmented RASD in a 78-year-old Malay male of Fitzpatrick skin type IV who presented with a 5-year history of an 8 &amp;amp;times; 5 mm deeply pigmented, asymmetrical nodule on the left upper back, with a 2 mm central raised area showing less pigmentation. The lesion was clinically suspicious for malignant melanoma. Histopathological examination revealed characteristic features of RASD: a broad, plate-like, reticulated and pigmented epidermal proliferation with clusters of mature sebocytes at the bases of anastomosing rete ridges. Following biopsy confirmation, the residual lesion is being managed conservatively with observation. This case demonstrates an unusual heavily pigmented clinical presentation that completely obscured the typical yellowish hue associated with sebaceous differentiation, highlighting pigmented RASD as an important diagnostic pitfall in patients with skin of color. In conclusion, RASD should be included in the differential diagnosis of pigmented cutaneous lesions, especially in patients with skin of color. Recognition of this benign entity can prevent unnecessary aggressive surgical intervention.</description>
	<pubDate>2025-12-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 4: Deeply Pigmented Reticulated Acanthoma with Sebaceous Differentiation Mimicking Cutaneous Malignancy: A Case Report and Review of the Literature</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/4">doi: 10.3390/dermatopathology13010004</a></p>
	<p>Authors:
		Padol Chamninawakul
		Xiaotian Wu
		Joyce S. S. Lee
		</p>
	<p>Reticulated acanthoma with sebaceous differentiation (RASD) is a rare, benign cutaneous neoplasm. Its variable clinical presentation frequently mimics both benign and malignant entities, posing a significant diagnostic challenge. We report a case of pigmented RASD in a 78-year-old Malay male of Fitzpatrick skin type IV who presented with a 5-year history of an 8 &amp;amp;times; 5 mm deeply pigmented, asymmetrical nodule on the left upper back, with a 2 mm central raised area showing less pigmentation. The lesion was clinically suspicious for malignant melanoma. Histopathological examination revealed characteristic features of RASD: a broad, plate-like, reticulated and pigmented epidermal proliferation with clusters of mature sebocytes at the bases of anastomosing rete ridges. Following biopsy confirmation, the residual lesion is being managed conservatively with observation. This case demonstrates an unusual heavily pigmented clinical presentation that completely obscured the typical yellowish hue associated with sebaceous differentiation, highlighting pigmented RASD as an important diagnostic pitfall in patients with skin of color. In conclusion, RASD should be included in the differential diagnosis of pigmented cutaneous lesions, especially in patients with skin of color. Recognition of this benign entity can prevent unnecessary aggressive surgical intervention.</p>
	]]></content:encoded>

	<dc:title>Deeply Pigmented Reticulated Acanthoma with Sebaceous Differentiation Mimicking Cutaneous Malignancy: A Case Report and Review of the Literature</dc:title>
			<dc:creator>Padol Chamninawakul</dc:creator>
			<dc:creator>Xiaotian Wu</dc:creator>
			<dc:creator>Joyce S. S. Lee</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010004</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-12-30</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-12-30</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010004</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/3">

	<title>Dermatopathology, Vol. 13, Pages 3: Hypothetical Abductive Reasoning in Dermatology and Dermatopathology</title>
	<link>https://www.mdpi.com/2296-3529/13/1/3</link>
	<description>Abductive reasoning, or abduction, is a key process in scientific discovery and medical diagnosis. In everyday dermatology and dermatopathology, however, it functions as the practical engine behind differential diagnosis, clinicopathologic correlation, and disciplined pattern recognition. In this paper, we retain the epistemological foundation of abduction but translate it into usable steps for clinicians and dermatopathologists. We distinguish abduction from deduction and induction; separate creative abduction (which generates new concepts) from selective abduction (daily diagnostic choice); and show how both operate within a simple Select-and-Test (ST) Model: select a hypothesis, deduce what else should be true, test against data, and then update. We then reinterpret Ackerman&amp;amp;rsquo;s algorithmic method of pattern analysis as an operationalization of the ST-Model. Through a couple of concise case vignettes, we illustrate visual and manipulative abduction, nonmonotonic updates, and the role of artifacts (dermoscopy, DIF, stains) as so-called epistemic mediators. Finally, we map contemporary AI tools to selective abduction and propose practical guardrails for fairness, transparency, and accountability. The result is a pragmatic framework that preserves philosophical depth while addressing the daily needs of dermatologists and dermatopathologists in the clinic and at the microscope.</description>
	<pubDate>2025-12-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 3: Hypothetical Abductive Reasoning in Dermatology and Dermatopathology</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/3">doi: 10.3390/dermatopathology13010003</a></p>
	<p>Authors:
		Carlo Francesco Tomasini
		Lorenzo Magnani
		</p>
	<p>Abductive reasoning, or abduction, is a key process in scientific discovery and medical diagnosis. In everyday dermatology and dermatopathology, however, it functions as the practical engine behind differential diagnosis, clinicopathologic correlation, and disciplined pattern recognition. In this paper, we retain the epistemological foundation of abduction but translate it into usable steps for clinicians and dermatopathologists. We distinguish abduction from deduction and induction; separate creative abduction (which generates new concepts) from selective abduction (daily diagnostic choice); and show how both operate within a simple Select-and-Test (ST) Model: select a hypothesis, deduce what else should be true, test against data, and then update. We then reinterpret Ackerman&amp;amp;rsquo;s algorithmic method of pattern analysis as an operationalization of the ST-Model. Through a couple of concise case vignettes, we illustrate visual and manipulative abduction, nonmonotonic updates, and the role of artifacts (dermoscopy, DIF, stains) as so-called epistemic mediators. Finally, we map contemporary AI tools to selective abduction and propose practical guardrails for fairness, transparency, and accountability. The result is a pragmatic framework that preserves philosophical depth while addressing the daily needs of dermatologists and dermatopathologists in the clinic and at the microscope.</p>
	]]></content:encoded>

	<dc:title>Hypothetical Abductive Reasoning in Dermatology and Dermatopathology</dc:title>
			<dc:creator>Carlo Francesco Tomasini</dc:creator>
			<dc:creator>Lorenzo Magnani</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010003</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-12-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-12-25</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010003</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/2">

	<title>Dermatopathology, Vol. 13, Pages 2: Increased Expression of Angiopoietin 2 and Tie2 in Rosacea</title>
	<link>https://www.mdpi.com/2296-3529/13/1/2</link>
	<description>In this study we evaluated the expression of Angiopoietin 1, Angiopoietin 2, and Tie2 by immunohistochemistry in the skin of 10 patients with erythemato telangiectatic and papulopustular rosacea. Significantly increased expression of Tie2 and Angiopoietin 2 in the endothelial cells of the dermal vessels in rosacea skin vs. non-lesional skin (100% and 33.3% for Tie2, and 100% and 50% for Angiopoietin 2) was observed. There was no difference in the expression of Angiopoietin 1 and phosphorylated Tie2 (pTie2) between the lesional skin of rosacea and non-lesional skin.</description>
	<pubDate>2025-12-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 2: Increased Expression of Angiopoietin 2 and Tie2 in Rosacea</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/2">doi: 10.3390/dermatopathology13010002</a></p>
	<p>Authors:
		Aysin Kaya
		Jean-Hilaire Saurat
		Nathalie Satta
		Gürkan Kaya
		</p>
	<p>In this study we evaluated the expression of Angiopoietin 1, Angiopoietin 2, and Tie2 by immunohistochemistry in the skin of 10 patients with erythemato telangiectatic and papulopustular rosacea. Significantly increased expression of Tie2 and Angiopoietin 2 in the endothelial cells of the dermal vessels in rosacea skin vs. non-lesional skin (100% and 33.3% for Tie2, and 100% and 50% for Angiopoietin 2) was observed. There was no difference in the expression of Angiopoietin 1 and phosphorylated Tie2 (pTie2) between the lesional skin of rosacea and non-lesional skin.</p>
	]]></content:encoded>

	<dc:title>Increased Expression of Angiopoietin 2 and Tie2 in Rosacea</dc:title>
			<dc:creator>Aysin Kaya</dc:creator>
			<dc:creator>Jean-Hilaire Saurat</dc:creator>
			<dc:creator>Nathalie Satta</dc:creator>
			<dc:creator>Gürkan Kaya</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010002</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-12-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-12-25</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010002</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/13/1/1">

	<title>Dermatopathology, Vol. 13, Pages 1: Artificial Intelligence for Lentigo Maligna: Automated Margin Assessment via Sox-10-Based Melanocyte Density Mapping</title>
	<link>https://www.mdpi.com/2296-3529/13/1/1</link>
	<description>Lentigo maligna (LM) is a melanoma in situ with high cumulative sun damage. Histological evaluation of resection margins is difficult and time-consuming. Melanocyte density (MD) is a suitable, quantifiable, and reproducible diagnostic criterion. In this retrospective single-centre study, we investigated whether an artificial intelligence (AI) tool can support the assessment of LM. Training and evaluation were based on MD in Sox-10-stained digitalised slides. In total, 86 whole slide images (WSIs) from LM patients were annotated and used as a training set. The test set consisted of 177 slides. The tool was trained to detect the epidermis, measure its length, and determine the MD. A cut-off of &amp;amp;ge;30 melanocytes per 0.5 mm of epidermis length was defined as positive. Our AI model automatically recognises the epidermis and measures the MD. The model was trained on nuclear immunohistochemical signals and can also be applied to other nuclear stains, such as PRAME or MITF. The WSI is automatically visualised by a three-colour heat map with a subdivision into low, borderline, and high melanocyte density. The cut-offs can be adjusted individually. Compared to manually counted ground truth MD, the AI model achieved high sensitivity (87.84%), specificity (72.82%), and accuracy (79.10%), and an area under the curve (AUC) of 0.818 in the test set. This automated tool can assist (dermato) pathologists by providing a quick overview of the WSI at first glance and making the time-consuming assessment of resection margins more efficient and more reproducible. The AI model can provide significant benefits in the daily routine workflow.</description>
	<pubDate>2025-12-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 13, Pages 1: Artificial Intelligence for Lentigo Maligna: Automated Margin Assessment via Sox-10-Based Melanocyte Density Mapping</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/13/1/1">doi: 10.3390/dermatopathology13010001</a></p>
	<p>Authors:
		Rieke Löper
		Lennart Abels
		Daniel Otero Baguer
		Felix Bremmer
		Michael P. Schön
		Christina Mitteldorf
		</p>
	<p>Lentigo maligna (LM) is a melanoma in situ with high cumulative sun damage. Histological evaluation of resection margins is difficult and time-consuming. Melanocyte density (MD) is a suitable, quantifiable, and reproducible diagnostic criterion. In this retrospective single-centre study, we investigated whether an artificial intelligence (AI) tool can support the assessment of LM. Training and evaluation were based on MD in Sox-10-stained digitalised slides. In total, 86 whole slide images (WSIs) from LM patients were annotated and used as a training set. The test set consisted of 177 slides. The tool was trained to detect the epidermis, measure its length, and determine the MD. A cut-off of &amp;amp;ge;30 melanocytes per 0.5 mm of epidermis length was defined as positive. Our AI model automatically recognises the epidermis and measures the MD. The model was trained on nuclear immunohistochemical signals and can also be applied to other nuclear stains, such as PRAME or MITF. The WSI is automatically visualised by a three-colour heat map with a subdivision into low, borderline, and high melanocyte density. The cut-offs can be adjusted individually. Compared to manually counted ground truth MD, the AI model achieved high sensitivity (87.84%), specificity (72.82%), and accuracy (79.10%), and an area under the curve (AUC) of 0.818 in the test set. This automated tool can assist (dermato) pathologists by providing a quick overview of the WSI at first glance and making the time-consuming assessment of resection margins more efficient and more reproducible. The AI model can provide significant benefits in the daily routine workflow.</p>
	]]></content:encoded>

	<dc:title>Artificial Intelligence for Lentigo Maligna: Automated Margin Assessment via Sox-10-Based Melanocyte Density Mapping</dc:title>
			<dc:creator>Rieke Löper</dc:creator>
			<dc:creator>Lennart Abels</dc:creator>
			<dc:creator>Daniel Otero Baguer</dc:creator>
			<dc:creator>Felix Bremmer</dc:creator>
			<dc:creator>Michael P. Schön</dc:creator>
			<dc:creator>Christina Mitteldorf</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology13010001</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-12-19</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-12-19</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/dermatopathology13010001</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/13/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/43">

	<title>Dermatopathology, Vol. 12, Pages 43: Is Radiotherapy a Risk Factor for Melanoma?</title>
	<link>https://www.mdpi.com/2296-3529/12/4/43</link>
	<description>Melanoma is a highly aggressive skin cancer primarily linked to ultraviolet (UV) radiation. However, the potential role of ionizing radiation from radiotherapy in melanoma development remains unclear. This review synthesizes data from epidemiologic studies and case reports on melanoma after radiation exposure. Evidence indicates that childhood radiotherapy, even at low doses, is associated with an increased melanoma risk, plausibly reflecting the heightened radiosensitivity of developing melanocytes. Occupational radiation exposure, particularly in earlier eras with insufficient shielding, also appears to elevate risk. In patients exposed to radiation in adulthood, findings are mixed: large population datasets suggest a modest increase in melanoma following therapeutic radiation, whereas some case&amp;amp;ndash;control analyses do not demonstrate a clear dose&amp;amp;ndash;response relationship. UV radiation promotes melanomagenesis through direct DNA photoproducts driving characteristic C&amp;amp;gt;T transitions at dipyrimidine sites, alongside oxidative stress and local immune modulation that facilitate malignant transformation. Collectively, individuals with prior radiotherapy, especially those irradiated in childhood, should be considered at increased melanoma risk and may benefit from long-term, targeted surveillance of irradiated fields. Awareness of this association between radiation exposure and melanoma may also support clinicopathologic correlation during the diagnostic evaluation of melanocytic lesions. Future work should define dose&amp;amp;ndash;response relationships in contemporary radiotherapy methods, characterize molecular signatures of ionizing radiation-associated melanomas, and establish evidence-based surveillance strategies for high-risk cohorts.</description>
	<pubDate>2025-11-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 43: Is Radiotherapy a Risk Factor for Melanoma?</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/43">doi: 10.3390/dermatopathology12040043</a></p>
	<p>Authors:
		Sumeyye Ozer
		Priya Agarwal
		Noah Musolff
		Brendan Plann-Curley
		Gizem Cosgun
		Helen Yanyu Sun
		Babar Rao
		</p>
	<p>Melanoma is a highly aggressive skin cancer primarily linked to ultraviolet (UV) radiation. However, the potential role of ionizing radiation from radiotherapy in melanoma development remains unclear. This review synthesizes data from epidemiologic studies and case reports on melanoma after radiation exposure. Evidence indicates that childhood radiotherapy, even at low doses, is associated with an increased melanoma risk, plausibly reflecting the heightened radiosensitivity of developing melanocytes. Occupational radiation exposure, particularly in earlier eras with insufficient shielding, also appears to elevate risk. In patients exposed to radiation in adulthood, findings are mixed: large population datasets suggest a modest increase in melanoma following therapeutic radiation, whereas some case&amp;amp;ndash;control analyses do not demonstrate a clear dose&amp;amp;ndash;response relationship. UV radiation promotes melanomagenesis through direct DNA photoproducts driving characteristic C&amp;amp;gt;T transitions at dipyrimidine sites, alongside oxidative stress and local immune modulation that facilitate malignant transformation. Collectively, individuals with prior radiotherapy, especially those irradiated in childhood, should be considered at increased melanoma risk and may benefit from long-term, targeted surveillance of irradiated fields. Awareness of this association between radiation exposure and melanoma may also support clinicopathologic correlation during the diagnostic evaluation of melanocytic lesions. Future work should define dose&amp;amp;ndash;response relationships in contemporary radiotherapy methods, characterize molecular signatures of ionizing radiation-associated melanomas, and establish evidence-based surveillance strategies for high-risk cohorts.</p>
	]]></content:encoded>

	<dc:title>Is Radiotherapy a Risk Factor for Melanoma?</dc:title>
			<dc:creator>Sumeyye Ozer</dc:creator>
			<dc:creator>Priya Agarwal</dc:creator>
			<dc:creator>Noah Musolff</dc:creator>
			<dc:creator>Brendan Plann-Curley</dc:creator>
			<dc:creator>Gizem Cosgun</dc:creator>
			<dc:creator>Helen Yanyu Sun</dc:creator>
			<dc:creator>Babar Rao</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040043</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-11-17</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-11-17</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>43</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040043</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/43</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/42">

	<title>Dermatopathology, Vol. 12, Pages 42: Translating Features to Findings: Deep Learning for Melanoma Subtype Prediction</title>
	<link>https://www.mdpi.com/2296-3529/12/4/42</link>
	<description>Melanoma subtyping plays a vital role in histopathological diagnosis, informing prognosis and, in some cases, guiding targeted therapy. However, conventional histologic classification is constrained by inter-rater reliability, morphologic overlap, and the underrepresentation of rare subtypes. Deep learning (DL)&amp;amp;mdash;particularly convolutional neural networks (CNNs)&amp;amp;mdash;presents a compelling opportunity to enhance diagnostic precision and reproducibility through automated analysis of histopathologic slides. This review examines the clinical importance and diagnostic challenges of melanoma subtyping, outlines core DL methodologies in dermatopathology, and synthesizes current advances in applying DL to subtype classification. Pertinent limitations including dataset imbalance, a lack of interpretability, and domain generalizability are discussed. Additionally, emerging directions such as multimodal integration, synthetic data generation, federated learning, and explainable AI are highlighted as potential solutions. As these technologies mature, DL holds considerable promise in advancing melanoma diagnostics and supporting more personalized, accurate, and equitable patient care.</description>
	<pubDate>2025-11-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 42: Translating Features to Findings: Deep Learning for Melanoma Subtype Prediction</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/42">doi: 10.3390/dermatopathology12040042</a></p>
	<p>Authors:
		Dorra Guermazi
		Sarina Khemchandani
		Samer Wahood
		Cuong Nguyen
		Elie Saliba
		</p>
	<p>Melanoma subtyping plays a vital role in histopathological diagnosis, informing prognosis and, in some cases, guiding targeted therapy. However, conventional histologic classification is constrained by inter-rater reliability, morphologic overlap, and the underrepresentation of rare subtypes. Deep learning (DL)&amp;amp;mdash;particularly convolutional neural networks (CNNs)&amp;amp;mdash;presents a compelling opportunity to enhance diagnostic precision and reproducibility through automated analysis of histopathologic slides. This review examines the clinical importance and diagnostic challenges of melanoma subtyping, outlines core DL methodologies in dermatopathology, and synthesizes current advances in applying DL to subtype classification. Pertinent limitations including dataset imbalance, a lack of interpretability, and domain generalizability are discussed. Additionally, emerging directions such as multimodal integration, synthetic data generation, federated learning, and explainable AI are highlighted as potential solutions. As these technologies mature, DL holds considerable promise in advancing melanoma diagnostics and supporting more personalized, accurate, and equitable patient care.</p>
	]]></content:encoded>

	<dc:title>Translating Features to Findings: Deep Learning for Melanoma Subtype Prediction</dc:title>
			<dc:creator>Dorra Guermazi</dc:creator>
			<dc:creator>Sarina Khemchandani</dc:creator>
			<dc:creator>Samer Wahood</dc:creator>
			<dc:creator>Cuong Nguyen</dc:creator>
			<dc:creator>Elie Saliba</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040042</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-11-12</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-11-12</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>42</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040042</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/42</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/41">

	<title>Dermatopathology, Vol. 12, Pages 41: Asymmetric Lip Hyperpigmentation in a Transplant Patient</title>
	<link>https://www.mdpi.com/2296-3529/12/4/41</link>
	<description>A 56-year-old patient presented to our dermatology clinic with asymmetric hyperpigmentation on her lower lip, which had developed over the previous six to twelve months. Her medical history included kidney and pancreas transplants, requiring chronic immunosuppression, and two lip filler injections with hyaluronic acid (HA). Clinical examination revealed irregular pigmented macules limited strictly to the lower lip. Histological analysis showed epidermal melanosis, pigmentary incontinence, solar elastosis, and amorphous dermal HA deposits, without evidence of melanocytic hyperplasia or granulomatous inflammation.</description>
	<pubDate>2025-11-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 41: Asymmetric Lip Hyperpigmentation in a Transplant Patient</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/41">doi: 10.3390/dermatopathology12040041</a></p>
	<p>Authors:
		Vincent Kimpe
		David Alvarez Martinez
		Sébastien Menzinger
		Gürkan Kaya
		</p>
	<p>A 56-year-old patient presented to our dermatology clinic with asymmetric hyperpigmentation on her lower lip, which had developed over the previous six to twelve months. Her medical history included kidney and pancreas transplants, requiring chronic immunosuppression, and two lip filler injections with hyaluronic acid (HA). Clinical examination revealed irregular pigmented macules limited strictly to the lower lip. Histological analysis showed epidermal melanosis, pigmentary incontinence, solar elastosis, and amorphous dermal HA deposits, without evidence of melanocytic hyperplasia or granulomatous inflammation.</p>
	]]></content:encoded>

	<dc:title>Asymmetric Lip Hyperpigmentation in a Transplant Patient</dc:title>
			<dc:creator>Vincent Kimpe</dc:creator>
			<dc:creator>David Alvarez Martinez</dc:creator>
			<dc:creator>Sébastien Menzinger</dc:creator>
			<dc:creator>Gürkan Kaya</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040041</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-11-10</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-11-10</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Clinicopathological Challenge</prism:section>
	<prism:startingPage>41</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040041</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/41</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/40">

	<title>Dermatopathology, Vol. 12, Pages 40: Indeterminate Subcutaneous Lesion of the Nasal Dorsum in an Adolescent: A Multidisciplinary Approach to a Rare Case of Spindle Cell Lipoma</title>
	<link>https://www.mdpi.com/2296-3529/12/4/40</link>
	<description>We report the case of a 16-year-old girl presenting with a painless, clinically stable subcutaneous swelling of the nasal dorsum with a three-year history. Despite an extensive multidisciplinary diagnostic work-up&amp;amp;mdash;including dermatological, otorhinolaryngological, and radiological evaluations (ultrasound, CT, and MRI)&amp;amp;mdash;the nature of the lesion remained indeterminate. In order to achieve a definitive diagnosis while preserving the nasal profile aesthetics, the mass was entirely excised via an endoscope-assisted closed rhinoseptoplasty approach. Histopathological analysis revealed a spindle cell lipoma characterized by CD34 positivity and a Ki-67 proliferation index of less than 1%. This finding is extremely rare in terms of both anatomical location and patient age. The present case highlights the crucial role of histopathological examination in establishing the correct diagnosis, supported by a multidisciplinary assessment.</description>
	<pubDate>2025-11-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 40: Indeterminate Subcutaneous Lesion of the Nasal Dorsum in an Adolescent: A Multidisciplinary Approach to a Rare Case of Spindle Cell Lipoma</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/40">doi: 10.3390/dermatopathology12040040</a></p>
	<p>Authors:
		Alessandro Serrone
		Chiara Rustichelli
		Gian Luca Fadda
		Giuseppe Riva
		Massimo Rizzo
		Giovanni Cavallo
		</p>
	<p>We report the case of a 16-year-old girl presenting with a painless, clinically stable subcutaneous swelling of the nasal dorsum with a three-year history. Despite an extensive multidisciplinary diagnostic work-up&amp;amp;mdash;including dermatological, otorhinolaryngological, and radiological evaluations (ultrasound, CT, and MRI)&amp;amp;mdash;the nature of the lesion remained indeterminate. In order to achieve a definitive diagnosis while preserving the nasal profile aesthetics, the mass was entirely excised via an endoscope-assisted closed rhinoseptoplasty approach. Histopathological analysis revealed a spindle cell lipoma characterized by CD34 positivity and a Ki-67 proliferation index of less than 1%. This finding is extremely rare in terms of both anatomical location and patient age. The present case highlights the crucial role of histopathological examination in establishing the correct diagnosis, supported by a multidisciplinary assessment.</p>
	]]></content:encoded>

	<dc:title>Indeterminate Subcutaneous Lesion of the Nasal Dorsum in an Adolescent: A Multidisciplinary Approach to a Rare Case of Spindle Cell Lipoma</dc:title>
			<dc:creator>Alessandro Serrone</dc:creator>
			<dc:creator>Chiara Rustichelli</dc:creator>
			<dc:creator>Gian Luca Fadda</dc:creator>
			<dc:creator>Giuseppe Riva</dc:creator>
			<dc:creator>Massimo Rizzo</dc:creator>
			<dc:creator>Giovanni Cavallo</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040040</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-11-04</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-11-04</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>40</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040040</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/40</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/39">

	<title>Dermatopathology, Vol. 12, Pages 39: Histopathologic Features and Molecular Markers of Encephalocraniocutaneous Lipomatosis (ECCL)</title>
	<link>https://www.mdpi.com/2296-3529/12/4/39</link>
	<description>Encephalocraniocutaneous lipomatosis (ECCL) is a rare congenital neurocutaneous disorder characterized by ocular, skin, and central nervous system manifestations. Despite its recognizable clinical features, such as nevus psiloliparus, histopathologic characterization of ECCL remains limited in the dermatopathology literature, and diagnosis is often clinical. This scarcity of published histopathological descriptions makes diagnostic confirmation challenging and underscores the value of synthesizing the available evidence. This comprehensive review synthesizes reported histopathological findings across cutaneous manifestations highlighting key tissue-level features that may aid diagnostic confirmation. Additionally, we review the emerging role of molecular diagnostics, particularly the identification of mosaic activating mutations in FGFR-1 and KRAS, which have been implicated in ECCL pathogenesis. By integrating clinicopathologic correlations with molecular insights, this review aims to enhance our dermatopathological understanding of ECCL, bolstering diagnostic reasoning and clinical decision making for this rare neurocutaneous condition.</description>
	<pubDate>2025-11-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 39: Histopathologic Features and Molecular Markers of Encephalocraniocutaneous Lipomatosis (ECCL)</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/39">doi: 10.3390/dermatopathology12040039</a></p>
	<p>Authors:
		Siddharth Venigalla
		Tanvir K. Dhaliwal
		Anvita Anumolu
		Lena Rafey
		Arturo P. Saavedra
		David D. Limbrick
		</p>
	<p>Encephalocraniocutaneous lipomatosis (ECCL) is a rare congenital neurocutaneous disorder characterized by ocular, skin, and central nervous system manifestations. Despite its recognizable clinical features, such as nevus psiloliparus, histopathologic characterization of ECCL remains limited in the dermatopathology literature, and diagnosis is often clinical. This scarcity of published histopathological descriptions makes diagnostic confirmation challenging and underscores the value of synthesizing the available evidence. This comprehensive review synthesizes reported histopathological findings across cutaneous manifestations highlighting key tissue-level features that may aid diagnostic confirmation. Additionally, we review the emerging role of molecular diagnostics, particularly the identification of mosaic activating mutations in FGFR-1 and KRAS, which have been implicated in ECCL pathogenesis. By integrating clinicopathologic correlations with molecular insights, this review aims to enhance our dermatopathological understanding of ECCL, bolstering diagnostic reasoning and clinical decision making for this rare neurocutaneous condition.</p>
	]]></content:encoded>

	<dc:title>Histopathologic Features and Molecular Markers of Encephalocraniocutaneous Lipomatosis (ECCL)</dc:title>
			<dc:creator>Siddharth Venigalla</dc:creator>
			<dc:creator>Tanvir K. Dhaliwal</dc:creator>
			<dc:creator>Anvita Anumolu</dc:creator>
			<dc:creator>Lena Rafey</dc:creator>
			<dc:creator>Arturo P. Saavedra</dc:creator>
			<dc:creator>David D. Limbrick</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040039</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-11-03</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-11-03</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>39</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040039</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/39</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/38">

	<title>Dermatopathology, Vol. 12, Pages 38: Comparative Clinicopathological Analysis of Oral Focal Mucinosis and Solitary Cutaneous Focal Mucinosis: A Case Series and Literature-Based Analysis</title>
	<link>https://www.mdpi.com/2296-3529/12/4/38</link>
	<description>Background/Objectives: Oral focal mucinosis (OFM) and solitary cutaneous focal mucinosis (SCFM) are rare, benign lesions characterized by localized mucin deposition in the stromal connective tissue. While both share similar histological features, they occur in distinct anatomical sites and clinical contexts and have not been directly compared in the literature. Method: This study presents a case series of 39 OFM cases diagnosed over 25 years, supplemented by a literature review of previously reported OFM cases, and compares the combined data with published cases of SCFM. The literature-based analysis included 116 OFM cases published in four articles and 138 cases of SCFM published in five articles. Demographic and clinical data were extracted and analyzed, including age, sex, lesion location, size, duration, symptoms, clinical impression, treatment, and recurrence. Results: The mean age of OFM patients was 41 years, with a slight female predominance, most commonly affecting the gingiva. SCFM cases were more common in males, with a higher mean age of 52 years and frequent occurrence on the extremities and trunk. Both lesions were predominantly asymptomatic and managed by conservative excision. Due to its rare occurrence and nonspecific clinical presentation, both entities were frequently clinically misdiagnosed. Conclusions: In conclusion, this is the first study to directly compare OFM with SCFM and represents the largest series of OFM reported to date. The study provides new comparative insights into SCFM and OFM, highlighting differences in age, gender, lesion site, size, and symptomatology. SCFM predominantly affects older males on the extremities, whereas OFM occurs in younger females, mainly in the gingiva, with larger, sometimes symptomatic lesions, and with a very low recurrence rate.</description>
	<pubDate>2025-10-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 38: Comparative Clinicopathological Analysis of Oral Focal Mucinosis and Solitary Cutaneous Focal Mucinosis: A Case Series and Literature-Based Analysis</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/38">doi: 10.3390/dermatopathology12040038</a></p>
	<p>Authors:
		Wickramasinghe Mudiyanselage Sithma Nilochana Wickramasinghe
		Primali Rukmal Jayasooriya
		Balapuwaduge Ranjit Rigobert Nihal Mendis
		Tommaso Lombardi
		</p>
	<p>Background/Objectives: Oral focal mucinosis (OFM) and solitary cutaneous focal mucinosis (SCFM) are rare, benign lesions characterized by localized mucin deposition in the stromal connective tissue. While both share similar histological features, they occur in distinct anatomical sites and clinical contexts and have not been directly compared in the literature. Method: This study presents a case series of 39 OFM cases diagnosed over 25 years, supplemented by a literature review of previously reported OFM cases, and compares the combined data with published cases of SCFM. The literature-based analysis included 116 OFM cases published in four articles and 138 cases of SCFM published in five articles. Demographic and clinical data were extracted and analyzed, including age, sex, lesion location, size, duration, symptoms, clinical impression, treatment, and recurrence. Results: The mean age of OFM patients was 41 years, with a slight female predominance, most commonly affecting the gingiva. SCFM cases were more common in males, with a higher mean age of 52 years and frequent occurrence on the extremities and trunk. Both lesions were predominantly asymptomatic and managed by conservative excision. Due to its rare occurrence and nonspecific clinical presentation, both entities were frequently clinically misdiagnosed. Conclusions: In conclusion, this is the first study to directly compare OFM with SCFM and represents the largest series of OFM reported to date. The study provides new comparative insights into SCFM and OFM, highlighting differences in age, gender, lesion site, size, and symptomatology. SCFM predominantly affects older males on the extremities, whereas OFM occurs in younger females, mainly in the gingiva, with larger, sometimes symptomatic lesions, and with a very low recurrence rate.</p>
	]]></content:encoded>

	<dc:title>Comparative Clinicopathological Analysis of Oral Focal Mucinosis and Solitary Cutaneous Focal Mucinosis: A Case Series and Literature-Based Analysis</dc:title>
			<dc:creator>Wickramasinghe Mudiyanselage Sithma Nilochana Wickramasinghe</dc:creator>
			<dc:creator>Primali Rukmal Jayasooriya</dc:creator>
			<dc:creator>Balapuwaduge Ranjit Rigobert Nihal Mendis</dc:creator>
			<dc:creator>Tommaso Lombardi</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040038</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-10-27</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-10-27</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>38</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040038</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/38</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/37">

	<title>Dermatopathology, Vol. 12, Pages 37: Cutaneous Neufibroma in the Absence of Classical NF1 Features: A Case Report and Literature Review</title>
	<link>https://www.mdpi.com/2296-3529/12/4/37</link>
	<description>Neurofibromatosis type 1 (NF1) is a prevalent neurocutaneous illness resulting from mutations in the NF1 gene, usually diagnosed according to clinical criteria set by the National Institutes of Health (NIH). These encompass caf&amp;amp;eacute;-au-lait macules, axillary freckling, Lisch nodules, ocular gliomas, osseous lesions, neurofibromas, and familial history. Atypical instances exhibiting partial or isolated characteristics, such as numerous cutaneous neurofibromas (cNFs) absent other classical manifestations, provide a diagnostic difficulty and may be little acknowledged in clinical environments. We describe a 47-year-old male with several soft, non-tender, pinkish-red papules and nodules dispersed throughout the face, torso, limbs, and back. A solitary caf&amp;amp;eacute;-au-lait macule measuring 3 x 2 cm was seen below the right breast, no axillary or inguinal freckling was observed, Lisch nodules were absent during ophthalmologic examination, and there was no pertinent family history. The histopathological examination of a skin lesion verified the diagnosis of cutaneous neurofibroma. According to the NIH guidelines, the patient did not satisfy the requirements for a conclusive diagnosis of NF1. This instance underscores the clinical intricacy of NF1 spectrum diseases and suggests the potential for mosaic NF1 or a minor phenotypic variation. The existence of several cNFs without systemic involvement undermines the adequacy of existing diagnostic paradigms, particularly in adults who exhibit no early-life signs. The psychosocial challenges linked to widespread cNF distribution highlight the necessity for a comprehensive assessment. Limitations encompass the lack of genetic testing, which would have facilitated the confirmation of the diagnosis and the assessment of probable mosaicism. Isolated cutaneous neurofibromas, devoid of other conventional NF1 characteristics, are an uncommon yet clinically pertinent manifestation. Clinicians must uphold a heightened level of suspicion for aberrant NF1 phenotypes and contemplate further examination, using molecular diagnostics where feasible. Reevaluating diagnostic criteria to include these polymorphisms is essential for prompt identification, effective care, and enhanced patient outcomes.</description>
	<pubDate>2025-10-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 37: Cutaneous Neufibroma in the Absence of Classical NF1 Features: A Case Report and Literature Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/37">doi: 10.3390/dermatopathology12040037</a></p>
	<p>Authors:
		Christine Suryani Novelita Sutrisno
		Desy Hinda Pramita
		Ita Puspita Dewi
		</p>
	<p>Neurofibromatosis type 1 (NF1) is a prevalent neurocutaneous illness resulting from mutations in the NF1 gene, usually diagnosed according to clinical criteria set by the National Institutes of Health (NIH). These encompass caf&amp;amp;eacute;-au-lait macules, axillary freckling, Lisch nodules, ocular gliomas, osseous lesions, neurofibromas, and familial history. Atypical instances exhibiting partial or isolated characteristics, such as numerous cutaneous neurofibromas (cNFs) absent other classical manifestations, provide a diagnostic difficulty and may be little acknowledged in clinical environments. We describe a 47-year-old male with several soft, non-tender, pinkish-red papules and nodules dispersed throughout the face, torso, limbs, and back. A solitary caf&amp;amp;eacute;-au-lait macule measuring 3 x 2 cm was seen below the right breast, no axillary or inguinal freckling was observed, Lisch nodules were absent during ophthalmologic examination, and there was no pertinent family history. The histopathological examination of a skin lesion verified the diagnosis of cutaneous neurofibroma. According to the NIH guidelines, the patient did not satisfy the requirements for a conclusive diagnosis of NF1. This instance underscores the clinical intricacy of NF1 spectrum diseases and suggests the potential for mosaic NF1 or a minor phenotypic variation. The existence of several cNFs without systemic involvement undermines the adequacy of existing diagnostic paradigms, particularly in adults who exhibit no early-life signs. The psychosocial challenges linked to widespread cNF distribution highlight the necessity for a comprehensive assessment. Limitations encompass the lack of genetic testing, which would have facilitated the confirmation of the diagnosis and the assessment of probable mosaicism. Isolated cutaneous neurofibromas, devoid of other conventional NF1 characteristics, are an uncommon yet clinically pertinent manifestation. Clinicians must uphold a heightened level of suspicion for aberrant NF1 phenotypes and contemplate further examination, using molecular diagnostics where feasible. Reevaluating diagnostic criteria to include these polymorphisms is essential for prompt identification, effective care, and enhanced patient outcomes.</p>
	]]></content:encoded>

	<dc:title>Cutaneous Neufibroma in the Absence of Classical NF1 Features: A Case Report and Literature Review</dc:title>
			<dc:creator>Christine Suryani Novelita Sutrisno</dc:creator>
			<dc:creator>Desy Hinda Pramita</dc:creator>
			<dc:creator>Ita Puspita Dewi</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040037</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-10-15</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-10-15</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>37</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040037</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/37</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/36">

	<title>Dermatopathology, Vol. 12, Pages 36: Basaloid Cell Hyperplasia Overlying Dermatofibroma</title>
	<link>https://www.mdpi.com/2296-3529/12/4/36</link>
	<description>Dermatofibromas (DFs) are benign neoplasms of the dermis typically found on the extremities of young adults. In approximately 3–5% of cases, basaloid cell hyperplasia (BCH) is observed overlying DFs. BCH is characterized by the proliferation of basaloid cells within the epidermis. BCH and superficial basal cell carcinoma (BCC) share many histological features, making their differentiation challenging. It is therefore unclear if the proliferation of basaloid cells in DFs represents an inductive process or, conversely, a malignant transformation indicative of BCC. The primary objective of our study was to determine whether BCH can be distinguished from superficial BCC using histology and immunhistological techniques. The histological and immunohistochemical characteristics of 43 DF samples with overlying BCH revealed significant similarities in staining patterns with those of superficial BCC described in the literature. These findings point to the need for innovative methods, such as molecular techniques, to refine diagnostic accuracy.</description>
	<pubDate>2025-10-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 36: Basaloid Cell Hyperplasia Overlying Dermatofibroma</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/36">doi: 10.3390/dermatopathology12040036</a></p>
	<p>Authors:
		Pablo Izarra
		Marwa Zohdy
		Helmut Beltraminelli
		Laurence Feldmeyer
		</p>
	<p>Dermatofibromas (DFs) are benign neoplasms of the dermis typically found on the extremities of young adults. In approximately 3–5% of cases, basaloid cell hyperplasia (BCH) is observed overlying DFs. BCH is characterized by the proliferation of basaloid cells within the epidermis. BCH and superficial basal cell carcinoma (BCC) share many histological features, making their differentiation challenging. It is therefore unclear if the proliferation of basaloid cells in DFs represents an inductive process or, conversely, a malignant transformation indicative of BCC. The primary objective of our study was to determine whether BCH can be distinguished from superficial BCC using histology and immunhistological techniques. The histological and immunohistochemical characteristics of 43 DF samples with overlying BCH revealed significant similarities in staining patterns with those of superficial BCC described in the literature. These findings point to the need for innovative methods, such as molecular techniques, to refine diagnostic accuracy.</p>
	]]></content:encoded>

	<dc:title>Basaloid Cell Hyperplasia Overlying Dermatofibroma</dc:title>
			<dc:creator>Pablo Izarra</dc:creator>
			<dc:creator>Marwa Zohdy</dc:creator>
			<dc:creator>Helmut Beltraminelli</dc:creator>
			<dc:creator>Laurence Feldmeyer</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040036</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-10-10</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-10-10</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>36</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040036</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/36</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/34">

	<title>Dermatopathology, Vol. 12, Pages 34: Benign Cutaneous Neoplasms with Syndromic Associations</title>
	<link>https://www.mdpi.com/2296-3529/12/4/34</link>
	<description>There are many benign skin neoplasms encountered in dermatopathology practice that can be associated with underlying genetic disorders. Although benign themselves, these lesions can offer insight into the potential for development of internal malignancies in patients with these hereditary syndromes. An astute dermatopathologist will recognize clues that suggest a syndromic association of these lesions, such as the presence of multiple lesions, distinct histologic growth patterns, and the results of ancillary immunohistochemical testing. The dermatopathologist can then guide the referring clinician to obtain additional clinical and family history and, if appropriate, pursue further screening and genetic testing. This review article will provide an overview of the clinical and histologic features associated with select common and uncommon benign skin neoplasms with syndromic associations.</description>
	<pubDate>2025-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 34: Benign Cutaneous Neoplasms with Syndromic Associations</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/34">doi: 10.3390/dermatopathology12040034</a></p>
	<p>Authors:
		Sean Lider
		Chanel Mandap
		Pavandeep Gill
		</p>
	<p>There are many benign skin neoplasms encountered in dermatopathology practice that can be associated with underlying genetic disorders. Although benign themselves, these lesions can offer insight into the potential for development of internal malignancies in patients with these hereditary syndromes. An astute dermatopathologist will recognize clues that suggest a syndromic association of these lesions, such as the presence of multiple lesions, distinct histologic growth patterns, and the results of ancillary immunohistochemical testing. The dermatopathologist can then guide the referring clinician to obtain additional clinical and family history and, if appropriate, pursue further screening and genetic testing. This review article will provide an overview of the clinical and histologic features associated with select common and uncommon benign skin neoplasms with syndromic associations.</p>
	]]></content:encoded>

	<dc:title>Benign Cutaneous Neoplasms with Syndromic Associations</dc:title>
			<dc:creator>Sean Lider</dc:creator>
			<dc:creator>Chanel Mandap</dc:creator>
			<dc:creator>Pavandeep Gill</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040034</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-10-08</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-10-08</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>34</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040034</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/34</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/35">

	<title>Dermatopathology, Vol. 12, Pages 35: Unilateral Acroangiodermatitis: From Histopathologic Confirmation to Treatment with PDL</title>
	<link>https://www.mdpi.com/2296-3529/12/4/35</link>
	<description>Acroangiodermatitis is an uncommon angioproliferative dermatosis, related to chronic circulatory diseases, such as chronic venous insufficiency and arteriovenous malformations. We describe the case of a 32-year-old healthy male presenting with a pruritic, brownish lesion on the dorsal surface of the left foot, evolving for ten years. Physical examination revealed a brown plaque, with a verrucous surface, on the distal dorsum and medial border of the left foot. Histopathology disclosed a marked neovascularization of the upper dermis, associated with erythrocyte extravasation and hemosiderin deposition. Immunochemistry for HHV-8 was negative. CT angiography revealed multiple serpiginous vessels on the dorsum of the left foot, suggestive of a venous malformation. The diagnosis of acroangiodermatitis was established and the patient started topical corticosteroids and compression stockings, without improvement. Although scarcely described in the literature, treatment with PDL was proposed given the vascular proliferation confined to the papillary dermis. After two sessions, a significant improvement was observed. This case emphasises dermatopathology as the gold standard for the differential diagnosis with Kaposi sarcoma. In addition, it highlights PDL as a promising therapeutic option, based on the superficial histopathological location.</description>
	<pubDate>2025-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 35: Unilateral Acroangiodermatitis: From Histopathologic Confirmation to Treatment with PDL</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/35">doi: 10.3390/dermatopathology12040035</a></p>
	<p>Authors:
		André Aparício Martins
		José Carlos Cardoso
		André Pinho
		</p>
	<p>Acroangiodermatitis is an uncommon angioproliferative dermatosis, related to chronic circulatory diseases, such as chronic venous insufficiency and arteriovenous malformations. We describe the case of a 32-year-old healthy male presenting with a pruritic, brownish lesion on the dorsal surface of the left foot, evolving for ten years. Physical examination revealed a brown plaque, with a verrucous surface, on the distal dorsum and medial border of the left foot. Histopathology disclosed a marked neovascularization of the upper dermis, associated with erythrocyte extravasation and hemosiderin deposition. Immunochemistry for HHV-8 was negative. CT angiography revealed multiple serpiginous vessels on the dorsum of the left foot, suggestive of a venous malformation. The diagnosis of acroangiodermatitis was established and the patient started topical corticosteroids and compression stockings, without improvement. Although scarcely described in the literature, treatment with PDL was proposed given the vascular proliferation confined to the papillary dermis. After two sessions, a significant improvement was observed. This case emphasises dermatopathology as the gold standard for the differential diagnosis with Kaposi sarcoma. In addition, it highlights PDL as a promising therapeutic option, based on the superficial histopathological location.</p>
	]]></content:encoded>

	<dc:title>Unilateral Acroangiodermatitis: From Histopathologic Confirmation to Treatment with PDL</dc:title>
			<dc:creator>André Aparício Martins</dc:creator>
			<dc:creator>José Carlos Cardoso</dc:creator>
			<dc:creator>André Pinho</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040035</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-10-08</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-10-08</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>35</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040035</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/35</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/4/33">

	<title>Dermatopathology, Vol. 12, Pages 33: Diagnostic Challenges in HHV-8-Associated Multicentric Castleman Disease in a Patient with Prior Kaposi Sarcoma</title>
	<link>https://www.mdpi.com/2296-3529/12/4/33</link>
	<description>Human herpesvirus-8 (HHV-8)-associated multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder with systemic and cutaneous manifestations that can be diagnostically challenging, especially in immunocompromised patients. We report the case of a 68-year-old man with HIV and biopsy-proven Kaposi sarcoma (KS), who developed progressive fevers, night sweats, weight loss, and fatigue, accompanied by diffuse lymphadenopathy, splenomegaly, and new erythematous and hyperpigmented lesions shortly after intravenous immunoglobulin therapy for Guillain&amp;amp;ndash;Barr&amp;amp;eacute; syndrome. A laboratory evaluation revealed that the patient had elevated total protein and polyclonal hypergammaglobulinemia, without monoclonality. Imaging demonstrated widespread lymphadenopathy and splenomegaly. A core lymph node biopsy showed polytypic plasmacytosis, but was non-diagnostic. Given the ongoing symptoms, an excisional biopsy was performed, revealing regressed germinal centers with increased interfollicular vascularity, mantle zone &amp;amp;ldquo;onion skinning,&amp;amp;rdquo; and HHV-8 LANA-1 nuclear positivity, establishing the diagnosis of HHV-8-associated MCD. Rituximab monotherapy was initiated, resulting in clinical improvement, resolution of the constitutional symptoms, and stabilization of ascites. This case highlights the importance of maintaining a high index of suspicion for MCD in patients with KS who develop new systemic or cutaneous findings, the limitations of a core biopsy, and the value of a timely excisional biopsy in guiding diagnosis and treatment.</description>
	<pubDate>2025-10-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 33: Diagnostic Challenges in HHV-8-Associated Multicentric Castleman Disease in a Patient with Prior Kaposi Sarcoma</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/4/33">doi: 10.3390/dermatopathology12040033</a></p>
	<p>Authors:
		Seraphima S. Sidhom
		Luke A. Laconi
		Christopher A. LaFond
		Steven C. Weindorf
		</p>
	<p>Human herpesvirus-8 (HHV-8)-associated multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder with systemic and cutaneous manifestations that can be diagnostically challenging, especially in immunocompromised patients. We report the case of a 68-year-old man with HIV and biopsy-proven Kaposi sarcoma (KS), who developed progressive fevers, night sweats, weight loss, and fatigue, accompanied by diffuse lymphadenopathy, splenomegaly, and new erythematous and hyperpigmented lesions shortly after intravenous immunoglobulin therapy for Guillain&amp;amp;ndash;Barr&amp;amp;eacute; syndrome. A laboratory evaluation revealed that the patient had elevated total protein and polyclonal hypergammaglobulinemia, without monoclonality. Imaging demonstrated widespread lymphadenopathy and splenomegaly. A core lymph node biopsy showed polytypic plasmacytosis, but was non-diagnostic. Given the ongoing symptoms, an excisional biopsy was performed, revealing regressed germinal centers with increased interfollicular vascularity, mantle zone &amp;amp;ldquo;onion skinning,&amp;amp;rdquo; and HHV-8 LANA-1 nuclear positivity, establishing the diagnosis of HHV-8-associated MCD. Rituximab monotherapy was initiated, resulting in clinical improvement, resolution of the constitutional symptoms, and stabilization of ascites. This case highlights the importance of maintaining a high index of suspicion for MCD in patients with KS who develop new systemic or cutaneous findings, the limitations of a core biopsy, and the value of a timely excisional biopsy in guiding diagnosis and treatment.</p>
	]]></content:encoded>

	<dc:title>Diagnostic Challenges in HHV-8-Associated Multicentric Castleman Disease in a Patient with Prior Kaposi Sarcoma</dc:title>
			<dc:creator>Seraphima S. Sidhom</dc:creator>
			<dc:creator>Luke A. Laconi</dc:creator>
			<dc:creator>Christopher A. LaFond</dc:creator>
			<dc:creator>Steven C. Weindorf</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12040033</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-10-02</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-10-02</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>33</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12040033</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/4/33</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/32">

	<title>Dermatopathology, Vol. 12, Pages 32: Treatment Resistant Acneiform Eruption in a Young Female: A Diagnostic Pitfall</title>
	<link>https://www.mdpi.com/2296-3529/12/3/32</link>
	<description>A 27-year-old female with no significant medical or dermatologic history presented with a persistent acneiform eruption on the face. The patient had been treated with multiple topical and systemic anti-acne treatments with no significant improvement over a period of two years. A punch biopsy was performed on the right cheek lesion showing dense lymphocytic infiltrates of the reticular dermis with peri- and intra-follicular distribution.</description>
	<pubDate>2025-09-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 32: Treatment Resistant Acneiform Eruption in a Young Female: A Diagnostic Pitfall</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/32">doi: 10.3390/dermatopathology12030032</a></p>
	<p>Authors:
		Ioannis-Alexios Koumprentziotis
		Evdoxia Panou
		Antonis Tsimpidakis
		Maria Gerochristou
		Theodoros Iliakis
		Leonidas Marinos
		Alexander Stratigos
		Vasiliki Nikolaou
		</p>
	<p>A 27-year-old female with no significant medical or dermatologic history presented with a persistent acneiform eruption on the face. The patient had been treated with multiple topical and systemic anti-acne treatments with no significant improvement over a period of two years. A punch biopsy was performed on the right cheek lesion showing dense lymphocytic infiltrates of the reticular dermis with peri- and intra-follicular distribution.</p>
	]]></content:encoded>

	<dc:title>Treatment Resistant Acneiform Eruption in a Young Female: A Diagnostic Pitfall</dc:title>
			<dc:creator>Ioannis-Alexios Koumprentziotis</dc:creator>
			<dc:creator>Evdoxia Panou</dc:creator>
			<dc:creator>Antonis Tsimpidakis</dc:creator>
			<dc:creator>Maria Gerochristou</dc:creator>
			<dc:creator>Theodoros Iliakis</dc:creator>
			<dc:creator>Leonidas Marinos</dc:creator>
			<dc:creator>Alexander Stratigos</dc:creator>
			<dc:creator>Vasiliki Nikolaou</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030032</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-09-17</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-09-17</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Clinicopathological Challenge</prism:section>
	<prism:startingPage>32</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030032</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/32</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/31">

	<title>Dermatopathology, Vol. 12, Pages 31: Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy</title>
	<link>https://www.mdpi.com/2296-3529/12/3/31</link>
	<description>Despite therapeutic advancements, malignant melanoma remains a leading cause of skin cancer-related mortality, with incidence continuing to rise globally. Traditional prognostic tools offer important clinical guidance but fail to capture the biological heterogeneity of melanoma or reliably predict responses to emerging therapies. In this review, we summarize recent advances in prognostic and predictive molecular biomarkers reported over the past five years. We discuss immunohistochemical and tissue-based markers, circulating biomarkers, microRNAs, and gene expression profiles that enhance risk stratification and inform surveillance strategies. We also review immune-related markers that may predict response to immune-checkpoint inhibitor therapy. Lastly, we highlight investigational biomarkers&amp;amp;mdash;including gene signatures, epigenomic alterations, and microbiome influences&amp;amp;mdash;that are shaping the future landscape. Together, these advances reflect a shift toward precision oncology in melanoma, with the integration of biomarker-driven strategies offering the potential to personalize treatment and improve patient outcomes.</description>
	<pubDate>2025-09-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 31: Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/31">doi: 10.3390/dermatopathology12030031</a></p>
	<p>Authors:
		Lauren Fleshner
		Alyssa Sayegh
		Mehmet Fatih Atak
		Rahim Hirani
		Banu Farabi
		Bijan Safai
		Shoshana Marmon
		</p>
	<p>Despite therapeutic advancements, malignant melanoma remains a leading cause of skin cancer-related mortality, with incidence continuing to rise globally. Traditional prognostic tools offer important clinical guidance but fail to capture the biological heterogeneity of melanoma or reliably predict responses to emerging therapies. In this review, we summarize recent advances in prognostic and predictive molecular biomarkers reported over the past five years. We discuss immunohistochemical and tissue-based markers, circulating biomarkers, microRNAs, and gene expression profiles that enhance risk stratification and inform surveillance strategies. We also review immune-related markers that may predict response to immune-checkpoint inhibitor therapy. Lastly, we highlight investigational biomarkers&amp;amp;mdash;including gene signatures, epigenomic alterations, and microbiome influences&amp;amp;mdash;that are shaping the future landscape. Together, these advances reflect a shift toward precision oncology in melanoma, with the integration of biomarker-driven strategies offering the potential to personalize treatment and improve patient outcomes.</p>
	]]></content:encoded>

	<dc:title>Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy</dc:title>
			<dc:creator>Lauren Fleshner</dc:creator>
			<dc:creator>Alyssa Sayegh</dc:creator>
			<dc:creator>Mehmet Fatih Atak</dc:creator>
			<dc:creator>Rahim Hirani</dc:creator>
			<dc:creator>Banu Farabi</dc:creator>
			<dc:creator>Bijan Safai</dc:creator>
			<dc:creator>Shoshana Marmon</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030031</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-09-12</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-09-12</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>31</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030031</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/31</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/30">

	<title>Dermatopathology, Vol. 12, Pages 30: Mimicking the LOX-Related Autosomal Recessive Congenital Ichthyosis Skin Disease Using a CRISPR-Cas9 System and Unravelling 12S-LOX Function in the Skin</title>
	<link>https://www.mdpi.com/2296-3529/12/3/30</link>
	<description>Stratum Corneum (SC) formation in the human epidermis requires lipid processing. Lipoxygenases (LOXs) such as 12R-Lipoxygenase (12R-LOX) and Epidermis-type lipoxygenase 3 (eLOX-3) contribute to this process. Mutations in their genes cause Autosomal Recessive Congenital Ichthyosis (ARCI) in patients. On the other hand, 12S-lipoxygenase (12S-LOX) is expressed in the human epidermis, but its role still remains to be clarified. The involvement of eLOX-3, 12R, and 12S-LOX in conditions or processes such as skin photodamage, wound healing, psoriasis, and atopic dermatitis is suggested but still remains unclear. In order to eventually gain a better understanding of the role of these LOXs in such processes, models of Tissue-Engineered Skins (TESs) with an impaired expression for the native form of either eLOX-3, 12R-LOX, or 12S-LOX were produced using CRISPR-Cas9(D10A) technology. All three models showed impaired keratinocyte differentiation and changes in the prevalence or the size of lipid droplets within the most superficial layers, thus reproducing features observed in ARCI and supporting a role for 12S-LOX in SC formation. Since eLOX-3 and 12R-LOX depleted TES&amp;amp;rsquo;s reproduced features observed in ARCI, such models can be considered as reliable tools for the functional studies of these LOXs in the human epidermis.</description>
	<pubDate>2025-09-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 30: Mimicking the LOX-Related Autosomal Recessive Congenital Ichthyosis Skin Disease Using a CRISPR-Cas9 System and Unravelling 12S-LOX Function in the Skin</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/30">doi: 10.3390/dermatopathology12030030</a></p>
	<p>Authors:
		Carolyne Simard-Bisson
		Sébastien Larochelle
		Véronique J. Moulin
		Bernard Fruteau de Laclos
		</p>
	<p>Stratum Corneum (SC) formation in the human epidermis requires lipid processing. Lipoxygenases (LOXs) such as 12R-Lipoxygenase (12R-LOX) and Epidermis-type lipoxygenase 3 (eLOX-3) contribute to this process. Mutations in their genes cause Autosomal Recessive Congenital Ichthyosis (ARCI) in patients. On the other hand, 12S-lipoxygenase (12S-LOX) is expressed in the human epidermis, but its role still remains to be clarified. The involvement of eLOX-3, 12R, and 12S-LOX in conditions or processes such as skin photodamage, wound healing, psoriasis, and atopic dermatitis is suggested but still remains unclear. In order to eventually gain a better understanding of the role of these LOXs in such processes, models of Tissue-Engineered Skins (TESs) with an impaired expression for the native form of either eLOX-3, 12R-LOX, or 12S-LOX were produced using CRISPR-Cas9(D10A) technology. All three models showed impaired keratinocyte differentiation and changes in the prevalence or the size of lipid droplets within the most superficial layers, thus reproducing features observed in ARCI and supporting a role for 12S-LOX in SC formation. Since eLOX-3 and 12R-LOX depleted TES&amp;amp;rsquo;s reproduced features observed in ARCI, such models can be considered as reliable tools for the functional studies of these LOXs in the human epidermis.</p>
	]]></content:encoded>

	<dc:title>Mimicking the LOX-Related Autosomal Recessive Congenital Ichthyosis Skin Disease Using a CRISPR-Cas9 System and Unravelling 12S-LOX Function in the Skin</dc:title>
			<dc:creator>Carolyne Simard-Bisson</dc:creator>
			<dc:creator>Sébastien Larochelle</dc:creator>
			<dc:creator>Véronique J. Moulin</dc:creator>
			<dc:creator>Bernard Fruteau de Laclos</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030030</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-09-11</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-09-11</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>30</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030030</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/30</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/29">

	<title>Dermatopathology, Vol. 12, Pages 29: Prognostic Value of Immunohistochemical T-Cell Marker Loss in Early-Stage Mycosis Fungoides: A Single-Center Cohort Study</title>
	<link>https://www.mdpi.com/2296-3529/12/3/29</link>
	<description>Introduction: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma, often exhibiting loss of pan-T-cell markers such as CD2, CD3, CD5, and CD7. While these immunophenotypic alterations assist in diagnosis, their prognostic relevance in early-stage MF remains uncertain. This study aimed to determine whether immunohistochemical loss of T-cell markers CD2, CD3, CD5, and CD7 in patients with early-stage mycosis fungoides is associated with overall survival and progression-free survival. Methods: This retrospective included 83 patients with stage IA&amp;amp;ndash;IIA MF diagnosed between 2003 and 2012 at a single institution. Immunohistochemical staining of archived biopsy specimens was performed for CD2, CD3, CD5, and CD7. Loss of marker expression was defined as absence in &amp;amp;ge;30% of lymphocytes. Clinical and histopathological data were correlated with survival and progression outcomes using Kaplan&amp;amp;ndash;Meier curves and log-rank tests. Results: Loss of at least one T-cell marker was identified in 66% of patients, most commonly CD7 (72%), followed by CD5 (11%) and CD2 (11%). No cases showed loss of CD3 expression. CD7 loss was significantly associated with shorter progression-free survival (p &amp;amp;lt; 0.05), but not with overall survival. No significant associations were found between CD2 or CD5 loss and either survival or disease progression. Conclusions: CD7 loss was the only immunohistochemical abnormality significantly associated with earlier disease progression in early-stage MF, suggesting a potential prognostic role. In contrast, loss of CD2 and CD5 did not affect survival or progression, and CD3 was preserved in all cases. These findings highlight the value of incorporating CD7 status into prognostic assessment, although larger studies are needed to confirm its utility.</description>
	<pubDate>2025-09-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 29: Prognostic Value of Immunohistochemical T-Cell Marker Loss in Early-Stage Mycosis Fungoides: A Single-Center Cohort Study</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/29">doi: 10.3390/dermatopathology12030029</a></p>
	<p>Authors:
		Sandra Jerkovic Gulin
		Ivana Ilic
		Dario Gulin
		Georgios Kravvas
		Romana Ceovic
		</p>
	<p>Introduction: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma, often exhibiting loss of pan-T-cell markers such as CD2, CD3, CD5, and CD7. While these immunophenotypic alterations assist in diagnosis, their prognostic relevance in early-stage MF remains uncertain. This study aimed to determine whether immunohistochemical loss of T-cell markers CD2, CD3, CD5, and CD7 in patients with early-stage mycosis fungoides is associated with overall survival and progression-free survival. Methods: This retrospective included 83 patients with stage IA&amp;amp;ndash;IIA MF diagnosed between 2003 and 2012 at a single institution. Immunohistochemical staining of archived biopsy specimens was performed for CD2, CD3, CD5, and CD7. Loss of marker expression was defined as absence in &amp;amp;ge;30% of lymphocytes. Clinical and histopathological data were correlated with survival and progression outcomes using Kaplan&amp;amp;ndash;Meier curves and log-rank tests. Results: Loss of at least one T-cell marker was identified in 66% of patients, most commonly CD7 (72%), followed by CD5 (11%) and CD2 (11%). No cases showed loss of CD3 expression. CD7 loss was significantly associated with shorter progression-free survival (p &amp;amp;lt; 0.05), but not with overall survival. No significant associations were found between CD2 or CD5 loss and either survival or disease progression. Conclusions: CD7 loss was the only immunohistochemical abnormality significantly associated with earlier disease progression in early-stage MF, suggesting a potential prognostic role. In contrast, loss of CD2 and CD5 did not affect survival or progression, and CD3 was preserved in all cases. These findings highlight the value of incorporating CD7 status into prognostic assessment, although larger studies are needed to confirm its utility.</p>
	]]></content:encoded>

	<dc:title>Prognostic Value of Immunohistochemical T-Cell Marker Loss in Early-Stage Mycosis Fungoides: A Single-Center Cohort Study</dc:title>
			<dc:creator>Sandra Jerkovic Gulin</dc:creator>
			<dc:creator>Ivana Ilic</dc:creator>
			<dc:creator>Dario Gulin</dc:creator>
			<dc:creator>Georgios Kravvas</dc:creator>
			<dc:creator>Romana Ceovic</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030029</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-09-10</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-09-10</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>29</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030029</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/29</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/28">

	<title>Dermatopathology, Vol. 12, Pages 28: An Unusual Presentation of Dermatofibroma with Ulcer: A Case Report</title>
	<link>https://www.mdpi.com/2296-3529/12/3/28</link>
	<description>Dermatofibroma is a common mesenchymal skin lesion that typically presents as a firm, slow-growing nodule. Generally, such lesions are asymptomatic; however, they can also cause discomfort in some cases. Ulceration is an uncommon feature of dermatofibroma, and diagnosis in such cases is often difficult. We report a case of a 67-year-old female with multiple comorbidities, including pancreatic cancer undergoing neoadjuvant chemotherapy, who was admitted for acute pulmonary embolism. The patient presented with an incidental medial thigh lesion. The lesion was asymptomatic, ulcerated, and oozing pus one month before presentation. Clinical examination revealed a 3 &amp;amp;times; 2 cm deep ulcer with a punched-out edge, a dry yellow-white base, and a firm violaceous border. Histopathology confirmed dermatofibroma with epidermal hyperplasia, dermal spindle cell proliferation, histiocytes, and collagen trapping. Immunohistochemistry was positive for CD68, CD10, and Factor XIII. Due to the deteriorating condition of the patient, no intervention was provided to her, and she succumbed to her primary illness. This case is unique due to its atypical ulcerative presentation in a patient with complex systemic illness and emphasizes distinguishing between benign lesions and malignant mimics, especially in cases which have ambiguous clinical presentation.</description>
	<pubDate>2025-09-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 28: An Unusual Presentation of Dermatofibroma with Ulcer: A Case Report</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/28">doi: 10.3390/dermatopathology12030028</a></p>
	<p>Authors:
		Lamia Alakrash
		Renad AlKanaan
		Rema Aldihan
		Alanoud Alsuhibani
		Salman Almalki
		</p>
	<p>Dermatofibroma is a common mesenchymal skin lesion that typically presents as a firm, slow-growing nodule. Generally, such lesions are asymptomatic; however, they can also cause discomfort in some cases. Ulceration is an uncommon feature of dermatofibroma, and diagnosis in such cases is often difficult. We report a case of a 67-year-old female with multiple comorbidities, including pancreatic cancer undergoing neoadjuvant chemotherapy, who was admitted for acute pulmonary embolism. The patient presented with an incidental medial thigh lesion. The lesion was asymptomatic, ulcerated, and oozing pus one month before presentation. Clinical examination revealed a 3 &amp;amp;times; 2 cm deep ulcer with a punched-out edge, a dry yellow-white base, and a firm violaceous border. Histopathology confirmed dermatofibroma with epidermal hyperplasia, dermal spindle cell proliferation, histiocytes, and collagen trapping. Immunohistochemistry was positive for CD68, CD10, and Factor XIII. Due to the deteriorating condition of the patient, no intervention was provided to her, and she succumbed to her primary illness. This case is unique due to its atypical ulcerative presentation in a patient with complex systemic illness and emphasizes distinguishing between benign lesions and malignant mimics, especially in cases which have ambiguous clinical presentation.</p>
	]]></content:encoded>

	<dc:title>An Unusual Presentation of Dermatofibroma with Ulcer: A Case Report</dc:title>
			<dc:creator>Lamia Alakrash</dc:creator>
			<dc:creator>Renad AlKanaan</dc:creator>
			<dc:creator>Rema Aldihan</dc:creator>
			<dc:creator>Alanoud Alsuhibani</dc:creator>
			<dc:creator>Salman Almalki</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030028</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-09-04</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-09-04</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>28</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030028</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/28</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/27">

	<title>Dermatopathology, Vol. 12, Pages 27: Reply to Demiral et al. Comment on &amp;ldquo;Mahmood, M.N. Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site. Dermatopathology 2024, 11, 52&amp;ndash;61&amp;rdquo;</title>
	<link>https://www.mdpi.com/2296-3529/12/3/27</link>
	<description>I have reviewed the insightful comments on my review article titled &amp;amp;ldquo;Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site&amp;amp;rdquo; [...]</description>
	<pubDate>2025-09-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 27: Reply to Demiral et al. Comment on &amp;ldquo;Mahmood, M.N. Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site. Dermatopathology 2024, 11, 52&amp;ndash;61&amp;rdquo;</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/27">doi: 10.3390/dermatopathology12030027</a></p>
	<p>Authors:
		Muhammad N. Mahmood
		</p>
	<p>I have reviewed the insightful comments on my review article titled &amp;amp;ldquo;Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site&amp;amp;rdquo; [...]</p>
	]]></content:encoded>

	<dc:title>Reply to Demiral et al. Comment on &amp;amp;ldquo;Mahmood, M.N. Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site. Dermatopathology 2024, 11, 52&amp;amp;ndash;61&amp;amp;rdquo;</dc:title>
			<dc:creator>Muhammad N. Mahmood</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030027</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-09-04</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-09-04</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Reply</prism:section>
	<prism:startingPage>27</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030027</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/27</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/26">

	<title>Dermatopathology, Vol. 12, Pages 26: Comment on Mahmood, M.N. Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site. Dermatopathology 2024, 11, 52&amp;ndash;61</title>
	<link>https://www.mdpi.com/2296-3529/12/3/26</link>
	<description>Compilation written by Muhammad N [...]</description>
	<pubDate>2025-08-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 26: Comment on Mahmood, M.N. Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site. Dermatopathology 2024, 11, 52&amp;ndash;61</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/26">doi: 10.3390/dermatopathology12030026</a></p>
	<p>Authors:
		Şebnem Demiral
		Yunus Özcan
		Mehmet Gamsızkan
		</p>
	<p>Compilation written by Muhammad N [...]</p>
	]]></content:encoded>

	<dc:title>Comment on Mahmood, M.N. Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site. Dermatopathology 2024, 11, 52&amp;amp;ndash;61</dc:title>
			<dc:creator>Şebnem Demiral</dc:creator>
			<dc:creator>Yunus Özcan</dc:creator>
			<dc:creator>Mehmet Gamsızkan</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030026</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-08-26</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-08-26</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Comment</prism:section>
	<prism:startingPage>26</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030026</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/26</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/25">

	<title>Dermatopathology, Vol. 12, Pages 25: Immunohistochemical Characterisation of the Interstitial Inflammatory Environment: T-Cell- and B-Cell-Dominant Subtypes of Hidradenitis Suppurativa</title>
	<link>https://www.mdpi.com/2296-3529/12/3/25</link>
	<description>Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a complex immune response. Given the considerable heterogeneity of the clinical phenotype of HS, this study aimed to analyse the immunohistochemical pattern of interstitial inflammation. Methods: Immunohistochemical analysis was performed on skin samples from 49 patients with HS. The immunohistochemical markers CD3, CD4 and CD8 for T-cells, CD20 for B-cells, CD138 for plasma cells and CD30, CD56, Bcl-2 and Bcl-6 were stained on lesional skin. Results: The analysis of immune cell dominance in patients with HS revealed that 33.3% of the cohort exhibited B-cell dominance, defined as a ratio of the sum of CD20+ and CD138+ cells to CD3+ cells greater than 1, while the majority (66.7%) demonstrated T-cell dominance, defined as a ratio of CD3+ cells to the sum of CD20+ and CD138+ cells greater than 1. B-cell-dominant HS is associated with a significantly elevated probability of mammary involvement (13.3% vs. 0%; p = 0.041). T-cell-dominant HS patients tended to demonstrate a higher mean tobacco consumption, but not significantly (20 vs. 5 tobacco pack-years; p = 0.06). CD4-dominant HS patients exhibited a significantly greater involvement of the mons pubis (62.5% vs. 28.6%, p = 0.023) compared to CD8-dominant patients, who demonstrated a significantly higher number of abscesses (p = 0.027). Conclusions: For the first time, we describe the clinical and immunohistochemical characteristics of T-cell- and B-cell-dominant HS. Although HS seems to be more dominated by T-cells, a B-cell dominance was found in 33% of cases.</description>
	<pubDate>2025-08-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 25: Immunohistochemical Characterisation of the Interstitial Inflammatory Environment: T-Cell- and B-Cell-Dominant Subtypes of Hidradenitis Suppurativa</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/25">doi: 10.3390/dermatopathology12030025</a></p>
	<p>Authors:
		Nessr Abu Rached
		Stefanie Bruckmüller
		Martin Doerler
		Hanna Telkemeyer
		Lennart Ocker
		Yannik Haven
		Daniel Myszkowski
		Markus Stücker
		Eggert Stockfleth
		Falk G. Bechara
		</p>
	<p>Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a complex immune response. Given the considerable heterogeneity of the clinical phenotype of HS, this study aimed to analyse the immunohistochemical pattern of interstitial inflammation. Methods: Immunohistochemical analysis was performed on skin samples from 49 patients with HS. The immunohistochemical markers CD3, CD4 and CD8 for T-cells, CD20 for B-cells, CD138 for plasma cells and CD30, CD56, Bcl-2 and Bcl-6 were stained on lesional skin. Results: The analysis of immune cell dominance in patients with HS revealed that 33.3% of the cohort exhibited B-cell dominance, defined as a ratio of the sum of CD20+ and CD138+ cells to CD3+ cells greater than 1, while the majority (66.7%) demonstrated T-cell dominance, defined as a ratio of CD3+ cells to the sum of CD20+ and CD138+ cells greater than 1. B-cell-dominant HS is associated with a significantly elevated probability of mammary involvement (13.3% vs. 0%; p = 0.041). T-cell-dominant HS patients tended to demonstrate a higher mean tobacco consumption, but not significantly (20 vs. 5 tobacco pack-years; p = 0.06). CD4-dominant HS patients exhibited a significantly greater involvement of the mons pubis (62.5% vs. 28.6%, p = 0.023) compared to CD8-dominant patients, who demonstrated a significantly higher number of abscesses (p = 0.027). Conclusions: For the first time, we describe the clinical and immunohistochemical characteristics of T-cell- and B-cell-dominant HS. Although HS seems to be more dominated by T-cells, a B-cell dominance was found in 33% of cases.</p>
	]]></content:encoded>

	<dc:title>Immunohistochemical Characterisation of the Interstitial Inflammatory Environment: T-Cell- and B-Cell-Dominant Subtypes of Hidradenitis Suppurativa</dc:title>
			<dc:creator>Nessr Abu Rached</dc:creator>
			<dc:creator>Stefanie Bruckmüller</dc:creator>
			<dc:creator>Martin Doerler</dc:creator>
			<dc:creator>Hanna Telkemeyer</dc:creator>
			<dc:creator>Lennart Ocker</dc:creator>
			<dc:creator>Yannik Haven</dc:creator>
			<dc:creator>Daniel Myszkowski</dc:creator>
			<dc:creator>Markus Stücker</dc:creator>
			<dc:creator>Eggert Stockfleth</dc:creator>
			<dc:creator>Falk G. Bechara</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030025</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-08-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-08-25</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>25</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030025</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/25</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/24">

	<title>Dermatopathology, Vol. 12, Pages 24: Pilomatricoma in Syndromic Contexts: A Literature Review and a Report of a Case in Apert Syndrome</title>
	<link>https://www.mdpi.com/2296-3529/12/3/24</link>
	<description>Pilomatricomas are benign tumors originating from hair follicle matrix cells and represent the most common skin tumors in pediatric patients. Pilomatricomas may be associated with genetic syndromes such as myotonic dystrophy, familial adenomatous polyposis (FAP), Turner syndrome, Rubinstein&amp;amp;ndash;Taybi syndrome, Kabuki syndrome, and Sotos syndrome. This study reviews the literature on pilomatricomas occurring in syndromic contexts and presents a novel case linked to Apert syndrome. A systematic review was conducted using PubMed and Cochrane databases, focusing on case reports, case series, and reviews describing pilomatricomas associated with syndromes. A total of 1272 articles were initially screened; after removing duplicates and excluding articles without syndromic diagnoses or lacking sufficient data, 81 full-text articles were reviewed. Overall, 96 cases of pilomatricomas associated with genetic syndromes were identified. Reports of patients with Apert syndrome who do not develop pilomatricomas are absent in the literature. Pilomatricomas predominantly affect pediatric patients, with a slight female predominance, and are often the first manifestation of underlying genetic syndromes. Our study highlights previously unreported associations of pilomatricoma with Apert syndrome, providing molecular insights. This study contributes to understanding the clinical and molecular features of pilomatricomas in syndromic contexts and underscores the importance of genetic analysis for accurate diagnosis and management.</description>
	<pubDate>2025-08-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 24: Pilomatricoma in Syndromic Contexts: A Literature Review and a Report of a Case in Apert Syndrome</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/24">doi: 10.3390/dermatopathology12030024</a></p>
	<p>Authors:
		Gianmarco Saponaro
		Elisa De Paolis
		Mattia Todaro
		Francesca Azzuni
		Giulio Gasparini
		Antonio Bosso
		Giuliano Ascani
		Angelo Minucci
		Alessandro Moro
		</p>
	<p>Pilomatricomas are benign tumors originating from hair follicle matrix cells and represent the most common skin tumors in pediatric patients. Pilomatricomas may be associated with genetic syndromes such as myotonic dystrophy, familial adenomatous polyposis (FAP), Turner syndrome, Rubinstein&amp;amp;ndash;Taybi syndrome, Kabuki syndrome, and Sotos syndrome. This study reviews the literature on pilomatricomas occurring in syndromic contexts and presents a novel case linked to Apert syndrome. A systematic review was conducted using PubMed and Cochrane databases, focusing on case reports, case series, and reviews describing pilomatricomas associated with syndromes. A total of 1272 articles were initially screened; after removing duplicates and excluding articles without syndromic diagnoses or lacking sufficient data, 81 full-text articles were reviewed. Overall, 96 cases of pilomatricomas associated with genetic syndromes were identified. Reports of patients with Apert syndrome who do not develop pilomatricomas are absent in the literature. Pilomatricomas predominantly affect pediatric patients, with a slight female predominance, and are often the first manifestation of underlying genetic syndromes. Our study highlights previously unreported associations of pilomatricoma with Apert syndrome, providing molecular insights. This study contributes to understanding the clinical and molecular features of pilomatricomas in syndromic contexts and underscores the importance of genetic analysis for accurate diagnosis and management.</p>
	]]></content:encoded>

	<dc:title>Pilomatricoma in Syndromic Contexts: A Literature Review and a Report of a Case in Apert Syndrome</dc:title>
			<dc:creator>Gianmarco Saponaro</dc:creator>
			<dc:creator>Elisa De Paolis</dc:creator>
			<dc:creator>Mattia Todaro</dc:creator>
			<dc:creator>Francesca Azzuni</dc:creator>
			<dc:creator>Giulio Gasparini</dc:creator>
			<dc:creator>Antonio Bosso</dc:creator>
			<dc:creator>Giuliano Ascani</dc:creator>
			<dc:creator>Angelo Minucci</dc:creator>
			<dc:creator>Alessandro Moro</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030024</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-08-01</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-08-01</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>24</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030024</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/24</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/23">

	<title>Dermatopathology, Vol. 12, Pages 23: Immunohistopathological Analysis of Spongiosis Formation in Atopic Dermatitis Compared with Other Skin Diseases</title>
	<link>https://www.mdpi.com/2296-3529/12/3/23</link>
	<description>Whether the spongiotic reaction caused by the interaction of keratinocytes, T-lymphocytes, inflammatory dendritic epidermal cells (IDECs), and Langerhans cells (LCs) observed in atopic dermatitis (AD) represents a common feature of spongiosis in various skin diseases remains unclear. We analyzed the characteristics of spongiosis in AD compared with those in other eczematous dermatitis and inflammatory skin diseases by using immunohistochemical methods. Infiltration of IDECs (CD11c+ cells and/or CD206+ cells) and T-lymphocytes, accompanied by degenerated keratinocytes and aggregated LCs (CD207+ cells), was frequently observed as a common feature of spongiosis in multiple conditions. However, IDECs expressing IgE were identified exclusively in IgE-mediated AD. Aggregation of IDECs was predominantly observed in the spongiosis of adaptive immune-mediated eczematous disorders, such as AD and allergic contact dermatitis. These IDEC aggregations constituted the major components of the epidermal dendritic cell clusters seen in AD and other eczematous or eczematoid dermatoses, and may serve as a useful distinguishing marker from Pautrier collections seen in cutaneous T-cell lymphoma. These findings suggest that IDECs, in cooperation with other immune cells, may play a pivotal role in spongiosis formation in AD and various skin diseases, although the underlying immunopathological mechanisms differ among these conditions.</description>
	<pubDate>2025-08-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 23: Immunohistopathological Analysis of Spongiosis Formation in Atopic Dermatitis Compared with Other Skin Diseases</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/23">doi: 10.3390/dermatopathology12030023</a></p>
	<p>Authors:
		Ryoji Tanei
		Yasuko Hasegawa
		</p>
	<p>Whether the spongiotic reaction caused by the interaction of keratinocytes, T-lymphocytes, inflammatory dendritic epidermal cells (IDECs), and Langerhans cells (LCs) observed in atopic dermatitis (AD) represents a common feature of spongiosis in various skin diseases remains unclear. We analyzed the characteristics of spongiosis in AD compared with those in other eczematous dermatitis and inflammatory skin diseases by using immunohistochemical methods. Infiltration of IDECs (CD11c+ cells and/or CD206+ cells) and T-lymphocytes, accompanied by degenerated keratinocytes and aggregated LCs (CD207+ cells), was frequently observed as a common feature of spongiosis in multiple conditions. However, IDECs expressing IgE were identified exclusively in IgE-mediated AD. Aggregation of IDECs was predominantly observed in the spongiosis of adaptive immune-mediated eczematous disorders, such as AD and allergic contact dermatitis. These IDEC aggregations constituted the major components of the epidermal dendritic cell clusters seen in AD and other eczematous or eczematoid dermatoses, and may serve as a useful distinguishing marker from Pautrier collections seen in cutaneous T-cell lymphoma. These findings suggest that IDECs, in cooperation with other immune cells, may play a pivotal role in spongiosis formation in AD and various skin diseases, although the underlying immunopathological mechanisms differ among these conditions.</p>
	]]></content:encoded>

	<dc:title>Immunohistopathological Analysis of Spongiosis Formation in Atopic Dermatitis Compared with Other Skin Diseases</dc:title>
			<dc:creator>Ryoji Tanei</dc:creator>
			<dc:creator>Yasuko Hasegawa</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030023</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-08-01</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-08-01</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>23</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030023</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/23</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/22">

	<title>Dermatopathology, Vol. 12, Pages 22: Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides</title>
	<link>https://www.mdpi.com/2296-3529/12/3/22</link>
	<description>In this review, we explore the complexities of objectively assessing the response to immunotherapy in mycosis fungoides (MF), a prevalent form of cutaneous T-cell lymphoma. The core challenge lies in distinguishing between reactive and malignant lymphocytes amidst treatment, particularly given the absence of uniform pathological biomarkers for MF. We highlight the vital role of emerging histological technologies, such as multispectral imaging and spatial transcriptomics, in offering a more profound insight into the tumor microenvironment (TME) and its dynamic response to immunomodulatory therapies. Drawing on parallels with melanoma&amp;amp;mdash;another immunogenic skin cancer&amp;amp;mdash;our review suggests that methodologies and insights from melanoma could be instrumental in refining the approach to MF. We specifically focus on the prognostic implications of various TME cell types, including CD8+ tumor-infiltrating lymphocytes, natural killer (NK) cells, and histiocytes, in predicting therapy responses. The review culminates in a discussion about adapting and evolving treatment response quantification strategies from melanoma research to the distinct context of MF, advocating for the implementation of novel techniques like high-throughput T-cell receptor gene rearrangement analysis. This exploration underscores the urgent need for continued innovation and standardization in evaluating responses to immunotherapies in MF, a field rapidly evolving with new therapeutic strategies.</description>
	<pubDate>2025-07-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 22: Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/22">doi: 10.3390/dermatopathology12030022</a></p>
	<p>Authors:
		Amy Xiao
		Arivarasan Karunamurthy
		Oleg Akilov
		</p>
	<p>In this review, we explore the complexities of objectively assessing the response to immunotherapy in mycosis fungoides (MF), a prevalent form of cutaneous T-cell lymphoma. The core challenge lies in distinguishing between reactive and malignant lymphocytes amidst treatment, particularly given the absence of uniform pathological biomarkers for MF. We highlight the vital role of emerging histological technologies, such as multispectral imaging and spatial transcriptomics, in offering a more profound insight into the tumor microenvironment (TME) and its dynamic response to immunomodulatory therapies. Drawing on parallels with melanoma&amp;amp;mdash;another immunogenic skin cancer&amp;amp;mdash;our review suggests that methodologies and insights from melanoma could be instrumental in refining the approach to MF. We specifically focus on the prognostic implications of various TME cell types, including CD8+ tumor-infiltrating lymphocytes, natural killer (NK) cells, and histiocytes, in predicting therapy responses. The review culminates in a discussion about adapting and evolving treatment response quantification strategies from melanoma research to the distinct context of MF, advocating for the implementation of novel techniques like high-throughput T-cell receptor gene rearrangement analysis. This exploration underscores the urgent need for continued innovation and standardization in evaluating responses to immunotherapies in MF, a field rapidly evolving with new therapeutic strategies.</p>
	]]></content:encoded>

	<dc:title>Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides</dc:title>
			<dc:creator>Amy Xiao</dc:creator>
			<dc:creator>Arivarasan Karunamurthy</dc:creator>
			<dc:creator>Oleg Akilov</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030022</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-07-29</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-07-29</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>22</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030022</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/22</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/21">

	<title>Dermatopathology, Vol. 12, Pages 21: When Classic Signs Deceive: A Widespread Papulosquamous Eruption in Skin of Colour</title>
	<link>https://www.mdpi.com/2296-3529/12/3/21</link>
	<description>A 29-year-old gentleman of African descent presented to the emergency department with a three month history of a rash affecting the trunk, upper limbs, and thighs. The patient was unsure of any triggers and denied any preceding illness, new medications, illicit drug use, or recent vaccinations. On examination, there was a widespread papulosquamous eruption characterised by scaly, hyperpigmented papules and plaques involving the trunk, upper arms, and upper thighs. A definitive diagnosis was established through a diagnostic skin biopsy of a fresh lesion.</description>
	<pubDate>2025-07-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 21: When Classic Signs Deceive: A Widespread Papulosquamous Eruption in Skin of Colour</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/21">doi: 10.3390/dermatopathology12030021</a></p>
	<p>Authors:
		Ji Fung Yong
		Claudine Howard-James
		Stephen Crowther
		Anne-Marie Tobin
		Caitriona Hackett
		</p>
	<p>A 29-year-old gentleman of African descent presented to the emergency department with a three month history of a rash affecting the trunk, upper limbs, and thighs. The patient was unsure of any triggers and denied any preceding illness, new medications, illicit drug use, or recent vaccinations. On examination, there was a widespread papulosquamous eruption characterised by scaly, hyperpigmented papules and plaques involving the trunk, upper arms, and upper thighs. A definitive diagnosis was established through a diagnostic skin biopsy of a fresh lesion.</p>
	]]></content:encoded>

	<dc:title>When Classic Signs Deceive: A Widespread Papulosquamous Eruption in Skin of Colour</dc:title>
			<dc:creator>Ji Fung Yong</dc:creator>
			<dc:creator>Claudine Howard-James</dc:creator>
			<dc:creator>Stephen Crowther</dc:creator>
			<dc:creator>Anne-Marie Tobin</dc:creator>
			<dc:creator>Caitriona Hackett</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030021</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-07-21</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-07-21</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Clinicopathological Challenge</prism:section>
	<prism:startingPage>21</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030021</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/21</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/20">

	<title>Dermatopathology, Vol. 12, Pages 20: Basal Cell Carcinoma with Sarcomatoid Differentiation&amp;mdash;A Rare Type and Its Possible Origin</title>
	<link>https://www.mdpi.com/2296-3529/12/3/20</link>
	<description>Background: We present an interesting case involving a tumour comprising both basal cell tumour cells and sarcomatoid tumour cells. An 86-year-old woman presented with an erythematous lesion on her left cheek. Clinical and dermoscopic findings suggested BCC. Complete excision and histopathological examination revealed a BCC with a separate proliferation of atypical spindle and epithelioid cells. Immunohistochemical staining supported the diagnosis, with basaloid cells positive for CK5/6 and Ber-EP4 and sarcomatoid cells positive for CD10 and vimentin. Results: Histology and immunohistochemistry confirmed a basal cell carcinoma with sarcomatoid differentiation. The close proximity of sarcomatoid cells to the BCC component suggests a potential role of epithelial&amp;amp;ndash;mesenchymal interactions in tumour development. Further investigations into the exact origin of this tumour are required. Conclusion: Basal cell carcinoma with sarcomatoid differentiation is rare. This case highlights the importance of thorough histological and immunohistochemical evaluation. Further studies are necessary to better understand the pathogenesis of such collision tumours.</description>
	<pubDate>2025-07-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 20: Basal Cell Carcinoma with Sarcomatoid Differentiation&amp;mdash;A Rare Type and Its Possible Origin</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/20">doi: 10.3390/dermatopathology12030020</a></p>
	<p>Authors:
		Nessr Abu Rached
		Natalie Orlinski
		Eggert Stockfleth
		Markus Stücker
		Martin Doerler
		</p>
	<p>Background: We present an interesting case involving a tumour comprising both basal cell tumour cells and sarcomatoid tumour cells. An 86-year-old woman presented with an erythematous lesion on her left cheek. Clinical and dermoscopic findings suggested BCC. Complete excision and histopathological examination revealed a BCC with a separate proliferation of atypical spindle and epithelioid cells. Immunohistochemical staining supported the diagnosis, with basaloid cells positive for CK5/6 and Ber-EP4 and sarcomatoid cells positive for CD10 and vimentin. Results: Histology and immunohistochemistry confirmed a basal cell carcinoma with sarcomatoid differentiation. The close proximity of sarcomatoid cells to the BCC component suggests a potential role of epithelial&amp;amp;ndash;mesenchymal interactions in tumour development. Further investigations into the exact origin of this tumour are required. Conclusion: Basal cell carcinoma with sarcomatoid differentiation is rare. This case highlights the importance of thorough histological and immunohistochemical evaluation. Further studies are necessary to better understand the pathogenesis of such collision tumours.</p>
	]]></content:encoded>

	<dc:title>Basal Cell Carcinoma with Sarcomatoid Differentiation&amp;amp;mdash;A Rare Type and Its Possible Origin</dc:title>
			<dc:creator>Nessr Abu Rached</dc:creator>
			<dc:creator>Natalie Orlinski</dc:creator>
			<dc:creator>Eggert Stockfleth</dc:creator>
			<dc:creator>Markus Stücker</dc:creator>
			<dc:creator>Martin Doerler</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030020</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-07-08</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-07-08</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>20</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030020</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/20</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/3/19">

	<title>Dermatopathology, Vol. 12, Pages 19: Non-Invasive Diagnostic Techniques in Penile Intraepithelial Neoplasia (PeIN): Insights from Reflectance Confocal Microscopy (RCM), Line-Field Confocal Optical Coherence Tomography (LC-OCT), and Correlation with Histopathological Features</title>
	<link>https://www.mdpi.com/2296-3529/12/3/19</link>
	<description>Penile intraepithelial neoplasia (PeIN) is a rare but clinically significant condition that can progress to invasive squamous carcinoma. Early diagnosis is crucial but often challenging due to its heterogeneous clinical and dermoscopic presentation, which can mimic other benign or malignant lesions. In this study, we report two cases of pigmented penile lesions evaluated using non-invasive imaging techniques: reflectance confocal microscopy (RCM) and line-field confocal optical coherence tomography (LC-OCT). Both methods revealed characteristic features such as hyperkeratosis, parakeratosis, acanthosis, nuclear pleomorphism of keratinocytes, and the presence of bright intraepithelial dendritic cells, correlating closely with histopathological findings of high-grade basaloid PeIN. Our findings highlight the valuable role of RCM and LC-OCT in improving the differential diagnosis of genital lesions, potentially reducing the need for invasive diagnostic procedures and ensuring early, appropriate management.</description>
	<pubDate>2025-07-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 19: Non-Invasive Diagnostic Techniques in Penile Intraepithelial Neoplasia (PeIN): Insights from Reflectance Confocal Microscopy (RCM), Line-Field Confocal Optical Coherence Tomography (LC-OCT), and Correlation with Histopathological Features</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/3/19">doi: 10.3390/dermatopathology12030019</a></p>
	<p>Authors:
		Caterina Damiani
		Cesare Ariasi
		Giuseppe La Rosa
		Francesca Di Lauro
		Mariachiara Arisi
		Vincenzo Maione
		Marina Venturini
		Simone Soglia
		</p>
	<p>Penile intraepithelial neoplasia (PeIN) is a rare but clinically significant condition that can progress to invasive squamous carcinoma. Early diagnosis is crucial but often challenging due to its heterogeneous clinical and dermoscopic presentation, which can mimic other benign or malignant lesions. In this study, we report two cases of pigmented penile lesions evaluated using non-invasive imaging techniques: reflectance confocal microscopy (RCM) and line-field confocal optical coherence tomography (LC-OCT). Both methods revealed characteristic features such as hyperkeratosis, parakeratosis, acanthosis, nuclear pleomorphism of keratinocytes, and the presence of bright intraepithelial dendritic cells, correlating closely with histopathological findings of high-grade basaloid PeIN. Our findings highlight the valuable role of RCM and LC-OCT in improving the differential diagnosis of genital lesions, potentially reducing the need for invasive diagnostic procedures and ensuring early, appropriate management.</p>
	]]></content:encoded>

	<dc:title>Non-Invasive Diagnostic Techniques in Penile Intraepithelial Neoplasia (PeIN): Insights from Reflectance Confocal Microscopy (RCM), Line-Field Confocal Optical Coherence Tomography (LC-OCT), and Correlation with Histopathological Features</dc:title>
			<dc:creator>Caterina Damiani</dc:creator>
			<dc:creator>Cesare Ariasi</dc:creator>
			<dc:creator>Giuseppe La Rosa</dc:creator>
			<dc:creator>Francesca Di Lauro</dc:creator>
			<dc:creator>Mariachiara Arisi</dc:creator>
			<dc:creator>Vincenzo Maione</dc:creator>
			<dc:creator>Marina Venturini</dc:creator>
			<dc:creator>Simone Soglia</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12030019</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-07-07</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-07-07</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>19</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12030019</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/3/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/18">

	<title>Dermatopathology, Vol. 12, Pages 18: Influence of Aging and Diabetes on the Mechanical Properties of Mouse Skin</title>
	<link>https://www.mdpi.com/2296-3529/12/2/18</link>
	<description>Background: Diabetics accumulate Advanced Glycation End products (AGEs) such as N&amp;amp;epsilon;-(carboxymethyl)lysine (CML) in their skin, which can provoke changes in the skin&amp;amp;rsquo;s biomechanical properties. The same changes are also observed during aging. Collagen is one of the first targets of glycation, and this leads to the disruption of the dermis, potentially contributing to the skin complications seen in diabetes, like impaired wound healing and the formation of chronic ulcers. We therefore investigated whether it was possible to detect differences in the biomechanical properties of the reticular dermis by comparing C57/BL6 control mice, type 1 and type 2 diabetic mice, and aged mice. Methods: To investigate this, we used an Atomic Force Microscope (a type of local probe microscope used to visualize the surface topography of a sample) to measure the elastic modulus of each skin sample. The elastic modulus is a parameter that describes a tissue&amp;amp;rsquo;s resistance to elastic deformation when stress is applied. We also determined whether diabetes is associated with the accumulation of AGEs via Western blots. Results: We found that type 2 diabetic mice and aged mice had a stiffer reticular dermis than young control mice. No differences were found in type 1 diabetic mice. The results of the Western blot did not reveal any significant differences in the CML content in different types of mice, although a non-significant increase was found in type 2 diabetic and aged mice. We show that there is a significant positive correlation between the amount of CML in a mouse and the rigidity of its reticular dermis. Conclusions/interpretation: We have demonstrated that increased glycation in mouse skin is correlated with the biomechanical properties of that skin, which explains the wound healing defects diabetic patient&amp;amp;rsquo;s experience. AFM is therefore a powerful technique that could be used to characterize the mechanical effects of treatments aimed at reducing the level of AGEs in the skin.</description>
	<pubDate>2025-06-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 18: Influence of Aging and Diabetes on the Mechanical Properties of Mouse Skin</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/18">doi: 10.3390/dermatopathology12020018</a></p>
	<p>Authors:
		Sarah Miny
		Gaël Runel
		Julien Chlasta
		Christelle Bonod
		</p>
	<p>Background: Diabetics accumulate Advanced Glycation End products (AGEs) such as N&amp;amp;epsilon;-(carboxymethyl)lysine (CML) in their skin, which can provoke changes in the skin&amp;amp;rsquo;s biomechanical properties. The same changes are also observed during aging. Collagen is one of the first targets of glycation, and this leads to the disruption of the dermis, potentially contributing to the skin complications seen in diabetes, like impaired wound healing and the formation of chronic ulcers. We therefore investigated whether it was possible to detect differences in the biomechanical properties of the reticular dermis by comparing C57/BL6 control mice, type 1 and type 2 diabetic mice, and aged mice. Methods: To investigate this, we used an Atomic Force Microscope (a type of local probe microscope used to visualize the surface topography of a sample) to measure the elastic modulus of each skin sample. The elastic modulus is a parameter that describes a tissue&amp;amp;rsquo;s resistance to elastic deformation when stress is applied. We also determined whether diabetes is associated with the accumulation of AGEs via Western blots. Results: We found that type 2 diabetic mice and aged mice had a stiffer reticular dermis than young control mice. No differences were found in type 1 diabetic mice. The results of the Western blot did not reveal any significant differences in the CML content in different types of mice, although a non-significant increase was found in type 2 diabetic and aged mice. We show that there is a significant positive correlation between the amount of CML in a mouse and the rigidity of its reticular dermis. Conclusions/interpretation: We have demonstrated that increased glycation in mouse skin is correlated with the biomechanical properties of that skin, which explains the wound healing defects diabetic patient&amp;amp;rsquo;s experience. AFM is therefore a powerful technique that could be used to characterize the mechanical effects of treatments aimed at reducing the level of AGEs in the skin.</p>
	]]></content:encoded>

	<dc:title>Influence of Aging and Diabetes on the Mechanical Properties of Mouse Skin</dc:title>
			<dc:creator>Sarah Miny</dc:creator>
			<dc:creator>Gaël Runel</dc:creator>
			<dc:creator>Julien Chlasta</dc:creator>
			<dc:creator>Christelle Bonod</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020018</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-06-17</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-06-17</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>18</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020018</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/17">

	<title>Dermatopathology, Vol. 12, Pages 17: Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease</title>
	<link>https://www.mdpi.com/2296-3529/12/2/17</link>
	<description>Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by keratinocyte hyperproliferation, impaired epidermal barrier function, and immune dysregulation. The Th17/IL-23 axis plays a central role in its pathogenesis, promoting the production of key pro-inflammatory cytokines such as IL-17, IL-23, and TNF-&amp;amp;alpha;, which sustain chronic inflammation and epidermal remodeling. Emerging evidence suggests that SARS-CoV-2 may trigger new-onset or exacerbate existing psoriasis, likely through viral protein-induced activation of toll-like receptors (TLR2 and TLR4). This leads to NF-&amp;amp;kappa;B activation, cytokine release, and enhanced Th17 responses, disrupting immune homeostasis. Erythrodermic psoriasis (EP), a rare and severe variant, presents with generalized erythema and desquamation, often accompanied by systemic complications, including infection, electrolyte imbalance, and hemodynamic instability. In a murine model of SARS-CoV-2 infection, we found notable cutaneous changes: dermal collagen deposition, hair follicle destruction, and subcutaneous adipose loss. Parallel findings were seen in a rare clinical case (only the third reported case) of EP in a patient with refractory psoriasis, who developed erythroderma after off-label initiation of dupilumab therapy. The patient&amp;amp;rsquo;s histopathology closely mirrored the changes seen in the SARS-CoV-2 model. Histological evaluations also reveal similarities between psoriasis flare-ups following dupilumab treatment and cutaneous manifestations of COVID-19, suggesting a shared inflammatory pathway, potentially mediated by heightened type 1 and type 17 responses. This overlap raises the possibility of a latent connection between SARS-CoV-2 infection and increased psoriasis severity. Since the introduction of COVID-19 vaccines, sporadic cases of EP have been reported post-vaccination. Although rare, these events imply that vaccine-induced immune modulation may influence psoriasis activity. Our findings highlight a convergence of inflammatory mediators&amp;amp;mdash;including IL-1, IL-6, IL-17, TNF-&amp;amp;alpha;, TLRs, and NF-&amp;amp;kappa;B&amp;amp;mdash;across three triggers: SARS-CoV-2, vaccination, and dupilumab. Further mechanistic studies are essential to clarify these relationships and guide management in complex psoriasis cases.</description>
	<pubDate>2025-06-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 17: Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/17">doi: 10.3390/dermatopathology12020017</a></p>
	<p>Authors:
		Aya Fadel
		Jayakumar Nithura
		Zahraa F. Saadoon
		Lamia Naseer
		Angelo Lopez-Lacayo
		Ligia Elena Rojas Solano
		Chaveli Palau Morales
		Robert J. Hernandez
		Hussain Hussain
		</p>
	<p>Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by keratinocyte hyperproliferation, impaired epidermal barrier function, and immune dysregulation. The Th17/IL-23 axis plays a central role in its pathogenesis, promoting the production of key pro-inflammatory cytokines such as IL-17, IL-23, and TNF-&amp;amp;alpha;, which sustain chronic inflammation and epidermal remodeling. Emerging evidence suggests that SARS-CoV-2 may trigger new-onset or exacerbate existing psoriasis, likely through viral protein-induced activation of toll-like receptors (TLR2 and TLR4). This leads to NF-&amp;amp;kappa;B activation, cytokine release, and enhanced Th17 responses, disrupting immune homeostasis. Erythrodermic psoriasis (EP), a rare and severe variant, presents with generalized erythema and desquamation, often accompanied by systemic complications, including infection, electrolyte imbalance, and hemodynamic instability. In a murine model of SARS-CoV-2 infection, we found notable cutaneous changes: dermal collagen deposition, hair follicle destruction, and subcutaneous adipose loss. Parallel findings were seen in a rare clinical case (only the third reported case) of EP in a patient with refractory psoriasis, who developed erythroderma after off-label initiation of dupilumab therapy. The patient&amp;amp;rsquo;s histopathology closely mirrored the changes seen in the SARS-CoV-2 model. Histological evaluations also reveal similarities between psoriasis flare-ups following dupilumab treatment and cutaneous manifestations of COVID-19, suggesting a shared inflammatory pathway, potentially mediated by heightened type 1 and type 17 responses. This overlap raises the possibility of a latent connection between SARS-CoV-2 infection and increased psoriasis severity. Since the introduction of COVID-19 vaccines, sporadic cases of EP have been reported post-vaccination. Although rare, these events imply that vaccine-induced immune modulation may influence psoriasis activity. Our findings highlight a convergence of inflammatory mediators&amp;amp;mdash;including IL-1, IL-6, IL-17, TNF-&amp;amp;alpha;, TLRs, and NF-&amp;amp;kappa;B&amp;amp;mdash;across three triggers: SARS-CoV-2, vaccination, and dupilumab. Further mechanistic studies are essential to clarify these relationships and guide management in complex psoriasis cases.</p>
	]]></content:encoded>

	<dc:title>Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease</dc:title>
			<dc:creator>Aya Fadel</dc:creator>
			<dc:creator>Jayakumar Nithura</dc:creator>
			<dc:creator>Zahraa F. Saadoon</dc:creator>
			<dc:creator>Lamia Naseer</dc:creator>
			<dc:creator>Angelo Lopez-Lacayo</dc:creator>
			<dc:creator>Ligia Elena Rojas Solano</dc:creator>
			<dc:creator>Chaveli Palau Morales</dc:creator>
			<dc:creator>Robert J. Hernandez</dc:creator>
			<dc:creator>Hussain Hussain</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020017</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-06-09</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-06-09</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>17</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020017</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/16">

	<title>Dermatopathology, Vol. 12, Pages 16: Perforating Granuloma Annulare with Cysts and Comedones</title>
	<link>https://www.mdpi.com/2296-3529/12/2/16</link>
	<description>A 71-year-old Caucasian woman presented with lesions on both elbows. A physical examination revealed arcuate plaques with raised erythematous edges and central clearing. Comedones and cysts were evident on the border of the lesions. The dermatoscopic view showed the presence of pores, in addition to granuloma annulare changes. The biopsies showed changes according to granuloma annulare, but the granulomas were closely related to comedones and cysts. Furthermore, the presence of elastophagocytosis via multinucleated Langhans-type giant cells was evident. Verhoeff&amp;amp;ndash;van Gieson staining highlighted the transepithelial elimination of elastic fibers in the bottom of some cysts. The presence of comedones or cysts is exceptional in granuloma annulare. Only four similar cases have been reported. Although all previous cases showed lesions in sun-exposed areas over photodamaged skin, only our case showed transepithelial elimination of elastic fibers. Diabetes mellitus (DM) could play a role in the pathogenesis of this variant of actinic granuloma annulare, because most cases are associated with uncontrolled DM and the lesions improve after DM is controlled.</description>
	<pubDate>2025-05-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 16: Perforating Granuloma Annulare with Cysts and Comedones</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/16">doi: 10.3390/dermatopathology12020016</a></p>
	<p>Authors:
		Enric Piqué-Duran
		Mikel Azcue-Mayorga
		Belinda Roque-Quintana
		Odalys García-Vázquez
		Antonio Ruedas-Martínez
		</p>
	<p>A 71-year-old Caucasian woman presented with lesions on both elbows. A physical examination revealed arcuate plaques with raised erythematous edges and central clearing. Comedones and cysts were evident on the border of the lesions. The dermatoscopic view showed the presence of pores, in addition to granuloma annulare changes. The biopsies showed changes according to granuloma annulare, but the granulomas were closely related to comedones and cysts. Furthermore, the presence of elastophagocytosis via multinucleated Langhans-type giant cells was evident. Verhoeff&amp;amp;ndash;van Gieson staining highlighted the transepithelial elimination of elastic fibers in the bottom of some cysts. The presence of comedones or cysts is exceptional in granuloma annulare. Only four similar cases have been reported. Although all previous cases showed lesions in sun-exposed areas over photodamaged skin, only our case showed transepithelial elimination of elastic fibers. Diabetes mellitus (DM) could play a role in the pathogenesis of this variant of actinic granuloma annulare, because most cases are associated with uncontrolled DM and the lesions improve after DM is controlled.</p>
	]]></content:encoded>

	<dc:title>Perforating Granuloma Annulare with Cysts and Comedones</dc:title>
			<dc:creator>Enric Piqué-Duran</dc:creator>
			<dc:creator>Mikel Azcue-Mayorga</dc:creator>
			<dc:creator>Belinda Roque-Quintana</dc:creator>
			<dc:creator>Odalys García-Vázquez</dc:creator>
			<dc:creator>Antonio Ruedas-Martínez</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020016</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-05-29</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-05-29</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>16</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020016</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/15">

	<title>Dermatopathology, Vol. 12, Pages 15: Skin-Colored Papules on the Neck of a Postmenopausal Woman: A Diagnostic Challenge</title>
	<link>https://www.mdpi.com/2296-3529/12/2/15</link>
	<description>A 64-year-old patient presented for management of symptomatic skin-colored papules symmetrically distributed over the lateral neck over the past two years, which failed to improve on multiple topical corticosteroids, antifungal creams, and topical calcineurin inhibitor. Histopathologic examination showed a regular epidermis with increased melanophages in the papillary dermis, without vacuolar degeneration of the basement membrane. Verhoeff Van Gieson stain highlighted a band-like zone of attenuated elastic fibers in the papillary dermis, while Von Kossa stain was negative for calcified fibers. PAS staining was negative for fungal organisms and Alcian blue showed no increase in dermal mucin.</description>
	<pubDate>2025-05-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 15: Skin-Colored Papules on the Neck of a Postmenopausal Woman: A Diagnostic Challenge</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/15">doi: 10.3390/dermatopathology12020015</a></p>
	<p>Authors:
		Jason El Jalkh
		Pia Maria Obeid
		Dorra Guermazi
		Aya Soubra
		Elie Saliba
		</p>
	<p>A 64-year-old patient presented for management of symptomatic skin-colored papules symmetrically distributed over the lateral neck over the past two years, which failed to improve on multiple topical corticosteroids, antifungal creams, and topical calcineurin inhibitor. Histopathologic examination showed a regular epidermis with increased melanophages in the papillary dermis, without vacuolar degeneration of the basement membrane. Verhoeff Van Gieson stain highlighted a band-like zone of attenuated elastic fibers in the papillary dermis, while Von Kossa stain was negative for calcified fibers. PAS staining was negative for fungal organisms and Alcian blue showed no increase in dermal mucin.</p>
	]]></content:encoded>

	<dc:title>Skin-Colored Papules on the Neck of a Postmenopausal Woman: A Diagnostic Challenge</dc:title>
			<dc:creator>Jason El Jalkh</dc:creator>
			<dc:creator>Pia Maria Obeid</dc:creator>
			<dc:creator>Dorra Guermazi</dc:creator>
			<dc:creator>Aya Soubra</dc:creator>
			<dc:creator>Elie Saliba</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020015</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-05-14</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-05-14</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Clinicopathological Challenge</prism:section>
	<prism:startingPage>15</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020015</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/14">

	<title>Dermatopathology, Vol. 12, Pages 14: Cutaneous Metastases&amp;mdash;Histological Particularities of Multifaceted Entities</title>
	<link>https://www.mdpi.com/2296-3529/12/2/14</link>
	<description>Cutaneous metastases from internal organ cancers are diagnosed in approximately 0.2% of skin biopsies. This diagnosis can be the first sign of a previously undiagnosed malignancy with an internal organ origin. We conducted a retrospective study that included all cases of cutaneous metastases diagnosed in our hospital. A total of 25 patients were identified (14 females and 11 males). The average age of the patients included was 62.3. The most common primary cancer site was the lung for male patients, while for female patients it was the breast. In seven of our cases, cutaneous metastases were the first sign of an internal organ cancer. Common sites for cutaneous metastases in our study involved the anterior thoracic wall, the abdomen, and the scalp. Our study aims to highlight the importance of recognizing the histopathology of metastatic tumors and differentiating them from primary skin neoplasms. Immunohistochemistry is a mandatory tool for differential diagnosis in all cases, especially for patients who do not have a history of neoplasia.</description>
	<pubDate>2025-04-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 14: Cutaneous Metastases&amp;mdash;Histological Particularities of Multifaceted Entities</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/14">doi: 10.3390/dermatopathology12020014</a></p>
	<p>Authors:
		Andreea Cătălina Tinca
		Bianca Andreea Lazar
		Andreea Raluca Cozac-Szőke
		Georgian Nicolae Radu
		Simina Petra Simion
		Diana Maria Chiorean
		Irina Bianca Kosovski
		Adrian Horațiu Sabău
		Raluca Niculescu
		Iuliu Gabriel Cocuz
		Raluca-Diana Hagău
		Emoke Andrea Szasz
		Sabin Gligore Turdean
		Ovidiu Simion Cotoi
		</p>
	<p>Cutaneous metastases from internal organ cancers are diagnosed in approximately 0.2% of skin biopsies. This diagnosis can be the first sign of a previously undiagnosed malignancy with an internal organ origin. We conducted a retrospective study that included all cases of cutaneous metastases diagnosed in our hospital. A total of 25 patients were identified (14 females and 11 males). The average age of the patients included was 62.3. The most common primary cancer site was the lung for male patients, while for female patients it was the breast. In seven of our cases, cutaneous metastases were the first sign of an internal organ cancer. Common sites for cutaneous metastases in our study involved the anterior thoracic wall, the abdomen, and the scalp. Our study aims to highlight the importance of recognizing the histopathology of metastatic tumors and differentiating them from primary skin neoplasms. Immunohistochemistry is a mandatory tool for differential diagnosis in all cases, especially for patients who do not have a history of neoplasia.</p>
	]]></content:encoded>

	<dc:title>Cutaneous Metastases&amp;amp;mdash;Histological Particularities of Multifaceted Entities</dc:title>
			<dc:creator>Andreea Cătălina Tinca</dc:creator>
			<dc:creator>Bianca Andreea Lazar</dc:creator>
			<dc:creator>Andreea Raluca Cozac-Szőke</dc:creator>
			<dc:creator>Georgian Nicolae Radu</dc:creator>
			<dc:creator>Simina Petra Simion</dc:creator>
			<dc:creator>Diana Maria Chiorean</dc:creator>
			<dc:creator>Irina Bianca Kosovski</dc:creator>
			<dc:creator>Adrian Horațiu Sabău</dc:creator>
			<dc:creator>Raluca Niculescu</dc:creator>
			<dc:creator>Iuliu Gabriel Cocuz</dc:creator>
			<dc:creator>Raluca-Diana Hagău</dc:creator>
			<dc:creator>Emoke Andrea Szasz</dc:creator>
			<dc:creator>Sabin Gligore Turdean</dc:creator>
			<dc:creator>Ovidiu Simion Cotoi</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020014</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-04-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-04-25</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>14</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020014</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/13">

	<title>Dermatopathology, Vol. 12, Pages 13: A Scoping Review on Melasma Treatments and Their Histopathologic Correlates</title>
	<link>https://www.mdpi.com/2296-3529/12/2/13</link>
	<description>Melasma is an incredibly common dyschromic disorder, mostly impacting women with skin of color. There are three variants of melasma based on the depth of pathologic involvement: epidermal, mixed, and dermal. While there are many treatments for melasma, there is a paucity of research on melasma treatments and their dermatopathological correlates. A scoping review was conducted of all human trials on melasma with histopathologic analysis, including 37 trials in the final analysis. Most studies were conducted on women with a Fitzpatrick skin type of III or greater. Strong histologic evidence supports the utilization of retinols/retinoids for epidermal melasma and microneedling for dermal melasma. There is a paucity of trials conducted on melasma utilizing histologic correlates, and fewer still that are comprehensive to include analyses on quality of life.</description>
	<pubDate>2025-04-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 13: A Scoping Review on Melasma Treatments and Their Histopathologic Correlates</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/13">doi: 10.3390/dermatopathology12020013</a></p>
	<p>Authors:
		Aurore D. Zhang
		Michelle Lazar
		Emiliya Akhundova
		Candice E. Brem
		Eric J. Beltrami
		Neelam A. Vashi
		</p>
	<p>Melasma is an incredibly common dyschromic disorder, mostly impacting women with skin of color. There are three variants of melasma based on the depth of pathologic involvement: epidermal, mixed, and dermal. While there are many treatments for melasma, there is a paucity of research on melasma treatments and their dermatopathological correlates. A scoping review was conducted of all human trials on melasma with histopathologic analysis, including 37 trials in the final analysis. Most studies were conducted on women with a Fitzpatrick skin type of III or greater. Strong histologic evidence supports the utilization of retinols/retinoids for epidermal melasma and microneedling for dermal melasma. There is a paucity of trials conducted on melasma utilizing histologic correlates, and fewer still that are comprehensive to include analyses on quality of life.</p>
	]]></content:encoded>

	<dc:title>A Scoping Review on Melasma Treatments and Their Histopathologic Correlates</dc:title>
			<dc:creator>Aurore D. Zhang</dc:creator>
			<dc:creator>Michelle Lazar</dc:creator>
			<dc:creator>Emiliya Akhundova</dc:creator>
			<dc:creator>Candice E. Brem</dc:creator>
			<dc:creator>Eric J. Beltrami</dc:creator>
			<dc:creator>Neelam A. Vashi</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020013</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-04-11</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-04-11</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020013</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/12">

	<title>Dermatopathology, Vol. 12, Pages 12: Congenital Melanocytic Nevus with Neurocristic Cutaneous Hamartoma: A Case Report</title>
	<link>https://www.mdpi.com/2296-3529/12/2/12</link>
	<description>Congenital melanocytic nevi (CMN) are benign tumors present at birth or arising in the first few months of life. A small subset of these nevi present with mild atypical features and heterogeneous differentiation, including Schwannian differentiation. We present a case of a 3-week-old with a 7 cm red/purple scalp nodule consistent with CMN with mild atypical heterogeneous areas. On histology, there were dermal nests of spindle cells in a fibrillar matrix, with increased vessels and clusters of small round melanocytes interspersed between collagen bundles and around adnexal structures. The lesion also exhibited rare pagetoid ascent of melanocytes as single cells and nests. Overall, these features were consistent with a CMN with nodular proliferative neurocristic cutaneous hamartoma (NCH) with a component of a compound mild atypical melanocytic proliferation. Next generation sequencing (NGS) identified a novel SH2B1::BRAF fusion. This case highlights the diagnostic challenges of heterogeneous differentiation within CMN in young children.</description>
	<pubDate>2025-04-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 12: Congenital Melanocytic Nevus with Neurocristic Cutaneous Hamartoma: A Case Report</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/12">doi: 10.3390/dermatopathology12020012</a></p>
	<p>Authors:
		Dina El-Rayes
		Katlin Wilson
		Sheilagh Maguiness
		Daniel Miller
		Gerardo Cazzato
		Alessio Giubellino
		</p>
	<p>Congenital melanocytic nevi (CMN) are benign tumors present at birth or arising in the first few months of life. A small subset of these nevi present with mild atypical features and heterogeneous differentiation, including Schwannian differentiation. We present a case of a 3-week-old with a 7 cm red/purple scalp nodule consistent with CMN with mild atypical heterogeneous areas. On histology, there were dermal nests of spindle cells in a fibrillar matrix, with increased vessels and clusters of small round melanocytes interspersed between collagen bundles and around adnexal structures. The lesion also exhibited rare pagetoid ascent of melanocytes as single cells and nests. Overall, these features were consistent with a CMN with nodular proliferative neurocristic cutaneous hamartoma (NCH) with a component of a compound mild atypical melanocytic proliferation. Next generation sequencing (NGS) identified a novel SH2B1::BRAF fusion. This case highlights the diagnostic challenges of heterogeneous differentiation within CMN in young children.</p>
	]]></content:encoded>

	<dc:title>Congenital Melanocytic Nevus with Neurocristic Cutaneous Hamartoma: A Case Report</dc:title>
			<dc:creator>Dina El-Rayes</dc:creator>
			<dc:creator>Katlin Wilson</dc:creator>
			<dc:creator>Sheilagh Maguiness</dc:creator>
			<dc:creator>Daniel Miller</dc:creator>
			<dc:creator>Gerardo Cazzato</dc:creator>
			<dc:creator>Alessio Giubellino</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020012</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-04-10</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-04-10</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>12</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020012</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/11">

	<title>Dermatopathology, Vol. 12, Pages 11: Dermatomyositis-like Eruptions, Hydroxyurea-Associated Squamous Dysplasia, and Nonmelanoma Skin Cancer: A Case Report and Systematic Review</title>
	<link>https://www.mdpi.com/2296-3529/12/2/11</link>
	<description>Hydroxyurea (HU), a cornerstone treatment for myeloproliferative disorders, is associated with a wide range of cutaneous side effects, from xerosis and hyperpigmentation to more severe conditions like dermatomyositis-like eruptions (DM-LE) and nonmelanoma skin cancers (NMSC), particularly squamous cell carcinoma (SCC). In this review, we present a unique case of HU-induced DM-LE with histological evidence of keratinocyte dysplasia and p53 overexpression, followed by a systematic analysis of similar cases. Our findings reveal that the clinical presentation of DM-LE, while typically considered benign, shares clinical and histological features with hydroxyurea-associated squamous dysplasia (HUSD), a precancerous condition that may progress to SCC in chronically exposed patients. Key insights include the characteristic histopathological findings of DM-LE, the role of chronic HU therapy and UV-induced damage in promoting p53 overexpression, and the overlap between DM-LE and HUSD. Regular dermatologic monitoring, patient education on photoprotection, and the careful assessment of skin lesions in long-term HU users are essential for the early detection and prevention of malignancies. This review underscores the importance of distinguishing between DM-LE, HUSD, and SCC to optimize management and minimize risks associated with HU therapy.</description>
	<pubDate>2025-03-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 11: Dermatomyositis-like Eruptions, Hydroxyurea-Associated Squamous Dysplasia, and Nonmelanoma Skin Cancer: A Case Report and Systematic Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/11">doi: 10.3390/dermatopathology12020011</a></p>
	<p>Authors:
		Giorgia Di Marco
		Gianmarco Diego Bigotto
		Eleonora Cossar
		Nathalie Rizzo
		Stefania Guida
		Franco Rongioletti
		</p>
	<p>Hydroxyurea (HU), a cornerstone treatment for myeloproliferative disorders, is associated with a wide range of cutaneous side effects, from xerosis and hyperpigmentation to more severe conditions like dermatomyositis-like eruptions (DM-LE) and nonmelanoma skin cancers (NMSC), particularly squamous cell carcinoma (SCC). In this review, we present a unique case of HU-induced DM-LE with histological evidence of keratinocyte dysplasia and p53 overexpression, followed by a systematic analysis of similar cases. Our findings reveal that the clinical presentation of DM-LE, while typically considered benign, shares clinical and histological features with hydroxyurea-associated squamous dysplasia (HUSD), a precancerous condition that may progress to SCC in chronically exposed patients. Key insights include the characteristic histopathological findings of DM-LE, the role of chronic HU therapy and UV-induced damage in promoting p53 overexpression, and the overlap between DM-LE and HUSD. Regular dermatologic monitoring, patient education on photoprotection, and the careful assessment of skin lesions in long-term HU users are essential for the early detection and prevention of malignancies. This review underscores the importance of distinguishing between DM-LE, HUSD, and SCC to optimize management and minimize risks associated with HU therapy.</p>
	]]></content:encoded>

	<dc:title>Dermatomyositis-like Eruptions, Hydroxyurea-Associated Squamous Dysplasia, and Nonmelanoma Skin Cancer: A Case Report and Systematic Review</dc:title>
			<dc:creator>Giorgia Di Marco</dc:creator>
			<dc:creator>Gianmarco Diego Bigotto</dc:creator>
			<dc:creator>Eleonora Cossar</dc:creator>
			<dc:creator>Nathalie Rizzo</dc:creator>
			<dc:creator>Stefania Guida</dc:creator>
			<dc:creator>Franco Rongioletti</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020011</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-03-30</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-03-30</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020011</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/10">

	<title>Dermatopathology, Vol. 12, Pages 10: Uncommon Collision Tumors: Dermoscopic and Histopathological Features of Basal Cell Carcinoma Overlying Dermatofibroma</title>
	<link>https://www.mdpi.com/2296-3529/12/2/10</link>
	<description>Dermatofibromas (DFs) represent prevalent benign fibrohistiocytic tumors, typically manifesting as solitary lesions. In the majority of cases, the clinical presentation and dermoscopic and histopathological features of DFs adhere to a characteristic profile. However, DFs may exhibit atypical clinical presentations and, more commonly, histologic attributes, posing challenges in differential diagnosis. Both DFs and basal cell carcinomas (BCCs) are frequently encountered cutaneous lesions, each characterized by distinct clinical and dermoscopic features and microscopic morphology. The simultaneous occurrence of these two entities within the same lesion is rare. DFs have been documented to form collision tumors in conjunction with a spectrum of benign and malignant lesions, encompassing not only BCC but also balloon cell nevus, squamous cell carcinoma (SCC), and melanoma. Alterations in the epidermis overlaying a DF range from simple hyperplasia to the proliferation of basaloid cells. Accurate diagnosis, leading to the complete excision of the lesion, is contingent upon the recognition of dermoscopic criteria, precluding misinterpretation as a benign lesion. We present two cases of collision tumors comprising DF and BCC. This case report underscores the paramount importance of dermoscopy and adherence to dermoscopic criteria in the assessment of collision lesions and the diagnostic process related to cutaneous malignancies.</description>
	<pubDate>2025-03-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 10: Uncommon Collision Tumors: Dermoscopic and Histopathological Features of Basal Cell Carcinoma Overlying Dermatofibroma</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/10">doi: 10.3390/dermatopathology12020010</a></p>
	<p>Authors:
		Amal Makansi
		Charlotta Enerbäck
		Maria Madentzoglou
		Georgios Kravvas
		Sandra Jerkovic Gulin
		</p>
	<p>Dermatofibromas (DFs) represent prevalent benign fibrohistiocytic tumors, typically manifesting as solitary lesions. In the majority of cases, the clinical presentation and dermoscopic and histopathological features of DFs adhere to a characteristic profile. However, DFs may exhibit atypical clinical presentations and, more commonly, histologic attributes, posing challenges in differential diagnosis. Both DFs and basal cell carcinomas (BCCs) are frequently encountered cutaneous lesions, each characterized by distinct clinical and dermoscopic features and microscopic morphology. The simultaneous occurrence of these two entities within the same lesion is rare. DFs have been documented to form collision tumors in conjunction with a spectrum of benign and malignant lesions, encompassing not only BCC but also balloon cell nevus, squamous cell carcinoma (SCC), and melanoma. Alterations in the epidermis overlaying a DF range from simple hyperplasia to the proliferation of basaloid cells. Accurate diagnosis, leading to the complete excision of the lesion, is contingent upon the recognition of dermoscopic criteria, precluding misinterpretation as a benign lesion. We present two cases of collision tumors comprising DF and BCC. This case report underscores the paramount importance of dermoscopy and adherence to dermoscopic criteria in the assessment of collision lesions and the diagnostic process related to cutaneous malignancies.</p>
	]]></content:encoded>

	<dc:title>Uncommon Collision Tumors: Dermoscopic and Histopathological Features of Basal Cell Carcinoma Overlying Dermatofibroma</dc:title>
			<dc:creator>Amal Makansi</dc:creator>
			<dc:creator>Charlotta Enerbäck</dc:creator>
			<dc:creator>Maria Madentzoglou</dc:creator>
			<dc:creator>Georgios Kravvas</dc:creator>
			<dc:creator>Sandra Jerkovic Gulin</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020010</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-03-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-03-25</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020010</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/2/9">

	<title>Dermatopathology, Vol. 12, Pages 9: Postherpetic Pseudolymphomatous Angiosarcoma Concealed Within Milia en Plaque: Expanding the Spectrum of Wolf Isotopic Response with a Literature Review</title>
	<link>https://www.mdpi.com/2296-3529/12/2/9</link>
	<description>The Wolf isotopic response (WIR) refers to the development of cutaneous lesions in areas of previously healed but unrelated skin disease. While most are observed in healed herpes zoster, WIR has been reported in various other contexts. Affected areas are believed to exhibit immune dysregulation, lymphatic dysfunction, and altered neuromediator activity, increasing susceptibility to inflammatory, neoplastic, and infectious conditions. This phenomenon aligns with the broader concept of the &amp;amp;ldquo;immunocompromised district&amp;amp;rdquo;, which also encompasses the Koebner phenomenon and its reverse. Herein, we present the case of a 96-year-old woman who developed multiple cysts and comedones at the site of a resolved herpes zoster. Due to persistent and refractory inflammation, curettage was performed, and histopathological examination revealed angiosarcoma with a pseudolymphomatous reaction interspersed among the cysts. The coexistence of multiple types of WIR is rare but not unprecedented, highlighting the importance of recognizing the diverse pathologic conditions that can arise in such settings. In this review, we explore the historical evolution of terminology used to describe lesions in vulnerable skin areas and related phenomena. We also provide an updated overview of current pathogenic theories and present a comprehensive compilation of postherpetic reactions reported to date.</description>
	<pubDate>2025-03-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 9: Postherpetic Pseudolymphomatous Angiosarcoma Concealed Within Milia en Plaque: Expanding the Spectrum of Wolf Isotopic Response with a Literature Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/2/9">doi: 10.3390/dermatopathology12020009</a></p>
	<p>Authors:
		Marina Corral-Forteza
		Noelia Pérez-Muñoz
		Maria-Teresa Fernández-Figueras
		</p>
	<p>The Wolf isotopic response (WIR) refers to the development of cutaneous lesions in areas of previously healed but unrelated skin disease. While most are observed in healed herpes zoster, WIR has been reported in various other contexts. Affected areas are believed to exhibit immune dysregulation, lymphatic dysfunction, and altered neuromediator activity, increasing susceptibility to inflammatory, neoplastic, and infectious conditions. This phenomenon aligns with the broader concept of the &amp;amp;ldquo;immunocompromised district&amp;amp;rdquo;, which also encompasses the Koebner phenomenon and its reverse. Herein, we present the case of a 96-year-old woman who developed multiple cysts and comedones at the site of a resolved herpes zoster. Due to persistent and refractory inflammation, curettage was performed, and histopathological examination revealed angiosarcoma with a pseudolymphomatous reaction interspersed among the cysts. The coexistence of multiple types of WIR is rare but not unprecedented, highlighting the importance of recognizing the diverse pathologic conditions that can arise in such settings. In this review, we explore the historical evolution of terminology used to describe lesions in vulnerable skin areas and related phenomena. We also provide an updated overview of current pathogenic theories and present a comprehensive compilation of postherpetic reactions reported to date.</p>
	]]></content:encoded>

	<dc:title>Postherpetic Pseudolymphomatous Angiosarcoma Concealed Within Milia en Plaque: Expanding the Spectrum of Wolf Isotopic Response with a Literature Review</dc:title>
			<dc:creator>Marina Corral-Forteza</dc:creator>
			<dc:creator>Noelia Pérez-Muñoz</dc:creator>
			<dc:creator>Maria-Teresa Fernández-Figueras</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12020009</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-03-22</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-03-22</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12020009</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/8">

	<title>Dermatopathology, Vol. 12, Pages 8: Hypertrophic Lichen Planus and Hypertrophic Skin Lesions Associated with Histological Lichenoid Infiltrate: A Case Report and Literature Review</title>
	<link>https://www.mdpi.com/2296-3529/12/1/8</link>
	<description>Hypertrophic lichen planus (HLP) is a chronic inflammatory skin condition defined by verrucous, pruritic, papules and plaques usually affecting the lower limbs. The diagnosis of HLP is primarily clinical. However, due to its feasible generalized presentation and similarities with other hypertrophic cutaneous disorders, histological evaluation is often necessary. Many dermatological conditions that present with a hypertrophic clinical appearance can arise from a histological lichenoid infiltrate (HCLI). Hence, we provide an overview of the clinical, histopathological, and prognostic features of selected HCLI, including HLP, hypertrophic lichenoid dermatitis, hypertrophic lichen sclerosus (HLS), lichen simplex chronicus (LSC), squamous cell carcinoma (SCC), keratoacanthoma (KA), pseudoepitheliomatous hyperplasia (PEH), viral warts, and lupus erythematosus/lichen planus (LE/LP) overlap. Choosing the appropriate procedure and the anatomical site for an incisional biopsy requires thoughtful consideration to ensure sufficient depth and improve diagnostic accuracy by identifying the histological features specific to each hypertrophic condition.</description>
	<pubDate>2025-02-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 8: Hypertrophic Lichen Planus and Hypertrophic Skin Lesions Associated with Histological Lichenoid Infiltrate: A Case Report and Literature Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/8">doi: 10.3390/dermatopathology12010008</a></p>
	<p>Authors:
		Biagio Scotti
		Cosimo Misciali
		Federico Bardazzi
		Bianca Maria Piraccini
		Michelangelo La Placa
		</p>
	<p>Hypertrophic lichen planus (HLP) is a chronic inflammatory skin condition defined by verrucous, pruritic, papules and plaques usually affecting the lower limbs. The diagnosis of HLP is primarily clinical. However, due to its feasible generalized presentation and similarities with other hypertrophic cutaneous disorders, histological evaluation is often necessary. Many dermatological conditions that present with a hypertrophic clinical appearance can arise from a histological lichenoid infiltrate (HCLI). Hence, we provide an overview of the clinical, histopathological, and prognostic features of selected HCLI, including HLP, hypertrophic lichenoid dermatitis, hypertrophic lichen sclerosus (HLS), lichen simplex chronicus (LSC), squamous cell carcinoma (SCC), keratoacanthoma (KA), pseudoepitheliomatous hyperplasia (PEH), viral warts, and lupus erythematosus/lichen planus (LE/LP) overlap. Choosing the appropriate procedure and the anatomical site for an incisional biopsy requires thoughtful consideration to ensure sufficient depth and improve diagnostic accuracy by identifying the histological features specific to each hypertrophic condition.</p>
	]]></content:encoded>

	<dc:title>Hypertrophic Lichen Planus and Hypertrophic Skin Lesions Associated with Histological Lichenoid Infiltrate: A Case Report and Literature Review</dc:title>
			<dc:creator>Biagio Scotti</dc:creator>
			<dc:creator>Cosimo Misciali</dc:creator>
			<dc:creator>Federico Bardazzi</dc:creator>
			<dc:creator>Bianca Maria Piraccini</dc:creator>
			<dc:creator>Michelangelo La Placa</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010008</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-02-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-02-25</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010008</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/7">

	<title>Dermatopathology, Vol. 12, Pages 7: Pediatric Kikuchi&amp;ndash;Fujimoto Disease: Case Report and Review of Cutaneous and Histopathologic Features in Childhood</title>
	<link>https://www.mdpi.com/2296-3529/12/1/7</link>
	<description>Kikuchi&amp;amp;ndash;Fujimoto disease (KFD) is a rare condition characterized by necrotizing lymphadenitis and fever, often associated with immune dysregulation. Histologically, it features necrotic foci with abundant histiocytes and plasmacytoid dendritic cells but notably lacks neutrophils and eosinophils. Recent evidence reveals a notable prevalence among pediatric patients, who may exhibit distinct features compared to adults. We reported the case of an 11-year-old girl presenting with persistent fever, cervical adenopathy, and a malar rash, leading to a diagnosis of KFD following lymph node biopsy, which revealed non-suppurative necrosis and histiocytic infiltration. Empirical treatment with antivirals and antibiotics was ineffective, but corticosteroid therapy achieved symptom remission. A literature review identified 48 relevant studies involving 386 pediatric cases, with histopathological findings consistent with classical descriptions of KFD. Cutaneous involvement was reported in 11.14% of cases, ranging from maculopapular rashes to lupus-like eruptions. Notable complications included the development of systemic lupus erythematous, Sj&amp;amp;ouml;gren syndrome, and rare instances of hemophagocytic syndrome or central nervous system involvement. Kikuchi&amp;amp;ndash;Fujimoto disease should be considered in the differential diagnosis of pediatric patients presenting with fever and lymphadenopathy, taking into account a higher frequency of cutaneous manifestations in pediatric cases. A skin biopsy may be helpful in diagnosing KFD and provide valuable information regarding the potential risk of developing systemic lupus erythematosus in the future.</description>
	<pubDate>2025-02-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 7: Pediatric Kikuchi&amp;ndash;Fujimoto Disease: Case Report and Review of Cutaneous and Histopathologic Features in Childhood</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/7">doi: 10.3390/dermatopathology12010007</a></p>
	<p>Authors:
		Alberto Soto-Moreno
		Francisco Vílchez-Márquez
		María Narváez-Simón
		Julia Castro-Martín
		Francisco Manuel Ramos-Pleguezuelos
		Agustín Soto-Díaz
		Jesús Tercedor-Sánchez
		Salvador Arias-Santiago
		</p>
	<p>Kikuchi&amp;amp;ndash;Fujimoto disease (KFD) is a rare condition characterized by necrotizing lymphadenitis and fever, often associated with immune dysregulation. Histologically, it features necrotic foci with abundant histiocytes and plasmacytoid dendritic cells but notably lacks neutrophils and eosinophils. Recent evidence reveals a notable prevalence among pediatric patients, who may exhibit distinct features compared to adults. We reported the case of an 11-year-old girl presenting with persistent fever, cervical adenopathy, and a malar rash, leading to a diagnosis of KFD following lymph node biopsy, which revealed non-suppurative necrosis and histiocytic infiltration. Empirical treatment with antivirals and antibiotics was ineffective, but corticosteroid therapy achieved symptom remission. A literature review identified 48 relevant studies involving 386 pediatric cases, with histopathological findings consistent with classical descriptions of KFD. Cutaneous involvement was reported in 11.14% of cases, ranging from maculopapular rashes to lupus-like eruptions. Notable complications included the development of systemic lupus erythematous, Sj&amp;amp;ouml;gren syndrome, and rare instances of hemophagocytic syndrome or central nervous system involvement. Kikuchi&amp;amp;ndash;Fujimoto disease should be considered in the differential diagnosis of pediatric patients presenting with fever and lymphadenopathy, taking into account a higher frequency of cutaneous manifestations in pediatric cases. A skin biopsy may be helpful in diagnosing KFD and provide valuable information regarding the potential risk of developing systemic lupus erythematosus in the future.</p>
	]]></content:encoded>

	<dc:title>Pediatric Kikuchi&amp;amp;ndash;Fujimoto Disease: Case Report and Review of Cutaneous and Histopathologic Features in Childhood</dc:title>
			<dc:creator>Alberto Soto-Moreno</dc:creator>
			<dc:creator>Francisco Vílchez-Márquez</dc:creator>
			<dc:creator>María Narváez-Simón</dc:creator>
			<dc:creator>Julia Castro-Martín</dc:creator>
			<dc:creator>Francisco Manuel Ramos-Pleguezuelos</dc:creator>
			<dc:creator>Agustín Soto-Díaz</dc:creator>
			<dc:creator>Jesús Tercedor-Sánchez</dc:creator>
			<dc:creator>Salvador Arias-Santiago</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010007</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-02-13</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-02-13</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010007</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/6">

	<title>Dermatopathology, Vol. 12, Pages 6: Histologic and Immunohistochemical Patterns in Lymphomatoid Papulosis: A Systematic Review of Published Cases</title>
	<link>https://www.mdpi.com/2296-3529/12/1/6</link>
	<description>Based on histologic and genetic patterns, the current World Health Organization (WHO) classification distinguishes six subtypes of lymphomatoid papulosis (Lyp). The aim of our article was to analyze the frequency of histologic and immunohistochemical features of different Lyp subtypes reported in the literature. We used PubMed advanced search builder to systematically review and evaluate English and German literature of Lyp from 1968 to April 2022. We considered only papers in which histopathologic features were mentioned in detail. We identified 48 publications with a total of 518 cases. The diagnoses were based on the diagnostic criteria at the time of publication. In Lyp A and Lyp B a CD8+ phenotype was more often reported than expected (53% and 52%, respectively). A double positive phenotype (CD4+/CD8+) was found in 28% of Lyp E and a double negative (CD4-/CD8-) in 50% of Lyp with 6p25.3 rearrangement. High rates of folliculo- and syringotropism were reported in both Lyp A and B. Surprisingly, strong epidermotropism occurred in 20/38 (53%) cases reported as Lyp B and in 43/64 (67%) of Lyp D cases. The predominating phenotype in Lyp D was CD8+, while TIA-1/granzymeB/perforin expression was reported in 37/46 (80%), and CD56 was expressed in 13/47 (28%) of the investigated cases. The limitation of the data is due to the retrospective approach with diagnostic criteria changing over time and on a case selection in some publications. However, the data indicate that the Lyp subtypes overlap more than assumed. They also show that a prospective study is needed to obtain valid data on the frequency distribution of certain histopathologic criteria.</description>
	<pubDate>2025-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 6: Histologic and Immunohistochemical Patterns in Lymphomatoid Papulosis: A Systematic Review of Published Cases</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/6">doi: 10.3390/dermatopathology12010006</a></p>
	<p>Authors:
		Torben Fricke
		Werner Kempf
		Michael P. Schön
		Christina Mitteldorf
		</p>
	<p>Based on histologic and genetic patterns, the current World Health Organization (WHO) classification distinguishes six subtypes of lymphomatoid papulosis (Lyp). The aim of our article was to analyze the frequency of histologic and immunohistochemical features of different Lyp subtypes reported in the literature. We used PubMed advanced search builder to systematically review and evaluate English and German literature of Lyp from 1968 to April 2022. We considered only papers in which histopathologic features were mentioned in detail. We identified 48 publications with a total of 518 cases. The diagnoses were based on the diagnostic criteria at the time of publication. In Lyp A and Lyp B a CD8+ phenotype was more often reported than expected (53% and 52%, respectively). A double positive phenotype (CD4+/CD8+) was found in 28% of Lyp E and a double negative (CD4-/CD8-) in 50% of Lyp with 6p25.3 rearrangement. High rates of folliculo- and syringotropism were reported in both Lyp A and B. Surprisingly, strong epidermotropism occurred in 20/38 (53%) cases reported as Lyp B and in 43/64 (67%) of Lyp D cases. The predominating phenotype in Lyp D was CD8+, while TIA-1/granzymeB/perforin expression was reported in 37/46 (80%), and CD56 was expressed in 13/47 (28%) of the investigated cases. The limitation of the data is due to the retrospective approach with diagnostic criteria changing over time and on a case selection in some publications. However, the data indicate that the Lyp subtypes overlap more than assumed. They also show that a prospective study is needed to obtain valid data on the frequency distribution of certain histopathologic criteria.</p>
	]]></content:encoded>

	<dc:title>Histologic and Immunohistochemical Patterns in Lymphomatoid Papulosis: A Systematic Review of Published Cases</dc:title>
			<dc:creator>Torben Fricke</dc:creator>
			<dc:creator>Werner Kempf</dc:creator>
			<dc:creator>Michael P. Schön</dc:creator>
			<dc:creator>Christina Mitteldorf</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010006</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-02-12</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-02-12</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010006</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/5">

	<title>Dermatopathology, Vol. 12, Pages 5: Acetone&amp;ndash;Ether&amp;ndash;Water Mouse Model of Persistent Itch Fully Resolves Without Latent Pruritic or Cross-Modality Priming</title>
	<link>https://www.mdpi.com/2296-3529/12/1/5</link>
	<description>Hyperalgesic priming is a model of the transition from acute to chronic pain. Whether a similar mechanism exists for &amp;amp;ldquo;pruritic priming&amp;amp;rdquo; of itch is unknown. Here, we tested the hypothesis that itchy skin in a commonly used mouse model of dry skin pruritus develops latent sensitization after resolution. Acetone&amp;amp;ndash;ether&amp;amp;ndash;water (AEW) treatment induced a dry and itchy skin condition in the mouse cheek that elicited site-directed scratching behavior. After cessation of treatment and the complete resolution of AEW-induced scratching, histaminergic and non-histaminergic pruritogens were administered to the cheek to test for altered site-directed scratching and wiping behavior. Each pruritogen was also tested following the resolution of carrageenan-induced nociceptor hypersensitivity to test for cross-modality priming. Peak AEW-induced scratching occurred 24 h after the final day of treatment, and 5 days were required for scratching levels to return to baseline. Likewise, epidermal thickening was the greatest on the final treatment day and completely returned to baseline after 5 days. After the resolution of itchy cheek skin, acute histamine- and non-histamine-evoked scratching and wiping behaviors were unchanged, nor were scratching and wiping behaviors to acute pruritogens altered after the resolution of carrageenan-induced hypersensitivity. The results indicate that persistent itch due to dry skin likely resolves completely, without producing a latent primed response to subsequent pruritic stimuli. We conclude that the mechanisms regulating hyperalgesic priming are likely distinct from pruritic signaling in the dry and itchy skin model.</description>
	<pubDate>2025-02-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 5: Acetone&amp;ndash;Ether&amp;ndash;Water Mouse Model of Persistent Itch Fully Resolves Without Latent Pruritic or Cross-Modality Priming</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/5">doi: 10.3390/dermatopathology12010005</a></p>
	<p>Authors:
		Zachary K. Ford
		Adam J. Kirry
		Steve Davidson
		</p>
	<p>Hyperalgesic priming is a model of the transition from acute to chronic pain. Whether a similar mechanism exists for &amp;amp;ldquo;pruritic priming&amp;amp;rdquo; of itch is unknown. Here, we tested the hypothesis that itchy skin in a commonly used mouse model of dry skin pruritus develops latent sensitization after resolution. Acetone&amp;amp;ndash;ether&amp;amp;ndash;water (AEW) treatment induced a dry and itchy skin condition in the mouse cheek that elicited site-directed scratching behavior. After cessation of treatment and the complete resolution of AEW-induced scratching, histaminergic and non-histaminergic pruritogens were administered to the cheek to test for altered site-directed scratching and wiping behavior. Each pruritogen was also tested following the resolution of carrageenan-induced nociceptor hypersensitivity to test for cross-modality priming. Peak AEW-induced scratching occurred 24 h after the final day of treatment, and 5 days were required for scratching levels to return to baseline. Likewise, epidermal thickening was the greatest on the final treatment day and completely returned to baseline after 5 days. After the resolution of itchy cheek skin, acute histamine- and non-histamine-evoked scratching and wiping behaviors were unchanged, nor were scratching and wiping behaviors to acute pruritogens altered after the resolution of carrageenan-induced hypersensitivity. The results indicate that persistent itch due to dry skin likely resolves completely, without producing a latent primed response to subsequent pruritic stimuli. We conclude that the mechanisms regulating hyperalgesic priming are likely distinct from pruritic signaling in the dry and itchy skin model.</p>
	]]></content:encoded>

	<dc:title>Acetone&amp;amp;ndash;Ether&amp;amp;ndash;Water Mouse Model of Persistent Itch Fully Resolves Without Latent Pruritic or Cross-Modality Priming</dc:title>
			<dc:creator>Zachary K. Ford</dc:creator>
			<dc:creator>Adam J. Kirry</dc:creator>
			<dc:creator>Steve Davidson</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010005</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-02-11</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-02-11</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010005</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/4">

	<title>Dermatopathology, Vol. 12, Pages 4: Asteroid Shower: Cutaneous Silica Granuloma with Asteroid Bodies</title>
	<link>https://www.mdpi.com/2296-3529/12/1/4</link>
	<description>Cutaneous silica granulomas are a form of foreign-body granulomatous reactions. They are characterized histopathologically by sarcoidal granulomas in association with silica crystals. Asteroid bodies, a classical histopathological feature of sarcoidosis, have not previously been reported in association with silica granulomas. Herein, we present the case of an 83-year-old man with an asymptomatic papule on the vertex scalp. Histopathology revealed a dermal granulomatous reaction to silica crystals. Asteroid bodies were observed in the cytoplasm of multinucleated giant cells. In the absence of systemic symptoms or laboratory findings suggestive of sarcoidosis, a final diagnosis of silica granuloma with asteroid bodies was made. While they have been observed in several other granulomatous reactions, the present case represents a novel association of asteroid bodies with silica granulomas.</description>
	<pubDate>2025-01-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 4: Asteroid Shower: Cutaneous Silica Granuloma with Asteroid Bodies</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/4">doi: 10.3390/dermatopathology12010004</a></p>
	<p>Authors:
		Fadwa Ahmed
		Christopher DiMarco
		</p>
	<p>Cutaneous silica granulomas are a form of foreign-body granulomatous reactions. They are characterized histopathologically by sarcoidal granulomas in association with silica crystals. Asteroid bodies, a classical histopathological feature of sarcoidosis, have not previously been reported in association with silica granulomas. Herein, we present the case of an 83-year-old man with an asymptomatic papule on the vertex scalp. Histopathology revealed a dermal granulomatous reaction to silica crystals. Asteroid bodies were observed in the cytoplasm of multinucleated giant cells. In the absence of systemic symptoms or laboratory findings suggestive of sarcoidosis, a final diagnosis of silica granuloma with asteroid bodies was made. While they have been observed in several other granulomatous reactions, the present case represents a novel association of asteroid bodies with silica granulomas.</p>
	]]></content:encoded>

	<dc:title>Asteroid Shower: Cutaneous Silica Granuloma with Asteroid Bodies</dc:title>
			<dc:creator>Fadwa Ahmed</dc:creator>
			<dc:creator>Christopher DiMarco</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010004</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-01-31</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-01-31</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010004</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/3">

	<title>Dermatopathology, Vol. 12, Pages 3: Dysplastic Nevi and Superficial Borderline Atypical Melanocytic Lesions: Description of an Algorithmic Clinico-Pathological Classification</title>
	<link>https://www.mdpi.com/2296-3529/12/1/3</link>
	<description>The diagnosis, interpretation, and classification of melanocytic tumors is a very complex topic in the pathology and dermatopathology field that lacks standardization and is still subject to discordance and debate. Here, we review the definitions of dysplastic nevus and superficial atypical melanocytic proliferations and provide an overview of some areas still subject to debate and some attempts of standardization. Furthermore, we describe an algorithmic classification, and provide some examples of clinico-pathological correlation. This step-by-step algorithm has an educational purpose and may automatize the work of dermatopathologists. We hope that through further molecular studies, this fine-grained scheme will prove to be related to the biological behavior of these atypical melanocytic lesions.</description>
	<pubDate>2025-01-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 3: Dysplastic Nevi and Superficial Borderline Atypical Melanocytic Lesions: Description of an Algorithmic Clinico-Pathological Classification</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/3">doi: 10.3390/dermatopathology12010003</a></p>
	<p>Authors:
		Sébastien Menzinger
		Rastine Merat
		Gürkan Kaya
		</p>
	<p>The diagnosis, interpretation, and classification of melanocytic tumors is a very complex topic in the pathology and dermatopathology field that lacks standardization and is still subject to discordance and debate. Here, we review the definitions of dysplastic nevus and superficial atypical melanocytic proliferations and provide an overview of some areas still subject to debate and some attempts of standardization. Furthermore, we describe an algorithmic classification, and provide some examples of clinico-pathological correlation. This step-by-step algorithm has an educational purpose and may automatize the work of dermatopathologists. We hope that through further molecular studies, this fine-grained scheme will prove to be related to the biological behavior of these atypical melanocytic lesions.</p>
	]]></content:encoded>

	<dc:title>Dysplastic Nevi and Superficial Borderline Atypical Melanocytic Lesions: Description of an Algorithmic Clinico-Pathological Classification</dc:title>
			<dc:creator>Sébastien Menzinger</dc:creator>
			<dc:creator>Rastine Merat</dc:creator>
			<dc:creator>Gürkan Kaya</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010003</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-01-21</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-01-21</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010003</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/2">

	<title>Dermatopathology, Vol. 12, Pages 2: Violaceous Nodules on the Left Forearm of an Immunosuppressed Patient Following Heart Transplantation for Cardiac Amyloidosis</title>
	<link>https://www.mdpi.com/2296-3529/12/1/2</link>
	<description>We present the case of a 60-year-old immunocompromised man who presented with two pruritic pink&amp;amp;ndash;red indurated nodules with overlying scale and focal areas of ulceration on his left dorsal and left medial forearm, which evolved over a 2-month period. The pathology showed numerous fungal hyphae present that were pauci-septate with various branched angles and variable hyphal thickness. Fungal cultures grew Rhizopus species and a universal fungal PCR detected the Rhizopus oryzae complex. Based on the clinicopathologic correlation, the diagnosis of cutaneous mucormycosis was made. Cutaneous mucormycosis is an aggressive fungal infection of the Mucorales family occurring after the inoculation of fungal spores in disrupted skin. It usually presents as a necrotic eschar but can also present as cellulitis that evolves into a necrotic ulcer. A prompt diagnosis is critical for the effective management of cutaneous mucormycosis. The treatment includes an immediate systemic treatment with amphotericin B and a surgical debridement of the necrotic regions. Given the wide range of presenting symptoms, clinical suspicion for this emergent condition must remain high in immunocompromised and diabetic patients.</description>
	<pubDate>2025-01-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 2: Violaceous Nodules on the Left Forearm of an Immunosuppressed Patient Following Heart Transplantation for Cardiac Amyloidosis</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/2">doi: 10.3390/dermatopathology12010002</a></p>
	<p>Authors:
		Zachary Corey
		Lydia A. Luu
		Sabrina Newman
		Shyam S. Raghavan
		</p>
	<p>We present the case of a 60-year-old immunocompromised man who presented with two pruritic pink&amp;amp;ndash;red indurated nodules with overlying scale and focal areas of ulceration on his left dorsal and left medial forearm, which evolved over a 2-month period. The pathology showed numerous fungal hyphae present that were pauci-septate with various branched angles and variable hyphal thickness. Fungal cultures grew Rhizopus species and a universal fungal PCR detected the Rhizopus oryzae complex. Based on the clinicopathologic correlation, the diagnosis of cutaneous mucormycosis was made. Cutaneous mucormycosis is an aggressive fungal infection of the Mucorales family occurring after the inoculation of fungal spores in disrupted skin. It usually presents as a necrotic eschar but can also present as cellulitis that evolves into a necrotic ulcer. A prompt diagnosis is critical for the effective management of cutaneous mucormycosis. The treatment includes an immediate systemic treatment with amphotericin B and a surgical debridement of the necrotic regions. Given the wide range of presenting symptoms, clinical suspicion for this emergent condition must remain high in immunocompromised and diabetic patients.</p>
	]]></content:encoded>

	<dc:title>Violaceous Nodules on the Left Forearm of an Immunosuppressed Patient Following Heart Transplantation for Cardiac Amyloidosis</dc:title>
			<dc:creator>Zachary Corey</dc:creator>
			<dc:creator>Lydia A. Luu</dc:creator>
			<dc:creator>Sabrina Newman</dc:creator>
			<dc:creator>Shyam S. Raghavan</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010002</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-01-16</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-01-16</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Clinicopathological Challenge</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010002</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/12/1/1">

	<title>Dermatopathology, Vol. 12, Pages 1: Squamomelanocytic Tumor, An Entity Still Shrouded in Mystery: Case Report and Literature Review</title>
	<link>https://www.mdpi.com/2296-3529/12/1/1</link>
	<description>Cutaneous squamomelanocytic tumor (SMT) is a very rare cutaneous malignancy, composed of a dual phenotypic population of both malignant melanocytes and keratinocytes, intimately intermingled together. Herein, we report a new case of a SMT occurring in an 82-year-old man, located on the scalp. Histopathology revealed a mixed population consisting of squamous cell carcinoma and melanoma within the same lesion, also confirmed using immunohistochemical staining for high molecular-weight cytokeratins (HMWCKs) and Melan-A. Moreover, to the best of our knowledge, for the first time, we tested SMT for the preferentially expressed antigen in melanoma (PRAME), which revealed a strong and diffuse positivity in the melanocytic component. These tumors need to be distinguished by more frequent collision tumors and colonization. Furthermore, we provide a comprehensive review of the literature, focusing on clinical and histopathological aspects, biological behavior and still-debated, but fascinating histogenesis of this elusive entity.</description>
	<pubDate>2025-01-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 12, Pages 1: Squamomelanocytic Tumor, An Entity Still Shrouded in Mystery: Case Report and Literature Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/12/1/1">doi: 10.3390/dermatopathology12010001</a></p>
	<p>Authors:
		Joana Sorino
		Mario Della Mura
		Anna Colagrande
		Cecilia Salzillo
		Giuseppe Ingravallo
		Gerardo Cazzato
		</p>
	<p>Cutaneous squamomelanocytic tumor (SMT) is a very rare cutaneous malignancy, composed of a dual phenotypic population of both malignant melanocytes and keratinocytes, intimately intermingled together. Herein, we report a new case of a SMT occurring in an 82-year-old man, located on the scalp. Histopathology revealed a mixed population consisting of squamous cell carcinoma and melanoma within the same lesion, also confirmed using immunohistochemical staining for high molecular-weight cytokeratins (HMWCKs) and Melan-A. Moreover, to the best of our knowledge, for the first time, we tested SMT for the preferentially expressed antigen in melanoma (PRAME), which revealed a strong and diffuse positivity in the melanocytic component. These tumors need to be distinguished by more frequent collision tumors and colonization. Furthermore, we provide a comprehensive review of the literature, focusing on clinical and histopathological aspects, biological behavior and still-debated, but fascinating histogenesis of this elusive entity.</p>
	]]></content:encoded>

	<dc:title>Squamomelanocytic Tumor, An Entity Still Shrouded in Mystery: Case Report and Literature Review</dc:title>
			<dc:creator>Joana Sorino</dc:creator>
			<dc:creator>Mario Della Mura</dc:creator>
			<dc:creator>Anna Colagrande</dc:creator>
			<dc:creator>Cecilia Salzillo</dc:creator>
			<dc:creator>Giuseppe Ingravallo</dc:creator>
			<dc:creator>Gerardo Cazzato</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology12010001</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2025-01-13</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2025-01-13</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/dermatopathology12010001</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/12/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/41">

	<title>Dermatopathology, Vol. 11, Pages 377-382: Potential Pitfalls of IgG4 Immunohistochemical Staining on Lesional Tissue in Cutaneous Acantholytic Disorders</title>
	<link>https://www.mdpi.com/2296-3529/11/4/41</link>
	<description>The diagnostic utility of immunohistochemistry on paraffin-embedded sections in bullous disorders is useful when frozen tissue is not available. In pemphigus vulgaris and pemphigus foliaceus, an intercellular lace-like staining pattern of IgG4 on lesional tissue by immunohistochemistry has been described, with a comparable sensitivity and specificity to direct immunofluorescence on perilesional tissue. This study aimed to evaluate the staining pattern of IgG4 in non-immunobullous disorders to highlight the potential pitfalls when using this stain. In this study, we conducted a retrospective review of our institution&amp;amp;rsquo;s database of non-immunobullous disorders where immunohistochemistry of IgG4 was performed to rule out pemphigus. We identified 27 cases where IgG4 immunohistochemistry was performed and observed intercellular IgG4 staining in some cases of Grover disease, bullous impetigo, irritated dermal hypersensitivity reaction, acantholytic actinic keratosis, and graft versus host disease. Our results indicate that the interpretation of IgG4 staining by immunohistochemistry in cutaneous acantholytic disorders should be approached with caution. Confirmation on cryosections with direct immunofluorescence study results is important in these settings.</description>
	<pubDate>2024-12-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 377-382: Potential Pitfalls of IgG4 Immunohistochemical Staining on Lesional Tissue in Cutaneous Acantholytic Disorders</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/41">doi: 10.3390/dermatopathology11040041</a></p>
	<p>Authors:
		Carla Stephan
		Linglei Ma
		</p>
	<p>The diagnostic utility of immunohistochemistry on paraffin-embedded sections in bullous disorders is useful when frozen tissue is not available. In pemphigus vulgaris and pemphigus foliaceus, an intercellular lace-like staining pattern of IgG4 on lesional tissue by immunohistochemistry has been described, with a comparable sensitivity and specificity to direct immunofluorescence on perilesional tissue. This study aimed to evaluate the staining pattern of IgG4 in non-immunobullous disorders to highlight the potential pitfalls when using this stain. In this study, we conducted a retrospective review of our institution&amp;amp;rsquo;s database of non-immunobullous disorders where immunohistochemistry of IgG4 was performed to rule out pemphigus. We identified 27 cases where IgG4 immunohistochemistry was performed and observed intercellular IgG4 staining in some cases of Grover disease, bullous impetigo, irritated dermal hypersensitivity reaction, acantholytic actinic keratosis, and graft versus host disease. Our results indicate that the interpretation of IgG4 staining by immunohistochemistry in cutaneous acantholytic disorders should be approached with caution. Confirmation on cryosections with direct immunofluorescence study results is important in these settings.</p>
	]]></content:encoded>

	<dc:title>Potential Pitfalls of IgG4 Immunohistochemical Staining on Lesional Tissue in Cutaneous Acantholytic Disorders</dc:title>
			<dc:creator>Carla Stephan</dc:creator>
			<dc:creator>Linglei Ma</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040041</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-12-19</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-12-19</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>377</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040041</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/41</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/40">

	<title>Dermatopathology, Vol. 11, Pages 374-376: New Insights in Paediatric Dermatopathology&amp;mdash;2nd Edition</title>
	<link>https://www.mdpi.com/2296-3529/11/4/40</link>
	<description>Paediatric dermatology is still an expanding subspeciality, which is well illustrated by the growing number of books and articles that have been published on this subject in recent years [...]</description>
	<pubDate>2024-12-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 374-376: New Insights in Paediatric Dermatopathology&amp;mdash;2nd Edition</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/40">doi: 10.3390/dermatopathology11040040</a></p>
	<p>Authors:
		Sylvie Fraitag
		</p>
	<p>Paediatric dermatology is still an expanding subspeciality, which is well illustrated by the growing number of books and articles that have been published on this subject in recent years [...]</p>
	]]></content:encoded>

	<dc:title>New Insights in Paediatric Dermatopathology&amp;amp;mdash;2nd Edition</dc:title>
			<dc:creator>Sylvie Fraitag</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040040</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-12-17</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-12-17</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>374</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040040</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/40</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/39">

	<title>Dermatopathology, Vol. 11, Pages 364-373: PRAME Staining of Adnexal Lesions and Common Skin Cancer Types: Biomarker with Potential Diagnostic Utility</title>
	<link>https://www.mdpi.com/2296-3529/11/4/39</link>
	<description>PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen first identified in tumor-reactive T-cell clones derived from a patient with metastatic melanoma. Immunohistochemistry (IHC) for PRAME is useful for diagnostic purposes to support a suspected diagnosis of melanoma. Anecdotally, PRAME has been observed to stain sebaceous units in glands in background skin. We examined the expression of PRAME in adnexal lesions and common skin cancers to determine whether it is of potential diagnostic utility in supporting the differentiation between sebaceous and non-sebaceous lesions. IRB approval from Mount Sinai Medical Center (MSMC) was obtained. This is a single-center retrospective cohort analysis over a ten-year period (1 January 2012, and 31 December 2023). We used the pathological database of skin lesions, including sebaceous, sweat gland, and follicular lesions, in addition to basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), from 81 patients who underwent shave/punch biopsies or surgical excisions. We evaluated the IHC staining percentage positivity and intensity for PRAME. Staining intensity was subcategorized into negative, weak, moderate, and strong, whereas expression percentage positivity was subcategorized into 0%, 1&amp;amp;ndash;25%, 26&amp;amp;ndash;50%, 51&amp;amp;ndash;75%, and 76&amp;amp;ndash;100%. Most sebaceous versus non-sebaceous lesions exhibited cytoplasmic staining of moderate to strong intensity in &amp;amp;gt;75% of cells. PRAME has a sensitivity and specificity of 100.0% and 86.7%, respectively, to support distinguishing between sebaceous and non-sebaceous adnexal lesions (regardless of whether they are benign or malignant). BCCs and SCCs showed weak to moderate nuclear staining for PRAME in &amp;amp;gt;75% of cells. None of the 13 lesions of hair follicle origin showed any staining. A total of 26 of the 32 lesions of sweat gland origin were negative while 6 (18.75%) showed positive staining. In conclusion, we confirm the potential utility of PRAME for supporting the distinction between sebaceous and non-sebaceous adnexal lesions on one hand, and on the other, distinguishing BCC and SCC that may show nuclear staining from sebaceous carcinoma that shows cytoplasmic staining.</description>
	<pubDate>2024-12-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 364-373: PRAME Staining of Adnexal Lesions and Common Skin Cancer Types: Biomarker with Potential Diagnostic Utility</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/39">doi: 10.3390/dermatopathology11040039</a></p>
	<p>Authors:
		Hisham F. Bahmad
		John Alexis
		</p>
	<p>PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen first identified in tumor-reactive T-cell clones derived from a patient with metastatic melanoma. Immunohistochemistry (IHC) for PRAME is useful for diagnostic purposes to support a suspected diagnosis of melanoma. Anecdotally, PRAME has been observed to stain sebaceous units in glands in background skin. We examined the expression of PRAME in adnexal lesions and common skin cancers to determine whether it is of potential diagnostic utility in supporting the differentiation between sebaceous and non-sebaceous lesions. IRB approval from Mount Sinai Medical Center (MSMC) was obtained. This is a single-center retrospective cohort analysis over a ten-year period (1 January 2012, and 31 December 2023). We used the pathological database of skin lesions, including sebaceous, sweat gland, and follicular lesions, in addition to basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), from 81 patients who underwent shave/punch biopsies or surgical excisions. We evaluated the IHC staining percentage positivity and intensity for PRAME. Staining intensity was subcategorized into negative, weak, moderate, and strong, whereas expression percentage positivity was subcategorized into 0%, 1&amp;amp;ndash;25%, 26&amp;amp;ndash;50%, 51&amp;amp;ndash;75%, and 76&amp;amp;ndash;100%. Most sebaceous versus non-sebaceous lesions exhibited cytoplasmic staining of moderate to strong intensity in &amp;amp;gt;75% of cells. PRAME has a sensitivity and specificity of 100.0% and 86.7%, respectively, to support distinguishing between sebaceous and non-sebaceous adnexal lesions (regardless of whether they are benign or malignant). BCCs and SCCs showed weak to moderate nuclear staining for PRAME in &amp;amp;gt;75% of cells. None of the 13 lesions of hair follicle origin showed any staining. A total of 26 of the 32 lesions of sweat gland origin were negative while 6 (18.75%) showed positive staining. In conclusion, we confirm the potential utility of PRAME for supporting the distinction between sebaceous and non-sebaceous adnexal lesions on one hand, and on the other, distinguishing BCC and SCC that may show nuclear staining from sebaceous carcinoma that shows cytoplasmic staining.</p>
	]]></content:encoded>

	<dc:title>PRAME Staining of Adnexal Lesions and Common Skin Cancer Types: Biomarker with Potential Diagnostic Utility</dc:title>
			<dc:creator>Hisham F. Bahmad</dc:creator>
			<dc:creator>John Alexis</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040039</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-12-12</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-12-12</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>364</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040039</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/39</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/38">

	<title>Dermatopathology, Vol. 11, Pages 354-363: A Rare Case of a Malignant Proliferating Trichilemmal Tumor: A Molecular Study Harboring Potential Therapeutic Significance and a Review of Literature</title>
	<link>https://www.mdpi.com/2296-3529/11/4/38</link>
	<description>Malignant proliferating trichilemmal tumors (MPTTs), arising from the external root sheath of hair follicles, are exceptionally rare, with limited documentation of their genetic alterations. We present a case of a 64-year-old African American woman who initially presented with a gradually enlarging nodule on her posterior scalp. An initial biopsy at an outside hospital suggested metastatic adenocarcinoma or squamous cell carcinoma (SCC) of an uncertain origin. A subsequent wide local excision revealed a 2.0 cm tumor demonstrating characteristic trichilemmal keratinization, characterized by an abrupt transition from the nucleated epithelium to a laminated keratinized layer, confirming MPTT. Immunohistochemistry demonstrated diffuse p53 expression, patchy CD 34 expression, focal HER2 membranous expression, and patchy p16 staining (negative HPV ISH). A molecular analysis identified TP53 mutation and amplifications in the ERBB2 (HER2), BRD4, and TYMS. Additional gene mutations of uncertain significance included HSPH1, ATM, PDCD1 (PD-1), BARD1, MSH3, LRP1B, KMT2C (MLL3), GNA11, and RUNX1. Assessments for the homologous recombination deficiency, PD-L1 expression, gene rearrangement, altered splicing, and DNA mismatch repair gene expression were negative. The confirmation of ERBB2 (HER2) amplification in the MPTT through a molecular analysis suggests potential therapeutic avenues involving anti-HER2 monoclonal antibodies. The presence of the TP53 mutation, without the concurrent gene mutations typically observed in SCC, significantly aided in this differential diagnosis.</description>
	<pubDate>2024-12-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 354-363: A Rare Case of a Malignant Proliferating Trichilemmal Tumor: A Molecular Study Harboring Potential Therapeutic Significance and a Review of Literature</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/38">doi: 10.3390/dermatopathology11040038</a></p>
	<p>Authors:
		Mokhtar H. Abdelhammed
		Hanna Siatecka
		A. Hafeez Diwan
		Christie J. Finch
		Angela D. Haskins
		David J. Hernandez
		Ya Xu
		</p>
	<p>Malignant proliferating trichilemmal tumors (MPTTs), arising from the external root sheath of hair follicles, are exceptionally rare, with limited documentation of their genetic alterations. We present a case of a 64-year-old African American woman who initially presented with a gradually enlarging nodule on her posterior scalp. An initial biopsy at an outside hospital suggested metastatic adenocarcinoma or squamous cell carcinoma (SCC) of an uncertain origin. A subsequent wide local excision revealed a 2.0 cm tumor demonstrating characteristic trichilemmal keratinization, characterized by an abrupt transition from the nucleated epithelium to a laminated keratinized layer, confirming MPTT. Immunohistochemistry demonstrated diffuse p53 expression, patchy CD 34 expression, focal HER2 membranous expression, and patchy p16 staining (negative HPV ISH). A molecular analysis identified TP53 mutation and amplifications in the ERBB2 (HER2), BRD4, and TYMS. Additional gene mutations of uncertain significance included HSPH1, ATM, PDCD1 (PD-1), BARD1, MSH3, LRP1B, KMT2C (MLL3), GNA11, and RUNX1. Assessments for the homologous recombination deficiency, PD-L1 expression, gene rearrangement, altered splicing, and DNA mismatch repair gene expression were negative. The confirmation of ERBB2 (HER2) amplification in the MPTT through a molecular analysis suggests potential therapeutic avenues involving anti-HER2 monoclonal antibodies. The presence of the TP53 mutation, without the concurrent gene mutations typically observed in SCC, significantly aided in this differential diagnosis.</p>
	]]></content:encoded>

	<dc:title>A Rare Case of a Malignant Proliferating Trichilemmal Tumor: A Molecular Study Harboring Potential Therapeutic Significance and a Review of Literature</dc:title>
			<dc:creator>Mokhtar H. Abdelhammed</dc:creator>
			<dc:creator>Hanna Siatecka</dc:creator>
			<dc:creator>A. Hafeez Diwan</dc:creator>
			<dc:creator>Christie J. Finch</dc:creator>
			<dc:creator>Angela D. Haskins</dc:creator>
			<dc:creator>David J. Hernandez</dc:creator>
			<dc:creator>Ya Xu</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040038</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-12-10</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-12-10</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>354</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040038</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/38</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/37">

	<title>Dermatopathology, Vol. 11, Pages 348-353: Digital Papillary Adenocarcinoma Is HPV-42-Associated and BRAFV600E Negative: Perspectives for Diagnostic Practice</title>
	<link>https://www.mdpi.com/2296-3529/11/4/37</link>
	<description>Digital papillary adenocarcinoma (DPAC) is a rare, low-grade sweat gland carcinoma primarily found on the hands, fingers, or toes and predominantly affecting males. Distinguishing DPAC from benign sweat gland tumors can be challenging. We present the case of a 52-year-old patient with a progressive tumor on the finger initially misdiagnosed as a viral wart. Histological examination revealed a cytologically basophilic sweat gland tumor with tubular structures, papillary protrusions, and a characteristic immunohistochemical staining pattern for CK 7 and Actin. HPV-42 positivity and molecular analysis confirmed the diagnosis of DPAC. HPV-42 has been strongly associated with DPAC. Additionally, p16 positivity and BRAFV600E negativity were observed. These findings aid in the differential diagnosis of acral sweat gland tumors and guide clinical management, including with respect to the potential for recurrence and metastasis.</description>
	<pubDate>2024-12-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 348-353: Digital Papillary Adenocarcinoma Is HPV-42-Associated and BRAFV600E Negative: Perspectives for Diagnostic Practice</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/37">doi: 10.3390/dermatopathology11040037</a></p>
	<p>Authors:
		Tassilo Dege
		Arno Rütten
		Matthias Goebeler
		Hermann Kneitz
		</p>
	<p>Digital papillary adenocarcinoma (DPAC) is a rare, low-grade sweat gland carcinoma primarily found on the hands, fingers, or toes and predominantly affecting males. Distinguishing DPAC from benign sweat gland tumors can be challenging. We present the case of a 52-year-old patient with a progressive tumor on the finger initially misdiagnosed as a viral wart. Histological examination revealed a cytologically basophilic sweat gland tumor with tubular structures, papillary protrusions, and a characteristic immunohistochemical staining pattern for CK 7 and Actin. HPV-42 positivity and molecular analysis confirmed the diagnosis of DPAC. HPV-42 has been strongly associated with DPAC. Additionally, p16 positivity and BRAFV600E negativity were observed. These findings aid in the differential diagnosis of acral sweat gland tumors and guide clinical management, including with respect to the potential for recurrence and metastasis.</p>
	]]></content:encoded>

	<dc:title>Digital Papillary Adenocarcinoma Is HPV-42-Associated and BRAFV600E Negative: Perspectives for Diagnostic Practice</dc:title>
			<dc:creator>Tassilo Dege</dc:creator>
			<dc:creator>Arno Rütten</dc:creator>
			<dc:creator>Matthias Goebeler</dc:creator>
			<dc:creator>Hermann Kneitz</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040037</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-12-09</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-12-09</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>348</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040037</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/37</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/36">

	<title>Dermatopathology, Vol. 11, Pages 342-347: Atypical Presentation of Spindle Cell Lipoma in a Young Male with a History of Malignant Melanoma</title>
	<link>https://www.mdpi.com/2296-3529/11/4/36</link>
	<description>Spindle cell lipoma (SCL) is a benign adipocytic tumor usually found in the subcutis of the posterior neck, upper back, and shoulder, predominantly in middle-aged males. This case report describes an atypical presentation of SCL in a 26-year-old male with a history of malignant melanoma. The patient presented with an erythematous plaque with central hyperpigmentation on the right upper arm, an uncommon location and presentation for SCL. Histopathological examination revealed an atypical myxoid spindle cell neoplasm with CD34 positivity and an overlying mildly atypical compound melanocytic nevus. The unusual clinical and histological features, combined with the patient&amp;amp;rsquo;s melanoma history, complicated the differential diagnosis, which included dermatofibrosarcoma protuberans (DFSP) and solitary fibrous tumors (SFTs). A wide local excision with 2 cm margins was performed, and subsequent pathology confirmed clear margins, supporting the diagnosis of SCL. This case highlights the importance of including SCL in the differential diagnosis of CD34-positive spindle cell tumors, even when clinical and histological presentations are atypical, and underscores the need for thorough histopathological evaluation and a broad differential diagnosis in patients with a history of melanoma.</description>
	<pubDate>2024-11-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 342-347: Atypical Presentation of Spindle Cell Lipoma in a Young Male with a History of Malignant Melanoma</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/36">doi: 10.3390/dermatopathology11040036</a></p>
	<p>Authors:
		Ty Theriot
		John David Cattar
		Lacey Falgout
		Nicholas Culotta
		Christopher Haas
		</p>
	<p>Spindle cell lipoma (SCL) is a benign adipocytic tumor usually found in the subcutis of the posterior neck, upper back, and shoulder, predominantly in middle-aged males. This case report describes an atypical presentation of SCL in a 26-year-old male with a history of malignant melanoma. The patient presented with an erythematous plaque with central hyperpigmentation on the right upper arm, an uncommon location and presentation for SCL. Histopathological examination revealed an atypical myxoid spindle cell neoplasm with CD34 positivity and an overlying mildly atypical compound melanocytic nevus. The unusual clinical and histological features, combined with the patient&amp;amp;rsquo;s melanoma history, complicated the differential diagnosis, which included dermatofibrosarcoma protuberans (DFSP) and solitary fibrous tumors (SFTs). A wide local excision with 2 cm margins was performed, and subsequent pathology confirmed clear margins, supporting the diagnosis of SCL. This case highlights the importance of including SCL in the differential diagnosis of CD34-positive spindle cell tumors, even when clinical and histological presentations are atypical, and underscores the need for thorough histopathological evaluation and a broad differential diagnosis in patients with a history of melanoma.</p>
	]]></content:encoded>

	<dc:title>Atypical Presentation of Spindle Cell Lipoma in a Young Male with a History of Malignant Melanoma</dc:title>
			<dc:creator>Ty Theriot</dc:creator>
			<dc:creator>John David Cattar</dc:creator>
			<dc:creator>Lacey Falgout</dc:creator>
			<dc:creator>Nicholas Culotta</dc:creator>
			<dc:creator>Christopher Haas</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040036</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-11-26</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-11-26</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>342</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040036</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/36</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/35">

	<title>Dermatopathology, Vol. 11, Pages 333-341: &amp;ldquo;Chasing Rainbows&amp;rdquo; Beyond Kaposi Sarcoma&amp;rsquo;s Dermoscopy: A Mini-Review</title>
	<link>https://www.mdpi.com/2296-3529/11/4/35</link>
	<description>The dermoscopic rainbow pattern (RP), also known as polychromatic pattern, is characterized by a multicolored appearance, resulting from the dispersion of polarized light as it penetrates various tissue components. Its separation into different wavelengths occurs according to the physics principles of scattering, absorption, and interference of light, creating the optical effect of RP. Even though the RP is regarded as a highly specific dermoscopic indicator of Kaposi&amp;amp;rsquo;s sarcoma, in the medical literature, it has also been documented as an atypical dermoscopic finding of other non-Kaposi skin entities. We aim to present two distinct cases&amp;amp;mdash;a pigmented basal cell carcinoma (pBCC) and an aneurysmatic dermatofibroma&amp;amp;mdash;that exhibited RP in dermoscopy and to conduct a thorough review of skin conditions that display RP, revealing any predisposing factors that could increase the likelihood of its occurrence in certain lesions. We identified 33 case reports and large-scale studies with diverse entities characterized by the presence of RP, including skin cancers (Merkel cell carcinoma, BCC, melanoma, etc.), adnexal tumors, special types of nevi (blue, deep penetrating), vascular lesions (acroangiodermatitis, strawberry angioma, angiokeratoma, aneurismatic dermatofibromas, etc.), granulation tissue, hypertrophic scars and fibrous lesions, skin infections (sporotrichosis and cutaneous leishmaniasis), and inflammatory dermatoses (lichen simplex and stasis dermatitis). According to our results, the majority of the lesions exhibiting the RP were located on the extremities. Identified precipitating factors included the nodular shape, lesion composition and vascularization, skin pigmentation, and lesions&amp;amp;rsquo; depth and thickness. These parameters lead to increased scattering and interference of light, producing a spectrum of colors that resemble a rainbow.</description>
	<pubDate>2024-11-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 333-341: &amp;ldquo;Chasing Rainbows&amp;rdquo; Beyond Kaposi Sarcoma&amp;rsquo;s Dermoscopy: A Mini-Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/35">doi: 10.3390/dermatopathology11040035</a></p>
	<p>Authors:
		Emmanouil Karampinis
		Olga Toli
		Georgia Pappa
		Anna Vardiampasi
		Melpomeni Theofili
		Efterpi Zafiriou
		Mattheos Bobos
		Aimilios Lallas
		Elizabeth Lazaridou
		Biswanath Behera
		Zoe Apalla
		</p>
	<p>The dermoscopic rainbow pattern (RP), also known as polychromatic pattern, is characterized by a multicolored appearance, resulting from the dispersion of polarized light as it penetrates various tissue components. Its separation into different wavelengths occurs according to the physics principles of scattering, absorption, and interference of light, creating the optical effect of RP. Even though the RP is regarded as a highly specific dermoscopic indicator of Kaposi&amp;amp;rsquo;s sarcoma, in the medical literature, it has also been documented as an atypical dermoscopic finding of other non-Kaposi skin entities. We aim to present two distinct cases&amp;amp;mdash;a pigmented basal cell carcinoma (pBCC) and an aneurysmatic dermatofibroma&amp;amp;mdash;that exhibited RP in dermoscopy and to conduct a thorough review of skin conditions that display RP, revealing any predisposing factors that could increase the likelihood of its occurrence in certain lesions. We identified 33 case reports and large-scale studies with diverse entities characterized by the presence of RP, including skin cancers (Merkel cell carcinoma, BCC, melanoma, etc.), adnexal tumors, special types of nevi (blue, deep penetrating), vascular lesions (acroangiodermatitis, strawberry angioma, angiokeratoma, aneurismatic dermatofibromas, etc.), granulation tissue, hypertrophic scars and fibrous lesions, skin infections (sporotrichosis and cutaneous leishmaniasis), and inflammatory dermatoses (lichen simplex and stasis dermatitis). According to our results, the majority of the lesions exhibiting the RP were located on the extremities. Identified precipitating factors included the nodular shape, lesion composition and vascularization, skin pigmentation, and lesions&amp;amp;rsquo; depth and thickness. These parameters lead to increased scattering and interference of light, producing a spectrum of colors that resemble a rainbow.</p>
	]]></content:encoded>

	<dc:title>&amp;amp;ldquo;Chasing Rainbows&amp;amp;rdquo; Beyond Kaposi Sarcoma&amp;amp;rsquo;s Dermoscopy: A Mini-Review</dc:title>
			<dc:creator>Emmanouil Karampinis</dc:creator>
			<dc:creator>Olga Toli</dc:creator>
			<dc:creator>Georgia Pappa</dc:creator>
			<dc:creator>Anna Vardiampasi</dc:creator>
			<dc:creator>Melpomeni Theofili</dc:creator>
			<dc:creator>Efterpi Zafiriou</dc:creator>
			<dc:creator>Mattheos Bobos</dc:creator>
			<dc:creator>Aimilios Lallas</dc:creator>
			<dc:creator>Elizabeth Lazaridou</dc:creator>
			<dc:creator>Biswanath Behera</dc:creator>
			<dc:creator>Zoe Apalla</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040035</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-11-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-11-25</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>333</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040035</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/35</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/34">

	<title>Dermatopathology, Vol. 11, Pages 330-332: A Case of Basal Cell Carcinoma Exacerbated with Akatsuki Disease</title>
	<link>https://www.mdpi.com/2296-3529/11/4/34</link>
	<description>Akatsuki disease (also known as pomade crust) is characterized by skin lesions resulting from inadequate skin hygiene. It is sometimes influenced by underlying psychological factors. Akatsuki disease sometimes mimics cutaneous horn or skin cancer. However, there are no previous reports of skin cancer accompanied with Akatsuki disease. Herein, we report a 79-year-old woman who was referred to our department with a tumor on her left cheek. Before performing a biopsy, we recommended that her family assist with regular facial cleansing. Two months later, the scales and crusts on her entire face had disappeared and the tumor on the left cheek had reduced. Skin biopsy was performed, and histological examination revealed ulcerative basaloid lobules consisting of cells with a small cytoplasm and large hyperchromatic nuclei. Peripheral palisading and tumor-stroma clefting were observed. A diagnosis of basal cell carcinoma was made.</description>
	<pubDate>2024-11-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 330-332: A Case of Basal Cell Carcinoma Exacerbated with Akatsuki Disease</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/34">doi: 10.3390/dermatopathology11040034</a></p>
	<p>Authors:
		Yuji Ohara
		Issei Kido
		Kozo Nakai
		</p>
	<p>Akatsuki disease (also known as pomade crust) is characterized by skin lesions resulting from inadequate skin hygiene. It is sometimes influenced by underlying psychological factors. Akatsuki disease sometimes mimics cutaneous horn or skin cancer. However, there are no previous reports of skin cancer accompanied with Akatsuki disease. Herein, we report a 79-year-old woman who was referred to our department with a tumor on her left cheek. Before performing a biopsy, we recommended that her family assist with regular facial cleansing. Two months later, the scales and crusts on her entire face had disappeared and the tumor on the left cheek had reduced. Skin biopsy was performed, and histological examination revealed ulcerative basaloid lobules consisting of cells with a small cytoplasm and large hyperchromatic nuclei. Peripheral palisading and tumor-stroma clefting were observed. A diagnosis of basal cell carcinoma was made.</p>
	]]></content:encoded>

	<dc:title>A Case of Basal Cell Carcinoma Exacerbated with Akatsuki Disease</dc:title>
			<dc:creator>Yuji Ohara</dc:creator>
			<dc:creator>Issei Kido</dc:creator>
			<dc:creator>Kozo Nakai</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040034</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-11-22</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-11-22</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>330</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040034</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/34</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/33">

	<title>Dermatopathology, Vol. 11, Pages 315-329: Image-Guided Radiation Therapy Is Equally Effective for Basal and Squamous Cell Carcinoma</title>
	<link>https://www.mdpi.com/2296-3529/11/4/33</link>
	<description>Non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are highly prevalent and a significant cause of morbidity. Image-guided superficial radiation therapy (IGSRT) uses integrated high-resolution dermal ultrasound to improve lesion visualization, but it is unknown whether efficacy varies by histology. This large retrospective cohort study was conducted to determine the effect of tumor histology on freedom from recurrence in 20,069 biopsy-proven NMSC lesions treated with IGSRT, including 9928 BCCs (49.5%), 5294 SCCs (26.4%), 4648 SCCIS cases (23.2%), and 199 lesions with &amp;amp;ge;2 NMSCs (1.0%). Freedom from recurrence at 2, 4, and 6 years was 99.60%, 99.45%, and 99.45% in BCC; 99.58%, 99.49%, and 99.49% in SCC; and 99.96%, 99.80%, and 99.80% in SCCIS. Freedom from recurrence at 2, 4, and 6 years following IGSRT did not differ significantly comparing BCC vs. non-BCC or SCC vs. non-SCC but were slightly lower among SCCIS vs. non-SCCIS (p = 0.002). There were no significant differences in freedom from recurrence when stratifying lesions by histologic subtype. This study demonstrates that there is no significant effect of histology on freedom from recurrence in IGSRT-treated NMSC except in SCCIS. These findings support IGSRT as a first-line therapeutic option for NMSC regardless of histology.</description>
	<pubDate>2024-11-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 315-329: Image-Guided Radiation Therapy Is Equally Effective for Basal and Squamous Cell Carcinoma</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/33">doi: 10.3390/dermatopathology11040033</a></p>
	<p>Authors:
		Erin M. McClure
		Clay J. Cockerell
		Stephen Hammond
		Evelyn S. Marienberg
		Bobby N. Koneru
		Jon Ward
		Jeffrey B. Stricker
		</p>
	<p>Non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are highly prevalent and a significant cause of morbidity. Image-guided superficial radiation therapy (IGSRT) uses integrated high-resolution dermal ultrasound to improve lesion visualization, but it is unknown whether efficacy varies by histology. This large retrospective cohort study was conducted to determine the effect of tumor histology on freedom from recurrence in 20,069 biopsy-proven NMSC lesions treated with IGSRT, including 9928 BCCs (49.5%), 5294 SCCs (26.4%), 4648 SCCIS cases (23.2%), and 199 lesions with &amp;amp;ge;2 NMSCs (1.0%). Freedom from recurrence at 2, 4, and 6 years was 99.60%, 99.45%, and 99.45% in BCC; 99.58%, 99.49%, and 99.49% in SCC; and 99.96%, 99.80%, and 99.80% in SCCIS. Freedom from recurrence at 2, 4, and 6 years following IGSRT did not differ significantly comparing BCC vs. non-BCC or SCC vs. non-SCC but were slightly lower among SCCIS vs. non-SCCIS (p = 0.002). There were no significant differences in freedom from recurrence when stratifying lesions by histologic subtype. This study demonstrates that there is no significant effect of histology on freedom from recurrence in IGSRT-treated NMSC except in SCCIS. These findings support IGSRT as a first-line therapeutic option for NMSC regardless of histology.</p>
	]]></content:encoded>

	<dc:title>Image-Guided Radiation Therapy Is Equally Effective for Basal and Squamous Cell Carcinoma</dc:title>
			<dc:creator>Erin M. McClure</dc:creator>
			<dc:creator>Clay J. Cockerell</dc:creator>
			<dc:creator>Stephen Hammond</dc:creator>
			<dc:creator>Evelyn S. Marienberg</dc:creator>
			<dc:creator>Bobby N. Koneru</dc:creator>
			<dc:creator>Jon Ward</dc:creator>
			<dc:creator>Jeffrey B. Stricker</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040033</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-11-19</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-11-19</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>315</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040033</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/33</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/32">

	<title>Dermatopathology, Vol. 11, Pages 303-314: Collision of Basal Cell Carcinoma with Apocrine&amp;ndash;Sebaceous&amp;ndash;Follicular Unit Neoplasms</title>
	<link>https://www.mdpi.com/2296-3529/11/4/32</link>
	<description>Background: Tumor collision is a rare event, with an estimated incidence of 0.0017%. Seborrheic keratosis, melanocytic nevi, and basal cell carcinoma (BCC) are by far the most common entities involved in collisions. Most authors consider collision to be an incidental event. I planned a retrospective study comparing BCC/apocrine&amp;amp;ndash;sebaceous&amp;amp;ndash;follicular unit (ASFu) neoplasm collisions with squamous cell carcinoma (SCC)/ASFu neoplasm collisions. Materials and methods: Files from 2005 to 2017 from Dr. Jos&amp;amp;eacute; Molina Orosa Hospital were assessed; in the review, cases of collisions between BCCs or SSCs and ASFu tumors, including cysts, were identified. Results: Out of 3247 BCC cases, 12 biopsies were retrieved. Of 825 biopsies, none belonged to the SCC group. The ASFu tumors that collided with a BCC were as follows: four hidrocystomas, three infundibular cysts, two steatocystomas, two trichilemmomas, one spiradenoma, and one clear-cell hidradenoma (one patient had two cysts associated with a BCC). These cases correspond to seven female patients and five male patients aged between 26 and 91 years old. A quarter of these patients were immunosuppressed. Most ASFu neoplasms were found to be located beneath the BCC (8/12). Discussion: To the best of my knowledge, this report describes three new collisions of BCCs with ASFu neoplasms (infundibular cysts, steatocystomas, and a spiradenoma). My results also suggest that immunosuppression could be a factor that predisposes a patient to these collisions. I review current hypotheses in an effort to explain these collisions and contribute some new theories.</description>
	<pubDate>2024-10-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 303-314: Collision of Basal Cell Carcinoma with Apocrine&amp;ndash;Sebaceous&amp;ndash;Follicular Unit Neoplasms</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/32">doi: 10.3390/dermatopathology11040032</a></p>
	<p>Authors:
		Enric Piqué-Duran
		</p>
	<p>Background: Tumor collision is a rare event, with an estimated incidence of 0.0017%. Seborrheic keratosis, melanocytic nevi, and basal cell carcinoma (BCC) are by far the most common entities involved in collisions. Most authors consider collision to be an incidental event. I planned a retrospective study comparing BCC/apocrine&amp;amp;ndash;sebaceous&amp;amp;ndash;follicular unit (ASFu) neoplasm collisions with squamous cell carcinoma (SCC)/ASFu neoplasm collisions. Materials and methods: Files from 2005 to 2017 from Dr. Jos&amp;amp;eacute; Molina Orosa Hospital were assessed; in the review, cases of collisions between BCCs or SSCs and ASFu tumors, including cysts, were identified. Results: Out of 3247 BCC cases, 12 biopsies were retrieved. Of 825 biopsies, none belonged to the SCC group. The ASFu tumors that collided with a BCC were as follows: four hidrocystomas, three infundibular cysts, two steatocystomas, two trichilemmomas, one spiradenoma, and one clear-cell hidradenoma (one patient had two cysts associated with a BCC). These cases correspond to seven female patients and five male patients aged between 26 and 91 years old. A quarter of these patients were immunosuppressed. Most ASFu neoplasms were found to be located beneath the BCC (8/12). Discussion: To the best of my knowledge, this report describes three new collisions of BCCs with ASFu neoplasms (infundibular cysts, steatocystomas, and a spiradenoma). My results also suggest that immunosuppression could be a factor that predisposes a patient to these collisions. I review current hypotheses in an effort to explain these collisions and contribute some new theories.</p>
	]]></content:encoded>

	<dc:title>Collision of Basal Cell Carcinoma with Apocrine&amp;amp;ndash;Sebaceous&amp;amp;ndash;Follicular Unit Neoplasms</dc:title>
			<dc:creator>Enric Piqué-Duran</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040032</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-10-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-10-25</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>303</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040032</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/32</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/31">

	<title>Dermatopathology, Vol. 11, Pages 293-302: Expression of TRPS1 in Metastatic Tumors of the Skin: An Immunohistochemical Study of 72 Cases</title>
	<link>https://www.mdpi.com/2296-3529/11/4/31</link>
	<description>TRPS1 (Tricho-rhino-phalangeal syndrome 1) is a GATA transcriptional activator gene encoding for a protein used as a sensitive immunohistochemical marker of breast carcinomas. In dermatopathology, TRPS1 is used as a marker of mammary and extramammary Paget&amp;amp;rsquo;s disease and is also expressed by a variety of primary cutaneous tumors, mostly of adnexal origin. So far, very limited data exist on the expression of TRPS1 in metastatic skin tumors. We studied the immunohistochemical expression of TRPS1 in 72 cutaneous metastatic tumors from the breast (n: 19) and other origins (n: 53) in order to assess its diagnostic usefulness. The intensity of TRPS1 immunostaining was expressed as a histoscore: the product of the percentage of positive cells (scored semi-quantitatively 0&amp;amp;ndash;4) and the staining intensity (scored 0&amp;amp;ndash;3). In normal skin, nuclear TRPS1 expression was predominantly observed in cells of adnexal structures (pilosebaceous follicles and sweat glands). Eighteen (18/19, 94.7%) metastatic breast carcinomas showed diffuse and strong TRPS1 positivity (histoscore 12). Lower reactivity was found in some other metastases, including from the lung (11/22), the female genital tract (3/4), and the kidney (2/4), whereas most (20/22) metastases from the digestive system and peritoneum, along with a case of metastatic prostate carcinoma, were negative. These results suggest that a high histoscore for TRPS1 is in favor of the mammary origin of metastatic cutaneous carcinoma. Although TRPS1 is not absolutely specific or sensitive to a particular primary, we consider that it can be added to a panel of other markers when investigating the origin of a cutaneous metastasis, namely when this is the first manifestation of the neoplastic disease.</description>
	<pubDate>2024-10-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 293-302: Expression of TRPS1 in Metastatic Tumors of the Skin: An Immunohistochemical Study of 72 Cases</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/31">doi: 10.3390/dermatopathology11040031</a></p>
	<p>Authors:
		Kassiani Boulogeorgou
		Christos Topalidis
		Triantafyllia Koletsa
		Georgia Karayannopoulou
		Jean Kanitakis
		</p>
	<p>TRPS1 (Tricho-rhino-phalangeal syndrome 1) is a GATA transcriptional activator gene encoding for a protein used as a sensitive immunohistochemical marker of breast carcinomas. In dermatopathology, TRPS1 is used as a marker of mammary and extramammary Paget&amp;amp;rsquo;s disease and is also expressed by a variety of primary cutaneous tumors, mostly of adnexal origin. So far, very limited data exist on the expression of TRPS1 in metastatic skin tumors. We studied the immunohistochemical expression of TRPS1 in 72 cutaneous metastatic tumors from the breast (n: 19) and other origins (n: 53) in order to assess its diagnostic usefulness. The intensity of TRPS1 immunostaining was expressed as a histoscore: the product of the percentage of positive cells (scored semi-quantitatively 0&amp;amp;ndash;4) and the staining intensity (scored 0&amp;amp;ndash;3). In normal skin, nuclear TRPS1 expression was predominantly observed in cells of adnexal structures (pilosebaceous follicles and sweat glands). Eighteen (18/19, 94.7%) metastatic breast carcinomas showed diffuse and strong TRPS1 positivity (histoscore 12). Lower reactivity was found in some other metastases, including from the lung (11/22), the female genital tract (3/4), and the kidney (2/4), whereas most (20/22) metastases from the digestive system and peritoneum, along with a case of metastatic prostate carcinoma, were negative. These results suggest that a high histoscore for TRPS1 is in favor of the mammary origin of metastatic cutaneous carcinoma. Although TRPS1 is not absolutely specific or sensitive to a particular primary, we consider that it can be added to a panel of other markers when investigating the origin of a cutaneous metastasis, namely when this is the first manifestation of the neoplastic disease.</p>
	]]></content:encoded>

	<dc:title>Expression of TRPS1 in Metastatic Tumors of the Skin: An Immunohistochemical Study of 72 Cases</dc:title>
			<dc:creator>Kassiani Boulogeorgou</dc:creator>
			<dc:creator>Christos Topalidis</dc:creator>
			<dc:creator>Triantafyllia Koletsa</dc:creator>
			<dc:creator>Georgia Karayannopoulou</dc:creator>
			<dc:creator>Jean Kanitakis</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040031</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-10-23</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-10-23</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>293</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040031</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/31</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/30">

	<title>Dermatopathology, Vol. 11, Pages 286-292: Undifferentiated Pleomorphic Sarcoma with Reactive Eccrine Syringofibroadenoma: A Case Report</title>
	<link>https://www.mdpi.com/2296-3529/11/4/30</link>
	<description>Undifferentiated pleomorphic sarcoma (UPS) is an aggressive soft tissue sarcoma with a poor prognosis. The patients are usually found to have metastasis when the primary tumor is diagnosed. Eccrine syringofibroadenoma (ESFA) is a rare cutaneous adnexal lesion of eccrine duct origin. There are five subtypes, one of which is reactive ESFA, known to occur in reaction to an inflammatory or neoplastic process. In this article, we report a case of the co-existence of both UPS and ESFA in a 70-year-old male patient, presenting with a painless, erythematous, irregular surface nodule with a peripherally extended brownish hyperkeratotic plaque on the right palm. The histologic findings revealed an ill-defined dermal tumor of atypical epithelioid and spindle-shaped cells with large pleomorphic hyperchromatic nuclei and abundant eosinophilic cytoplasm. Some of those cells were multinucleated giant cells in the stroma with vascular proliferation and mixed inflammatory cell infiltrate. The tumor cells, which were only positive for vimentin, supported the diagnosis of undifferentiated pleomorphic sarcoma (UPS). Meanwhile, the overlying epidermis demonstrated hyperkeratosis, papillated epidermal hyperplasia, and proliferation of anastomosing slender cords and strands of cuboid cells within loose fibrovascular stroma. These findings are the characteristics of eccrine syringofibroadenoma (ESFA). We describe here a patient in whom reactive ESFA occurred on and surrounded the UPS tumor.</description>
	<pubDate>2024-10-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 286-292: Undifferentiated Pleomorphic Sarcoma with Reactive Eccrine Syringofibroadenoma: A Case Report</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/30">doi: 10.3390/dermatopathology11040030</a></p>
	<p>Authors:
		Navinda Donsakul
		Suthep Jerasutus
		Ittipon Tubtieng
		Ravion Assavanatenapa
		Voraphol Vejjabhinanta
		</p>
	<p>Undifferentiated pleomorphic sarcoma (UPS) is an aggressive soft tissue sarcoma with a poor prognosis. The patients are usually found to have metastasis when the primary tumor is diagnosed. Eccrine syringofibroadenoma (ESFA) is a rare cutaneous adnexal lesion of eccrine duct origin. There are five subtypes, one of which is reactive ESFA, known to occur in reaction to an inflammatory or neoplastic process. In this article, we report a case of the co-existence of both UPS and ESFA in a 70-year-old male patient, presenting with a painless, erythematous, irregular surface nodule with a peripherally extended brownish hyperkeratotic plaque on the right palm. The histologic findings revealed an ill-defined dermal tumor of atypical epithelioid and spindle-shaped cells with large pleomorphic hyperchromatic nuclei and abundant eosinophilic cytoplasm. Some of those cells were multinucleated giant cells in the stroma with vascular proliferation and mixed inflammatory cell infiltrate. The tumor cells, which were only positive for vimentin, supported the diagnosis of undifferentiated pleomorphic sarcoma (UPS). Meanwhile, the overlying epidermis demonstrated hyperkeratosis, papillated epidermal hyperplasia, and proliferation of anastomosing slender cords and strands of cuboid cells within loose fibrovascular stroma. These findings are the characteristics of eccrine syringofibroadenoma (ESFA). We describe here a patient in whom reactive ESFA occurred on and surrounded the UPS tumor.</p>
	]]></content:encoded>

	<dc:title>Undifferentiated Pleomorphic Sarcoma with Reactive Eccrine Syringofibroadenoma: A Case Report</dc:title>
			<dc:creator>Navinda Donsakul</dc:creator>
			<dc:creator>Suthep Jerasutus</dc:creator>
			<dc:creator>Ittipon Tubtieng</dc:creator>
			<dc:creator>Ravion Assavanatenapa</dc:creator>
			<dc:creator>Voraphol Vejjabhinanta</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040030</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-10-20</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-10-20</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>286</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040030</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/30</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/29">

	<title>Dermatopathology, Vol. 11, Pages 272-285: Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers</title>
	<link>https://www.mdpi.com/2296-3529/11/4/29</link>
	<description>Considerable controversy exists within the field of dermatopathology in differentiating keratoacanthoma (KA) from squamous-cell carcinoma (SCC). KAs are rapidly growing, benign squamous tumors that are typically well differentiated. This controversy stems from the diverging perspectives on the management, classification, and diagnosis of each entity. Many believe that KAs are benign neoplasms in which intervention may be unnecessary since they are self-limiting and resolve on their own. On the other hand, SCC needs to be treated, as it carries significant morbidity and mortality risks. Early diagnosis and treatment are vital to prevent serious consequences of SCC. Nevertheless, KAs may resemble SCC grossly and microscopically. Various ancillary tests, including immunohistochemical (IHC) staining, have been proposed to differentiate between these entities, though mixed patterns of expression can limit the diagnostic utility of these techniques. Research into this topic is ongoing, with newer genetic and molecular findings illuminating the previously difficult-to-understand aspects of KA and increasing our understanding of this entity. In this review, KA and SCC will be compared along the lines of histological features, genetic, immune, and molecular markers, differential diagnosis, and management to clarify the similarities, differences, and misconceptions about both entities.</description>
	<pubDate>2024-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 272-285: Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/29">doi: 10.3390/dermatopathology11040029</a></p>
	<p>Authors:
		Hisham F. Bahmad
		Kalin Stoyanov
		Teresita Mendez
		Sally Trinh
		Kristy Terp
		Linda Qian
		John Alexis
		</p>
	<p>Considerable controversy exists within the field of dermatopathology in differentiating keratoacanthoma (KA) from squamous-cell carcinoma (SCC). KAs are rapidly growing, benign squamous tumors that are typically well differentiated. This controversy stems from the diverging perspectives on the management, classification, and diagnosis of each entity. Many believe that KAs are benign neoplasms in which intervention may be unnecessary since they are self-limiting and resolve on their own. On the other hand, SCC needs to be treated, as it carries significant morbidity and mortality risks. Early diagnosis and treatment are vital to prevent serious consequences of SCC. Nevertheless, KAs may resemble SCC grossly and microscopically. Various ancillary tests, including immunohistochemical (IHC) staining, have been proposed to differentiate between these entities, though mixed patterns of expression can limit the diagnostic utility of these techniques. Research into this topic is ongoing, with newer genetic and molecular findings illuminating the previously difficult-to-understand aspects of KA and increasing our understanding of this entity. In this review, KA and SCC will be compared along the lines of histological features, genetic, immune, and molecular markers, differential diagnosis, and management to clarify the similarities, differences, and misconceptions about both entities.</p>
	]]></content:encoded>

	<dc:title>Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers</dc:title>
			<dc:creator>Hisham F. Bahmad</dc:creator>
			<dc:creator>Kalin Stoyanov</dc:creator>
			<dc:creator>Teresita Mendez</dc:creator>
			<dc:creator>Sally Trinh</dc:creator>
			<dc:creator>Kristy Terp</dc:creator>
			<dc:creator>Linda Qian</dc:creator>
			<dc:creator>John Alexis</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040029</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-10-08</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-10-08</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>272</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040029</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/29</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/28">

	<title>Dermatopathology, Vol. 11, Pages 266-271: A Rapidly Growing Nodule on the Eyebrow of a Pediatric Patient</title>
	<link>https://www.mdpi.com/2296-3529/11/4/28</link>
	<description>A 11-year-old Caucasian girl presented to our Dermatology Unit with a 2-month history of an erythematous nodule, localized to the medial portion of her left eyebrow, rapidly growing in the two weeks before presentation. The histopathological examination revealed a dermal multi-nodular epithelial neoplasm composed of clear cells, squamous cells, and glandular cells, characterized by cytologic atypia, high mitotic activity, and an infiltrative deep growth pattern. The immunohistochemical profile of the lesion was as follows: CKAE1/AE3+, EMA+, CK8/18+, CK7+, CK19+, AR negative, p63 focally +, Ki67 25%, rare cells GCDFP15+, p53+.</description>
	<pubDate>2024-09-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 266-271: A Rapidly Growing Nodule on the Eyebrow of a Pediatric Patient</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/28">doi: 10.3390/dermatopathology11040028</a></p>
	<p>Authors:
		Italo Francesco Aromolo
		Michela Brena
		Nicola Adriano Monzani
		Fabio Caviggioli
		Emilio Berti
		Donata Micello
		Riccardo Cavalli
		</p>
	<p>A 11-year-old Caucasian girl presented to our Dermatology Unit with a 2-month history of an erythematous nodule, localized to the medial portion of her left eyebrow, rapidly growing in the two weeks before presentation. The histopathological examination revealed a dermal multi-nodular epithelial neoplasm composed of clear cells, squamous cells, and glandular cells, characterized by cytologic atypia, high mitotic activity, and an infiltrative deep growth pattern. The immunohistochemical profile of the lesion was as follows: CKAE1/AE3+, EMA+, CK8/18+, CK7+, CK19+, AR negative, p63 focally +, Ki67 25%, rare cells GCDFP15+, p53+.</p>
	]]></content:encoded>

	<dc:title>A Rapidly Growing Nodule on the Eyebrow of a Pediatric Patient</dc:title>
			<dc:creator>Italo Francesco Aromolo</dc:creator>
			<dc:creator>Michela Brena</dc:creator>
			<dc:creator>Nicola Adriano Monzani</dc:creator>
			<dc:creator>Fabio Caviggioli</dc:creator>
			<dc:creator>Emilio Berti</dc:creator>
			<dc:creator>Donata Micello</dc:creator>
			<dc:creator>Riccardo Cavalli</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040028</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-09-30</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-09-30</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Clinicopathological Challenge</prism:section>
	<prism:startingPage>266</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040028</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/28</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/4/27">

	<title>Dermatopathology, Vol. 11, Pages 253-265: Ethical Issues Regarding Dermatopathology Care for Service-Members: A Review</title>
	<link>https://www.mdpi.com/2296-3529/11/4/27</link>
	<description>Dermatologic care within the military faces unique ethical challenges. Service members are stationed across nationally and globally diverse settings, and therefore, dermatologic care rendered ranges from within resource-rich, advanced military medical treatment facilities to austere, resource-limited, deployed field environments. Additionally, military service members are often at unique risk for dermatologic disease, given occupational, environmental, and geographic exposures not commonly faced by their civilian counterparts. This review explores topics in dermatoethics via case analyses of ethical considerations within the scope of dermatologic care for military service members.</description>
	<pubDate>2024-09-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 253-265: Ethical Issues Regarding Dermatopathology Care for Service-Members: A Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/4/27">doi: 10.3390/dermatopathology11040027</a></p>
	<p>Authors:
		Samir Kamat
		Ross O’Hagan
		Catherine Brahe
		Curtis L. Hardy
		Vikas Shrivastava
		Jane M. Grant-Kels
		Angela M. Crotty
		</p>
	<p>Dermatologic care within the military faces unique ethical challenges. Service members are stationed across nationally and globally diverse settings, and therefore, dermatologic care rendered ranges from within resource-rich, advanced military medical treatment facilities to austere, resource-limited, deployed field environments. Additionally, military service members are often at unique risk for dermatologic disease, given occupational, environmental, and geographic exposures not commonly faced by their civilian counterparts. This review explores topics in dermatoethics via case analyses of ethical considerations within the scope of dermatologic care for military service members.</p>
	]]></content:encoded>

	<dc:title>Ethical Issues Regarding Dermatopathology Care for Service-Members: A Review</dc:title>
			<dc:creator>Samir Kamat</dc:creator>
			<dc:creator>Ross O’Hagan</dc:creator>
			<dc:creator>Catherine Brahe</dc:creator>
			<dc:creator>Curtis L. Hardy</dc:creator>
			<dc:creator>Vikas Shrivastava</dc:creator>
			<dc:creator>Jane M. Grant-Kels</dc:creator>
			<dc:creator>Angela M. Crotty</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11040027</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-09-24</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-09-24</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>253</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11040027</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/4/27</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/26">

	<title>Dermatopathology, Vol. 11, Pages 239-252: Enhancing Melanoma Diagnosis with Advanced Deep Learning Models Focusing on Vision Transformer, Swin Transformer, and ConvNeXt</title>
	<link>https://www.mdpi.com/2296-3529/11/3/26</link>
	<description>Skin tumors, especially melanoma, which is highly aggressive and progresses quickly to other sites, are an issue in various parts of the world. Nevertheless, the one and only way to save lives is to detect it at its initial stages. This study explores the application of advanced deep learning models for classifying benign and malignant melanoma using dermoscopic images. The aim of the study is to enhance the accuracy and efficiency of melanoma diagnosis with the ConvNeXt, Vision Transformer (ViT) Base-16, and Swin Transformer V2 Small (Swin V2 S) deep learning models. The ConvNeXt model, which integrates principles of both convolutional neural networks and transformers, demonstrated superior performance, with balanced precision and recall metrics. The dataset, sourced from Kaggle, comprises 13,900 uniformly sized images, preprocessed to standardize the inputs for the models. Experimental results revealed that ConvNeXt achieved the highest diagnostic accuracy among the tested models. Experimental results revealed that ConvNeXt achieved an accuracy of 91.5%, with balanced precision and recall rates of 90.45% and 92.8% for benign cases, and 92.61% and 90.2% for malignant cases, respectively. The F1-scores for ConvNeXt were 91.61% for benign cases and 91.39% for malignant cases. This research points out the potential of hybrid deep learning architectures in medical image analysis, particularly for early melanoma detection.</description>
	<pubDate>2024-08-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 239-252: Enhancing Melanoma Diagnosis with Advanced Deep Learning Models Focusing on Vision Transformer, Swin Transformer, and ConvNeXt</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/26">doi: 10.3390/dermatopathology11030026</a></p>
	<p>Authors:
		Serra Aksoy
		Pinar Demircioglu
		Ismail Bogrekci
		</p>
	<p>Skin tumors, especially melanoma, which is highly aggressive and progresses quickly to other sites, are an issue in various parts of the world. Nevertheless, the one and only way to save lives is to detect it at its initial stages. This study explores the application of advanced deep learning models for classifying benign and malignant melanoma using dermoscopic images. The aim of the study is to enhance the accuracy and efficiency of melanoma diagnosis with the ConvNeXt, Vision Transformer (ViT) Base-16, and Swin Transformer V2 Small (Swin V2 S) deep learning models. The ConvNeXt model, which integrates principles of both convolutional neural networks and transformers, demonstrated superior performance, with balanced precision and recall metrics. The dataset, sourced from Kaggle, comprises 13,900 uniformly sized images, preprocessed to standardize the inputs for the models. Experimental results revealed that ConvNeXt achieved the highest diagnostic accuracy among the tested models. Experimental results revealed that ConvNeXt achieved an accuracy of 91.5%, with balanced precision and recall rates of 90.45% and 92.8% for benign cases, and 92.61% and 90.2% for malignant cases, respectively. The F1-scores for ConvNeXt were 91.61% for benign cases and 91.39% for malignant cases. This research points out the potential of hybrid deep learning architectures in medical image analysis, particularly for early melanoma detection.</p>
	]]></content:encoded>

	<dc:title>Enhancing Melanoma Diagnosis with Advanced Deep Learning Models Focusing on Vision Transformer, Swin Transformer, and ConvNeXt</dc:title>
			<dc:creator>Serra Aksoy</dc:creator>
			<dc:creator>Pinar Demircioglu</dc:creator>
			<dc:creator>Ismail Bogrekci</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030026</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-08-15</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-08-15</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>239</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030026</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/26</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/25">

	<title>Dermatopathology, Vol. 11, Pages 238: Clinicopathological Challenge: A New Article Type in Dermatopathology</title>
	<link>https://www.mdpi.com/2296-3529/11/3/25</link>
	<description>As the Editor-in-Chief of Dermatopathology, I have the great pleasure of announcing a new article type: &amp;amp;ldquo;Clinicopathological Challenge&amp;amp;rdquo; [...]</description>
	<pubDate>2024-08-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 238: Clinicopathological Challenge: A New Article Type in Dermatopathology</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/25">doi: 10.3390/dermatopathology11030025</a></p>
	<p>Authors:
		Gürkan Kaya
		</p>
	<p>As the Editor-in-Chief of Dermatopathology, I have the great pleasure of announcing a new article type: &amp;amp;ldquo;Clinicopathological Challenge&amp;amp;rdquo; [...]</p>
	]]></content:encoded>

	<dc:title>Clinicopathological Challenge: A New Article Type in Dermatopathology</dc:title>
			<dc:creator>Gürkan Kaya</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030025</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-08-14</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-08-14</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>238</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030025</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/25</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/24">

	<title>Dermatopathology, Vol. 11, Pages 230-237: Interleukin-36 Is Highly Expressed in Skin Biopsies from Two Patients with Netherton Syndrome</title>
	<link>https://www.mdpi.com/2296-3529/11/3/24</link>
	<description>Netherton syndrome (NS) is a rare autosomal recessive disorder that occurs due to a loss-of-function mutation in SPINK5; this loss results in significant inflammation, as well as perturbations of the skin barrier&amp;amp;rsquo;s integrity and functionality. While it is unclear which inflammatory pathways contribute to the development of NS, recent studies have demonstrated the expression of interleukin (IL)-17/IL-36, as well as several Th2 cytokines. Consequently, immunohistochemistry (IHC) with IL-36 may serve as a potential tool for aiding the histopathological diagnosis of this condition. In this case series, we present two cases of NS and capture their immunostaining pattern with IL-36. Both cases demonstrated robust expression of IL-36. This finding bolsters the hypothesis that NS is partially driven by Th17 activation and suggests the potential utility of IL-36 IHC as part of the workup for this rare and diagnostically elusive entity. LEKTI IHC was negative in one biopsy, revealing a limitation of this stain in diagnosing NS.</description>
	<pubDate>2024-08-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 230-237: Interleukin-36 Is Highly Expressed in Skin Biopsies from Two Patients with Netherton Syndrome</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/24">doi: 10.3390/dermatopathology11030024</a></p>
	<p>Authors:
		Johannes Pawlowski
		Tatsiana Pukhalskaya
		Kelly Cordoro
		Marina Kristy Ibraheim
		Jeffrey P. North
		</p>
	<p>Netherton syndrome (NS) is a rare autosomal recessive disorder that occurs due to a loss-of-function mutation in SPINK5; this loss results in significant inflammation, as well as perturbations of the skin barrier&amp;amp;rsquo;s integrity and functionality. While it is unclear which inflammatory pathways contribute to the development of NS, recent studies have demonstrated the expression of interleukin (IL)-17/IL-36, as well as several Th2 cytokines. Consequently, immunohistochemistry (IHC) with IL-36 may serve as a potential tool for aiding the histopathological diagnosis of this condition. In this case series, we present two cases of NS and capture their immunostaining pattern with IL-36. Both cases demonstrated robust expression of IL-36. This finding bolsters the hypothesis that NS is partially driven by Th17 activation and suggests the potential utility of IL-36 IHC as part of the workup for this rare and diagnostically elusive entity. LEKTI IHC was negative in one biopsy, revealing a limitation of this stain in diagnosing NS.</p>
	]]></content:encoded>

	<dc:title>Interleukin-36 Is Highly Expressed in Skin Biopsies from Two Patients with Netherton Syndrome</dc:title>
			<dc:creator>Johannes Pawlowski</dc:creator>
			<dc:creator>Tatsiana Pukhalskaya</dc:creator>
			<dc:creator>Kelly Cordoro</dc:creator>
			<dc:creator>Marina Kristy Ibraheim</dc:creator>
			<dc:creator>Jeffrey P. North</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030024</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-08-12</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-08-12</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>230</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030024</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/24</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/23">

	<title>Dermatopathology, Vol. 11, Pages 218-229: IgG4-Related Disease (IgG4-RD) with Unique Combined Generalized Skin Rashes and Biliary Tract Manifestation: A Comprehensive Immunological Analysis</title>
	<link>https://www.mdpi.com/2296-3529/11/3/23</link>
	<description>IgG4-RD is a multisystem fibroinflammatory disease characterized by the infiltration of tissues by IgG4 plasma cells. Combined skin and biliary tract involvement in IgG4-RD has not been described. We present perhaps the most comprehensive analysis of lymphocyte subsets in the first case of IgG4-related generalized skin rash and first case of combined skin and biliary tract manifestations. A 55-year-old male presented with painful jaundice and generalized macular pigmented pruritic eruptions, and CT abdomen revealed biliary obstruction. Ampulla and skin biopsies were subjected to histology and immunostaining. Na&amp;amp;iuml;ve, central memory (TCM), effector memory (TEM), terminally differentiated effector memory (TEMRA) subsets of CD4+ and CD8+ T cells, T follicular helper subsets, na&amp;amp;iuml;ve, transitional, marginal zone (MZ), germinal center (GC), IgM memory, and class-switched memory (CSM) B cells, and T follicular regulatory, regulatory B cells, CD4 Treg, and CD8 Treg were analyzed. Serum IgG4 was elevated at 448 mg/dL. Ampula biopsy showed lamina propria fibrosis and increased IgG4-positive plasma cells. Skin punch biopsy showed lymphoplasmacytic infiltrates with a 67% ratio of IgG4+:IgG+ plasma cells. CD4+TN and CD4+TCM decreased, whereas CD4+TEM increased. Na&amp;amp;iuml;ve B cells increased; transitional, MZ, CSM, GC B cells, and plasmablasts decreased compared to control. CD4 Treg increased, whereas CD8 Treg and Breg decreased. In conclusion, IgG-RD may present with combined biliary tract and generalized dermatological manifestations. Changes in regulatory lymphocytes suggest their role in the pathogenesis of IgG4-RD.</description>
	<pubDate>2024-07-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 218-229: IgG4-Related Disease (IgG4-RD) with Unique Combined Generalized Skin Rashes and Biliary Tract Manifestation: A Comprehensive Immunological Analysis</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/23">doi: 10.3390/dermatopathology11030023</a></p>
	<p>Authors:
		Ye La Jung
		Sudhanshu Agrawal
		Beverly Wang
		Sudhir Gupta
		</p>
	<p>IgG4-RD is a multisystem fibroinflammatory disease characterized by the infiltration of tissues by IgG4 plasma cells. Combined skin and biliary tract involvement in IgG4-RD has not been described. We present perhaps the most comprehensive analysis of lymphocyte subsets in the first case of IgG4-related generalized skin rash and first case of combined skin and biliary tract manifestations. A 55-year-old male presented with painful jaundice and generalized macular pigmented pruritic eruptions, and CT abdomen revealed biliary obstruction. Ampulla and skin biopsies were subjected to histology and immunostaining. Na&amp;amp;iuml;ve, central memory (TCM), effector memory (TEM), terminally differentiated effector memory (TEMRA) subsets of CD4+ and CD8+ T cells, T follicular helper subsets, na&amp;amp;iuml;ve, transitional, marginal zone (MZ), germinal center (GC), IgM memory, and class-switched memory (CSM) B cells, and T follicular regulatory, regulatory B cells, CD4 Treg, and CD8 Treg were analyzed. Serum IgG4 was elevated at 448 mg/dL. Ampula biopsy showed lamina propria fibrosis and increased IgG4-positive plasma cells. Skin punch biopsy showed lymphoplasmacytic infiltrates with a 67% ratio of IgG4+:IgG+ plasma cells. CD4+TN and CD4+TCM decreased, whereas CD4+TEM increased. Na&amp;amp;iuml;ve B cells increased; transitional, MZ, CSM, GC B cells, and plasmablasts decreased compared to control. CD4 Treg increased, whereas CD8 Treg and Breg decreased. In conclusion, IgG-RD may present with combined biliary tract and generalized dermatological manifestations. Changes in regulatory lymphocytes suggest their role in the pathogenesis of IgG4-RD.</p>
	]]></content:encoded>

	<dc:title>IgG4-Related Disease (IgG4-RD) with Unique Combined Generalized Skin Rashes and Biliary Tract Manifestation: A Comprehensive Immunological Analysis</dc:title>
			<dc:creator>Ye La Jung</dc:creator>
			<dc:creator>Sudhanshu Agrawal</dc:creator>
			<dc:creator>Beverly Wang</dc:creator>
			<dc:creator>Sudhir Gupta</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030023</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-07-16</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-07-16</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>218</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030023</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/23</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/22">

	<title>Dermatopathology, Vol. 11, Pages 209-217: The Rarity in the Rarity: Presentation of Three Cases of Cutaneous Carcinosarcoma with Clinical and Histopathological Insights</title>
	<link>https://www.mdpi.com/2296-3529/11/3/22</link>
	<description>A cutaneous carcinosarcoma (cCS) is a rare and aggressive skin cancer characterized by both carcinomatous (epithelial) and sarcomatous (mesenchymal) components, making it a biphasic tumor. Despite its occurrence in various organs, a cCS is exceptionally rare in the skin, predominantly affecting older males. The etiology of a cCS is unclear, but it may originate from a single progenitor cell capable of dual differentiation or from a collision of carcinoma and sarcoma cells. Clinically, a cCS presents as a rapidly growing, painful, ulcerated nodule or plaque on sun-exposed skin, with a high risk of local invasion and metastasis. Histopathologically, a cCS includes various epithelial components, such as squamous cell carcinoma and basal cell carcinoma, along with undifferentiated sarcomatous components resembling atypical fibroxanthoma. The tumor may also exhibit heterologous differentiation like angiosarcomatous or rhabdomyosarcomatous features. We present three cases of a cCS, highlighting their clinical and histological characteristics and comparing them with previously reported cases. Understanding a cCS is complicated by its rarity and diverse presentation, emphasizing the need for further research to elucidate its pathogenesis and optimal management.</description>
	<pubDate>2024-07-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 209-217: The Rarity in the Rarity: Presentation of Three Cases of Cutaneous Carcinosarcoma with Clinical and Histopathological Insights</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/22">doi: 10.3390/dermatopathology11030022</a></p>
	<p>Authors:
		Gerardo Cazzato
		Anna Colagrande
		Valentina Caputo
		Giuseppe Ingravallo
		Eliano Cascardi
		Francesco Fortarezza
		Emanuela Bonoldi
		Franco Rongioletti
		</p>
	<p>A cutaneous carcinosarcoma (cCS) is a rare and aggressive skin cancer characterized by both carcinomatous (epithelial) and sarcomatous (mesenchymal) components, making it a biphasic tumor. Despite its occurrence in various organs, a cCS is exceptionally rare in the skin, predominantly affecting older males. The etiology of a cCS is unclear, but it may originate from a single progenitor cell capable of dual differentiation or from a collision of carcinoma and sarcoma cells. Clinically, a cCS presents as a rapidly growing, painful, ulcerated nodule or plaque on sun-exposed skin, with a high risk of local invasion and metastasis. Histopathologically, a cCS includes various epithelial components, such as squamous cell carcinoma and basal cell carcinoma, along with undifferentiated sarcomatous components resembling atypical fibroxanthoma. The tumor may also exhibit heterologous differentiation like angiosarcomatous or rhabdomyosarcomatous features. We present three cases of a cCS, highlighting their clinical and histological characteristics and comparing them with previously reported cases. Understanding a cCS is complicated by its rarity and diverse presentation, emphasizing the need for further research to elucidate its pathogenesis and optimal management.</p>
	]]></content:encoded>

	<dc:title>The Rarity in the Rarity: Presentation of Three Cases of Cutaneous Carcinosarcoma with Clinical and Histopathological Insights</dc:title>
			<dc:creator>Gerardo Cazzato</dc:creator>
			<dc:creator>Anna Colagrande</dc:creator>
			<dc:creator>Valentina Caputo</dc:creator>
			<dc:creator>Giuseppe Ingravallo</dc:creator>
			<dc:creator>Eliano Cascardi</dc:creator>
			<dc:creator>Francesco Fortarezza</dc:creator>
			<dc:creator>Emanuela Bonoldi</dc:creator>
			<dc:creator>Franco Rongioletti</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030022</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-07-15</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-07-15</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>209</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030022</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/22</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/21">

	<title>Dermatopathology, Vol. 11, Pages 200-208: TRPS1 Expression Is Frequently Seen in a Subset of Cutaneous Mesenchymal Neoplasms and Tumors of Uncertain Differentiation: A Potential Diagnostic Pitfall</title>
	<link>https://www.mdpi.com/2296-3529/11/3/21</link>
	<description>Although extensively studied in cutaneous epithelial neoplasms, the TRPS1 immunoreactivity in cutaneous mesenchymal neoplasms and tumors of uncertain differentiation (CMNTUDs), such as atypical fibroxanthoma (AFX), remains largely unexplored. We assessed TRPS1 immunoreactivity in 135 CMNTUDs, comprising 46 fibrohistiocytic/fibroblastic tumors, 28 vascular tumors, 24 peripheral nerve sheath tumors (PNSTs), 21 tumors of uncertain differentiation, and 16 smooth muscle tumors. Additionally, we included selected cases of melanoma with spindled cell morphology or desmoplastic features (n = 9) and sarcomatoid squamous cell carcinoma (SSCC) (n = 5) to compare TRPS1 expression patterns with those of AFX. TRPS1 expression was prevalent in dermatofibromas (24/24), leiomyomas (8/8), AFXs/pleomorphic dermal sarcoma (PDS) (20/21), dermatofibrosarcomas protuberans (14/22), and leiomyosarcomas (6/8). It was uncommon in angiosarcomas (3/20), Kaposi sarcomas (2/8), and neurofibromas (5/17) and absent in perineuriomas (0/2). AFXs/PDS exhibited the highest median H-score of 240, contrasting with minimal TRPS1 immunoreactivity in vascular neoplasms and PNSTs, with median H-scores consistently below 10. Significant differences in H-score were observed between AFXs/PDS and angiosarcomas (p &amp;amp;lt; 0.001), melanomas (p &amp;amp;lt; 0.001), and leiomyosarcomas (p = 0.029). However, no significant difference was found compared to SSCCs, suggesting limited discriminatory power of TRPS1 in this context. This study sheds light on TRPS1 expression patterns in a subset of CMNTUDs, extending beyond prior studies primarily focused on epithelial tumors, while underscoring potential pitfalls associated with TRPS1 immunohistochemistry.</description>
	<pubDate>2024-07-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 200-208: TRPS1 Expression Is Frequently Seen in a Subset of Cutaneous Mesenchymal Neoplasms and Tumors of Uncertain Differentiation: A Potential Diagnostic Pitfall</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/21">doi: 10.3390/dermatopathology11030021</a></p>
	<p>Authors:
		Moon Joo Kim
		Yi A. Liu
		Yunyi Wang
		Jing Ning
		Woo Cheal Cho
		</p>
	<p>Although extensively studied in cutaneous epithelial neoplasms, the TRPS1 immunoreactivity in cutaneous mesenchymal neoplasms and tumors of uncertain differentiation (CMNTUDs), such as atypical fibroxanthoma (AFX), remains largely unexplored. We assessed TRPS1 immunoreactivity in 135 CMNTUDs, comprising 46 fibrohistiocytic/fibroblastic tumors, 28 vascular tumors, 24 peripheral nerve sheath tumors (PNSTs), 21 tumors of uncertain differentiation, and 16 smooth muscle tumors. Additionally, we included selected cases of melanoma with spindled cell morphology or desmoplastic features (n = 9) and sarcomatoid squamous cell carcinoma (SSCC) (n = 5) to compare TRPS1 expression patterns with those of AFX. TRPS1 expression was prevalent in dermatofibromas (24/24), leiomyomas (8/8), AFXs/pleomorphic dermal sarcoma (PDS) (20/21), dermatofibrosarcomas protuberans (14/22), and leiomyosarcomas (6/8). It was uncommon in angiosarcomas (3/20), Kaposi sarcomas (2/8), and neurofibromas (5/17) and absent in perineuriomas (0/2). AFXs/PDS exhibited the highest median H-score of 240, contrasting with minimal TRPS1 immunoreactivity in vascular neoplasms and PNSTs, with median H-scores consistently below 10. Significant differences in H-score were observed between AFXs/PDS and angiosarcomas (p &amp;amp;lt; 0.001), melanomas (p &amp;amp;lt; 0.001), and leiomyosarcomas (p = 0.029). However, no significant difference was found compared to SSCCs, suggesting limited discriminatory power of TRPS1 in this context. This study sheds light on TRPS1 expression patterns in a subset of CMNTUDs, extending beyond prior studies primarily focused on epithelial tumors, while underscoring potential pitfalls associated with TRPS1 immunohistochemistry.</p>
	]]></content:encoded>

	<dc:title>TRPS1 Expression Is Frequently Seen in a Subset of Cutaneous Mesenchymal Neoplasms and Tumors of Uncertain Differentiation: A Potential Diagnostic Pitfall</dc:title>
			<dc:creator>Moon Joo Kim</dc:creator>
			<dc:creator>Yi A. Liu</dc:creator>
			<dc:creator>Yunyi Wang</dc:creator>
			<dc:creator>Jing Ning</dc:creator>
			<dc:creator>Woo Cheal Cho</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030021</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-07-15</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-07-15</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>200</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030021</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/21</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/20">

	<title>Dermatopathology, Vol. 11, Pages 192-199: Placental ACE2 Expression: A Possible Pathogenetic Mechanism for Infantile Hemangiomas</title>
	<link>https://www.mdpi.com/2296-3529/11/3/20</link>
	<description>ACE2 is a mono-carboxypeptidase with remarkable vasculo-protective properties, and its expression in the human placenta plays a central role in blood pressure homeostasis and fetal perfusion. Therefore, an alteration in the placental expression of ACE2 could be responsible for reduced placental perfusion and infantile hemangioma (IH) development. Study placentae were collected from patients affected by IHs who were referred to our Dermatology Clinic from 2016 to 2022, while control placentae were randomly collected while matching cases for gestational age. Immunohistochemical investigations were performed with a recombinant anti-ACE2 rabbit monoclonal antibody. A total of 47 placentae were examined, including 20 study placentae and 27 control ones. The mean placental weight was significantly lower in the study group (380.6 g vs. 502.3 g; p = 0.005), while subclinical chorioamnionitis occurred more frequently in the study group (20% vs. 0%, p = 0.03). The mean ACE2 expression was dramatically lower in the study group (&amp;amp;chi;2 = 42.1 p &amp;amp;lt; 0.001), and the mean placental weight was significantly lower when ACE2 was not expressed compared to the 25&amp;amp;ndash;75% and &amp;amp;gt;75% classes of expression (p &amp;amp;lt; 0.05). This study demonstrated that ACE2, as a marker for tissue hypoxia, is dramatically hypo-expressed in placentae belonging to mothers who delivered one or more babies with IH compared to the controls.</description>
	<pubDate>2024-07-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 192-199: Placental ACE2 Expression: A Possible Pathogenetic Mechanism for Infantile Hemangiomas</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/20">doi: 10.3390/dermatopathology11030020</a></p>
	<p>Authors:
		Aurora De Marco
		Gerardo Cazzato
		Rosalba Maggialetti
		Giuseppe Ingravallo
		Margherita Fanelli
		Antonella Vimercati
		Ettore Cicinelli
		Nicola Laforgia
		Iria Neri
		Ernesto Bonifazi
		Domenico Bonamonte
		</p>
	<p>ACE2 is a mono-carboxypeptidase with remarkable vasculo-protective properties, and its expression in the human placenta plays a central role in blood pressure homeostasis and fetal perfusion. Therefore, an alteration in the placental expression of ACE2 could be responsible for reduced placental perfusion and infantile hemangioma (IH) development. Study placentae were collected from patients affected by IHs who were referred to our Dermatology Clinic from 2016 to 2022, while control placentae were randomly collected while matching cases for gestational age. Immunohistochemical investigations were performed with a recombinant anti-ACE2 rabbit monoclonal antibody. A total of 47 placentae were examined, including 20 study placentae and 27 control ones. The mean placental weight was significantly lower in the study group (380.6 g vs. 502.3 g; p = 0.005), while subclinical chorioamnionitis occurred more frequently in the study group (20% vs. 0%, p = 0.03). The mean ACE2 expression was dramatically lower in the study group (&amp;amp;chi;2 = 42.1 p &amp;amp;lt; 0.001), and the mean placental weight was significantly lower when ACE2 was not expressed compared to the 25&amp;amp;ndash;75% and &amp;amp;gt;75% classes of expression (p &amp;amp;lt; 0.05). This study demonstrated that ACE2, as a marker for tissue hypoxia, is dramatically hypo-expressed in placentae belonging to mothers who delivered one or more babies with IH compared to the controls.</p>
	]]></content:encoded>

	<dc:title>Placental ACE2 Expression: A Possible Pathogenetic Mechanism for Infantile Hemangiomas</dc:title>
			<dc:creator>Aurora De Marco</dc:creator>
			<dc:creator>Gerardo Cazzato</dc:creator>
			<dc:creator>Rosalba Maggialetti</dc:creator>
			<dc:creator>Giuseppe Ingravallo</dc:creator>
			<dc:creator>Margherita Fanelli</dc:creator>
			<dc:creator>Antonella Vimercati</dc:creator>
			<dc:creator>Ettore Cicinelli</dc:creator>
			<dc:creator>Nicola Laforgia</dc:creator>
			<dc:creator>Iria Neri</dc:creator>
			<dc:creator>Ernesto Bonifazi</dc:creator>
			<dc:creator>Domenico Bonamonte</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030020</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-07-11</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-07-11</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>192</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030020</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/20</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/19">

	<title>Dermatopathology, Vol. 11, Pages 184-191: Histopathologic Evaluation of Atypical Fibroxanthoma or Pleomorphic Dermal Sarcoma Debulk Specimen from Mohs Surgery: A Requirement for Their Proper Distinction</title>
	<link>https://www.mdpi.com/2296-3529/11/3/19</link>
	<description>Pleomorphic dermal sarcomas can be clinically aggressive, with a higher tendency to cause local recurrence, metastasis, and death. Atypical fibroxanthoma and pleomorphic dermal sarcoma are histopathologically similar, and their distinction requires a systematic examination of the entire excised tumor. Since Mohs micrographic surgery is commonly utilized to treat atypical fibroxanthoma, a histopathologic evaluation of debulk specimens by permanent pathology is prudent to avoid underdiagnosing pleomorphic dermal sarcoma. This approach can improve risk assessment and treatment decisions, ultimately enhancing patient outcomes. Also, the proper distinction will facilitate the future development of accurate staging criteria and additional treatment modalities.</description>
	<pubDate>2024-07-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 184-191: Histopathologic Evaluation of Atypical Fibroxanthoma or Pleomorphic Dermal Sarcoma Debulk Specimen from Mohs Surgery: A Requirement for Their Proper Distinction</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/19">doi: 10.3390/dermatopathology11030019</a></p>
	<p>Authors:
		Muhammad N. Mahmood
		</p>
	<p>Pleomorphic dermal sarcomas can be clinically aggressive, with a higher tendency to cause local recurrence, metastasis, and death. Atypical fibroxanthoma and pleomorphic dermal sarcoma are histopathologically similar, and their distinction requires a systematic examination of the entire excised tumor. Since Mohs micrographic surgery is commonly utilized to treat atypical fibroxanthoma, a histopathologic evaluation of debulk specimens by permanent pathology is prudent to avoid underdiagnosing pleomorphic dermal sarcoma. This approach can improve risk assessment and treatment decisions, ultimately enhancing patient outcomes. Also, the proper distinction will facilitate the future development of accurate staging criteria and additional treatment modalities.</p>
	]]></content:encoded>

	<dc:title>Histopathologic Evaluation of Atypical Fibroxanthoma or Pleomorphic Dermal Sarcoma Debulk Specimen from Mohs Surgery: A Requirement for Their Proper Distinction</dc:title>
			<dc:creator>Muhammad N. Mahmood</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030019</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-07-03</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-07-03</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>184</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030019</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/3/18">

	<title>Dermatopathology, Vol. 11, Pages 177-183: Digital Papillary Adenocarcinoma: The Detection of Low-Risk Human Papillomaviruses and the BRAF p.V600E Mutation in a Subset of Cases</title>
	<link>https://www.mdpi.com/2296-3529/11/3/18</link>
	<description>Digital papillary adenocarcinoma (DPA) is a rare malignant neoplasm which arises from the sweat glands and has metastatic potential. DPA exhibits a wide range of architectural features and exhibits low-grade to high-grade features, so distinguishing DPA from benign skin neoplasms, including acral hidradenoma, poses significant diagnostic challenges. The recent literature suggests a strong association between DPA and human papillomavirus (HPV) 42, a low-risk HPV (LR-HPV) subtype, and a possible association between DPA and BRAF p.V600E. To explore these associations, we assessed the utility of in situ hybridization (ISH) for LR-HPV (types 6, 11, 40, 42, 43, 44) and immunohistochemistry (IHC) for BRAF p.V600E in diagnosing DPA and distinguishing DPA from acral hidradenoma. With institutional review board approval, we retrospectively identified 15 specimens of DPA (from 13 patients) and 3 cases of acral hidradenoma. Of the 13 DPA cases, 6 were negative for LR-HPV and BRAF p.V600E; 6 were positive for only LR-HPV; and 1 was positive for only BRAF p.V600E but negative for LR-HPV. All three cases of acral hidradenoma were negative for LR-HPV and BRAF p.V600E. As our sample size is limited, larger studies are needed to assess the value of detecting LR-HPV and BRAF p.V600E in the distinction of DPA and acral hidradenoma. However, our findings indicate a stronger association of DPA with LR-HPV than with BRAF p.V600E.</description>
	<pubDate>2024-06-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 177-183: Digital Papillary Adenocarcinoma: The Detection of Low-Risk Human Papillomaviruses and the BRAF p.V600E Mutation in a Subset of Cases</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/3/18">doi: 10.3390/dermatopathology11030018</a></p>
	<p>Authors:
		Feifan Chen
		Priyadharsini Nagarajan
		Phyu P. Aung
		</p>
	<p>Digital papillary adenocarcinoma (DPA) is a rare malignant neoplasm which arises from the sweat glands and has metastatic potential. DPA exhibits a wide range of architectural features and exhibits low-grade to high-grade features, so distinguishing DPA from benign skin neoplasms, including acral hidradenoma, poses significant diagnostic challenges. The recent literature suggests a strong association between DPA and human papillomavirus (HPV) 42, a low-risk HPV (LR-HPV) subtype, and a possible association between DPA and BRAF p.V600E. To explore these associations, we assessed the utility of in situ hybridization (ISH) for LR-HPV (types 6, 11, 40, 42, 43, 44) and immunohistochemistry (IHC) for BRAF p.V600E in diagnosing DPA and distinguishing DPA from acral hidradenoma. With institutional review board approval, we retrospectively identified 15 specimens of DPA (from 13 patients) and 3 cases of acral hidradenoma. Of the 13 DPA cases, 6 were negative for LR-HPV and BRAF p.V600E; 6 were positive for only LR-HPV; and 1 was positive for only BRAF p.V600E but negative for LR-HPV. All three cases of acral hidradenoma were negative for LR-HPV and BRAF p.V600E. As our sample size is limited, larger studies are needed to assess the value of detecting LR-HPV and BRAF p.V600E in the distinction of DPA and acral hidradenoma. However, our findings indicate a stronger association of DPA with LR-HPV than with BRAF p.V600E.</p>
	]]></content:encoded>

	<dc:title>Digital Papillary Adenocarcinoma: The Detection of Low-Risk Human Papillomaviruses and the BRAF p.V600E Mutation in a Subset of Cases</dc:title>
			<dc:creator>Feifan Chen</dc:creator>
			<dc:creator>Priyadharsini Nagarajan</dc:creator>
			<dc:creator>Phyu P. Aung</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11030018</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-06-28</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-06-28</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>177</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11030018</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/3/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/2/17">

	<title>Dermatopathology, Vol. 11, Pages 161-176: The Prognostic Value of Histopathological Features in Early-Stage Mycosis Fungoides: Insights from a Retrospective&amp;ndash;Prospective Cohort Study</title>
	<link>https://www.mdpi.com/2296-3529/11/2/17</link>
	<description>Primary cutaneous lymphomas (PCLs), especially mycosis fungoides (MF), pose significant diagnostic and therapeutic challenges. This study aims to correlate initial histological features with the disease course and survival in MF patients. A retrospective&amp;amp;ndash;prospective cohort study was conducted on 83 patients diagnosed with early-stage MF at the Departments of Dermatovenerology and Pathology, UHC Zagreb, from January 2003 to December 2012. The analyzed histopathological parameters included lichenoid dermal lymphocyte infiltrate, Pautrier microabscesses, and lymphocyte atypia. Patients with more than 30 guardian lymphocytes per 100 keratinocytes exhibited worse overall and progression-free survival. Furthermore, those with over 50% atypical lymphocytes demonstrated a faster progression rate. A dense lichenoid dermal infiltrate and a high count of lymphocyte &amp;amp;ldquo;keepers&amp;amp;rdquo; significantly increased the mortality risk within five years of diagnosis. This study did not fully confirm the hypothesis regarding the prognostic value of large Pautrier microabscesses but highlighted the importance of dense lichenoid infiltrates. The study identified new potential histopathological prognostic factors in early-stage MF, suggesting the need for larger studies to confirm these findings. The identification of such predictors could enhance the prognostic stratification and guide more tailored therapeutic approaches for MF patients.</description>
	<pubDate>2024-06-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 161-176: The Prognostic Value of Histopathological Features in Early-Stage Mycosis Fungoides: Insights from a Retrospective&amp;ndash;Prospective Cohort Study</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/2/17">doi: 10.3390/dermatopathology11020017</a></p>
	<p>Authors:
		Sandra Jerkovic Gulin
		Ivana Ilic
		Romana Ceovic
		</p>
	<p>Primary cutaneous lymphomas (PCLs), especially mycosis fungoides (MF), pose significant diagnostic and therapeutic challenges. This study aims to correlate initial histological features with the disease course and survival in MF patients. A retrospective&amp;amp;ndash;prospective cohort study was conducted on 83 patients diagnosed with early-stage MF at the Departments of Dermatovenerology and Pathology, UHC Zagreb, from January 2003 to December 2012. The analyzed histopathological parameters included lichenoid dermal lymphocyte infiltrate, Pautrier microabscesses, and lymphocyte atypia. Patients with more than 30 guardian lymphocytes per 100 keratinocytes exhibited worse overall and progression-free survival. Furthermore, those with over 50% atypical lymphocytes demonstrated a faster progression rate. A dense lichenoid dermal infiltrate and a high count of lymphocyte &amp;amp;ldquo;keepers&amp;amp;rdquo; significantly increased the mortality risk within five years of diagnosis. This study did not fully confirm the hypothesis regarding the prognostic value of large Pautrier microabscesses but highlighted the importance of dense lichenoid infiltrates. The study identified new potential histopathological prognostic factors in early-stage MF, suggesting the need for larger studies to confirm these findings. The identification of such predictors could enhance the prognostic stratification and guide more tailored therapeutic approaches for MF patients.</p>
	]]></content:encoded>

	<dc:title>The Prognostic Value of Histopathological Features in Early-Stage Mycosis Fungoides: Insights from a Retrospective&amp;amp;ndash;Prospective Cohort Study</dc:title>
			<dc:creator>Sandra Jerkovic Gulin</dc:creator>
			<dc:creator>Ivana Ilic</dc:creator>
			<dc:creator>Romana Ceovic</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11020017</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-06-14</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-06-14</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>161</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11020017</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/2/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/2/16">

	<title>Dermatopathology, Vol. 11, Pages 154-160: Giant Morpheaform Basal Cell Carcinoma Mimicking Scarring Alopecia: Exception Prone to Neglect</title>
	<link>https://www.mdpi.com/2296-3529/11/2/16</link>
	<description>A 74-year-old woman in good general health presented with a 5-year history of progressive hair loss over several years, interpreted as female androgenetic alopecia (AGA), and was treated with topical 5% Minoxidil without improvement. The patient&amp;amp;rsquo;s relevant medical history revealed infiltrating, triple-negative apocrine carcinoma of the right breast four years before, treated by quadrantectomy, radiation, lymphadenectomy and chemotherapy, with no recurrence at the last follow-up. On examination, there was an asymptomatic 15 &amp;amp;times; 15 cm firm and whitish area of scarring alopecia on the central scalp. Dermoscopy revealed multiple arborizing vessels and many telangiectasia. The clinical considerations included mainly cutaneous metastasis of breast carcinoma (alopecia neoplastica), pseudopelade of Broque and morpheaform basal cell carcinoma (BCC). A histopathologic examination revealed characteristic changes of morpheaform BCC with basaloid islands and cords of atypical basaloid cells diffusely infiltrating the dermis, embedded in a sclerotic and hypervascularized stroma. Secondary alopecia neoplastica due to morpheaform BCC on the scalp is an exceedingly rare entity, possessing subtle clinical features that may mimic both scarring and non-scarring alopecia. Delayed recognition may contribute to aggressive behavior and extensive local destruction. Treatment with hedgehog inhibitors in locally advanced BCC of the scalp, both in adjuvant and neoadjuvant modalities, is promising.</description>
	<pubDate>2024-06-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 154-160: Giant Morpheaform Basal Cell Carcinoma Mimicking Scarring Alopecia: Exception Prone to Neglect</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/2/16">doi: 10.3390/dermatopathology11020016</a></p>
	<p>Authors:
		Carlo Francesco Tomasini
		Giacomo Fiandrino
		Emanuele Mario Favale
		Francesca Antoci
		Stefania Barruscotti
		</p>
	<p>A 74-year-old woman in good general health presented with a 5-year history of progressive hair loss over several years, interpreted as female androgenetic alopecia (AGA), and was treated with topical 5% Minoxidil without improvement. The patient&amp;amp;rsquo;s relevant medical history revealed infiltrating, triple-negative apocrine carcinoma of the right breast four years before, treated by quadrantectomy, radiation, lymphadenectomy and chemotherapy, with no recurrence at the last follow-up. On examination, there was an asymptomatic 15 &amp;amp;times; 15 cm firm and whitish area of scarring alopecia on the central scalp. Dermoscopy revealed multiple arborizing vessels and many telangiectasia. The clinical considerations included mainly cutaneous metastasis of breast carcinoma (alopecia neoplastica), pseudopelade of Broque and morpheaform basal cell carcinoma (BCC). A histopathologic examination revealed characteristic changes of morpheaform BCC with basaloid islands and cords of atypical basaloid cells diffusely infiltrating the dermis, embedded in a sclerotic and hypervascularized stroma. Secondary alopecia neoplastica due to morpheaform BCC on the scalp is an exceedingly rare entity, possessing subtle clinical features that may mimic both scarring and non-scarring alopecia. Delayed recognition may contribute to aggressive behavior and extensive local destruction. Treatment with hedgehog inhibitors in locally advanced BCC of the scalp, both in adjuvant and neoadjuvant modalities, is promising.</p>
	]]></content:encoded>

	<dc:title>Giant Morpheaform Basal Cell Carcinoma Mimicking Scarring Alopecia: Exception Prone to Neglect</dc:title>
			<dc:creator>Carlo Francesco Tomasini</dc:creator>
			<dc:creator>Giacomo Fiandrino</dc:creator>
			<dc:creator>Emanuele Mario Favale</dc:creator>
			<dc:creator>Francesca Antoci</dc:creator>
			<dc:creator>Stefania Barruscotti</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11020016</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-06-05</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-06-05</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>154</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11020016</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/2/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/2/15">

	<title>Dermatopathology, Vol. 11, Pages 147-153: Poikilodermatous Plaque-like Hemangioma: Case Presentation and Literature Review</title>
	<link>https://www.mdpi.com/2296-3529/11/2/15</link>
	<description>Poikilodermatous plaque-like hemangioma (PPH) is a recently described clinical and pathological entity, with only 18 cases reported in the literature. Although uncommon, this benign condition presents consistent clinical and histological findings. We present a new case of PPH in an 81-year-old male and review the existing literature. The persistence over time and the need to distinguish PPH from more significant lesions underscore the importance of its clinical and pathological recognition.</description>
	<pubDate>2024-05-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 147-153: Poikilodermatous Plaque-like Hemangioma: Case Presentation and Literature Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/2/15">doi: 10.3390/dermatopathology11020015</a></p>
	<p>Authors:
		Pablo Díaz-Calvillo
		Francisco Vílchez-Márquez
		Francisco Manuel Ramos-Pleguezuelos
		Salvador Arias-Santiago
		</p>
	<p>Poikilodermatous plaque-like hemangioma (PPH) is a recently described clinical and pathological entity, with only 18 cases reported in the literature. Although uncommon, this benign condition presents consistent clinical and histological findings. We present a new case of PPH in an 81-year-old male and review the existing literature. The persistence over time and the need to distinguish PPH from more significant lesions underscore the importance of its clinical and pathological recognition.</p>
	]]></content:encoded>

	<dc:title>Poikilodermatous Plaque-like Hemangioma: Case Presentation and Literature Review</dc:title>
			<dc:creator>Pablo Díaz-Calvillo</dc:creator>
			<dc:creator>Francisco Vílchez-Márquez</dc:creator>
			<dc:creator>Francisco Manuel Ramos-Pleguezuelos</dc:creator>
			<dc:creator>Salvador Arias-Santiago</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11020015</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-05-21</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-05-21</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>147</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11020015</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/2/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/2/14">

	<title>Dermatopathology, Vol. 11, Pages 142-146: Intratarsal Keratinous Cyst Clinically Misdiagnosed as a Chalazion</title>
	<link>https://www.mdpi.com/2296-3529/11/2/14</link>
	<description>The intratarsal keratinous cyst (IKC) is a recently described entity, often clinically misdiagnosed as a chalazion. We report a case of a 61-year-old male patient with a chief complaint of a small lesion on the upper eyelid that evolved over six months. On physical examination, an asymptomatic, firm nodule was identified on the left upper eyelid. The patient reported no history of trauma. A provisional diagnosis of chalazion was established, and an excisional biopsy was performed. Histopathologically, the lesion was lined with a stratified squamous epithelium, with a corrugated epithelial surface showing abrupt keratinization without keratohyalin granules, and compact keratinous-appearing material in the cystic lumen. The diagnosis was IKC. No signs of recurrence were observed after one year of follow-up. It is essential to accurately diagnose IKC and distinguish it from chalazion and epidermal inclusion cysts, because IKC requires complete surgical excision and can exhibit multiple recurrences if not properly removed.</description>
	<pubDate>2024-04-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 142-146: Intratarsal Keratinous Cyst Clinically Misdiagnosed as a Chalazion</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/2/14">doi: 10.3390/dermatopathology11020014</a></p>
	<p>Authors:
		John Lennon Silva Cunha
		Clenia E. S. Andrade
		Fernando A. P. da Cunha Filho
		Alexandre R. da Paz
		Manuel A. Gordón-Núñez
		Pollianna M. Alves
		Cassiano F. W. Nonaka
		</p>
	<p>The intratarsal keratinous cyst (IKC) is a recently described entity, often clinically misdiagnosed as a chalazion. We report a case of a 61-year-old male patient with a chief complaint of a small lesion on the upper eyelid that evolved over six months. On physical examination, an asymptomatic, firm nodule was identified on the left upper eyelid. The patient reported no history of trauma. A provisional diagnosis of chalazion was established, and an excisional biopsy was performed. Histopathologically, the lesion was lined with a stratified squamous epithelium, with a corrugated epithelial surface showing abrupt keratinization without keratohyalin granules, and compact keratinous-appearing material in the cystic lumen. The diagnosis was IKC. No signs of recurrence were observed after one year of follow-up. It is essential to accurately diagnose IKC and distinguish it from chalazion and epidermal inclusion cysts, because IKC requires complete surgical excision and can exhibit multiple recurrences if not properly removed.</p>
	]]></content:encoded>

	<dc:title>Intratarsal Keratinous Cyst Clinically Misdiagnosed as a Chalazion</dc:title>
			<dc:creator>John Lennon Silva Cunha</dc:creator>
			<dc:creator>Clenia E. S. Andrade</dc:creator>
			<dc:creator>Fernando A. P. da Cunha Filho</dc:creator>
			<dc:creator>Alexandre R. da Paz</dc:creator>
			<dc:creator>Manuel A. Gordón-Núñez</dc:creator>
			<dc:creator>Pollianna M. Alves</dc:creator>
			<dc:creator>Cassiano F. W. Nonaka</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11020014</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-04-19</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-04-19</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>142</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11020014</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/2/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/13">

	<title>Dermatopathology, Vol. 11, Pages 130-141: Cutaneous Reactions after COVID-19 Vaccines: Analysis of the Clinical and Histopathological Spectrum&amp;mdash;Case Series and Review of the Literature</title>
	<link>https://www.mdpi.com/2296-3529/11/1/13</link>
	<description>(1) Background: Various cutaneous adverse drug reactions (ADRs) are observed with the implementation of mRNA COVID-19 vaccines. To gain insight into the clinicopathologic features, we analyzed the correlation of histological and clinical data in 48 patients with these ADRs. (2) Methods: Single-center retrospective study in patients with ADRs after mRNA COVID-19 vaccination (mRNA-1273 and BNT162b2 vaccines). (3) Results: Distant generalized ADRs prevailed (91%), often appearing clinically as spongiotic dermatitis or maculopapular exanthema. Histopathological analysis revealed spongiotic changes (46%) and dermal superficial perivascular predominantly lymphocytic infiltrates (17%). Eosinophils were found in 66% of biopsies, neutrophils in 29%, and plasma cells only in 8% of biopsies. Most ADRs occurred after the second vaccine dose (44%). Histologically spongiotic changes were associated with clinical features of spongiotic dermatitis in only 50% of patients and maculopapular exanthema in the remaining patients. ADRs represented an aggravation of preexisting skin disease in 23% of patients. ADRs regressed within 28 days or less in 53% of patients and persisted beyond a month in the remaining patients. (4) Conclusions: Our study demonstrates a diverse spectrum of generalized ADRs, revealing correlations between histology and clinical features but also instances of divergence. Interestingly, in about half of our patients, ADRs were self-limited, whereas ADRs extended beyond a month in the other half.</description>
	<pubDate>2024-03-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 130-141: Cutaneous Reactions after COVID-19 Vaccines: Analysis of the Clinical and Histopathological Spectrum&amp;mdash;Case Series and Review of the Literature</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/13">doi: 10.3390/dermatopathology11010013</a></p>
	<p>Authors:
		Ursina Schmid
		Jörg Galambos
		Katrin Pfaltz
		Ivan Hegyi
		Salomé Courvoisier
		Werner Kempf
		</p>
	<p>(1) Background: Various cutaneous adverse drug reactions (ADRs) are observed with the implementation of mRNA COVID-19 vaccines. To gain insight into the clinicopathologic features, we analyzed the correlation of histological and clinical data in 48 patients with these ADRs. (2) Methods: Single-center retrospective study in patients with ADRs after mRNA COVID-19 vaccination (mRNA-1273 and BNT162b2 vaccines). (3) Results: Distant generalized ADRs prevailed (91%), often appearing clinically as spongiotic dermatitis or maculopapular exanthema. Histopathological analysis revealed spongiotic changes (46%) and dermal superficial perivascular predominantly lymphocytic infiltrates (17%). Eosinophils were found in 66% of biopsies, neutrophils in 29%, and plasma cells only in 8% of biopsies. Most ADRs occurred after the second vaccine dose (44%). Histologically spongiotic changes were associated with clinical features of spongiotic dermatitis in only 50% of patients and maculopapular exanthema in the remaining patients. ADRs represented an aggravation of preexisting skin disease in 23% of patients. ADRs regressed within 28 days or less in 53% of patients and persisted beyond a month in the remaining patients. (4) Conclusions: Our study demonstrates a diverse spectrum of generalized ADRs, revealing correlations between histology and clinical features but also instances of divergence. Interestingly, in about half of our patients, ADRs were self-limited, whereas ADRs extended beyond a month in the other half.</p>
	]]></content:encoded>

	<dc:title>Cutaneous Reactions after COVID-19 Vaccines: Analysis of the Clinical and Histopathological Spectrum&amp;amp;mdash;Case Series and Review of the Literature</dc:title>
			<dc:creator>Ursina Schmid</dc:creator>
			<dc:creator>Jörg Galambos</dc:creator>
			<dc:creator>Katrin Pfaltz</dc:creator>
			<dc:creator>Ivan Hegyi</dc:creator>
			<dc:creator>Salomé Courvoisier</dc:creator>
			<dc:creator>Werner Kempf</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010013</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-03-14</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-03-14</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>130</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010013</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/12">

	<title>Dermatopathology, Vol. 11, Pages 129: The Leading Impact Journal in Dermatopathology</title>
	<link>https://www.mdpi.com/2296-3529/11/1/12</link>
	<description>As the Editor-in-Chief of Dermatopathology and the President of the European Society of Dermatopathology (ESDP), I have the great pleasure of celebrating the 10th anniversary of Dermatopathology, the only online journal in the field of cutaneous pathology and the official journal of the ESDP [...]</description>
	<pubDate>2024-03-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 129: The Leading Impact Journal in Dermatopathology</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/12">doi: 10.3390/dermatopathology11010012</a></p>
	<p>Authors:
		Gürkan Kaya
		</p>
	<p>As the Editor-in-Chief of Dermatopathology and the President of the European Society of Dermatopathology (ESDP), I have the great pleasure of celebrating the 10th anniversary of Dermatopathology, the only online journal in the field of cutaneous pathology and the official journal of the ESDP [...]</p>
	]]></content:encoded>

	<dc:title>The Leading Impact Journal in Dermatopathology</dc:title>
			<dc:creator>Gürkan Kaya</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010012</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-03-06</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-03-06</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>129</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010012</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/11">

	<title>Dermatopathology, Vol. 11, Pages 124-128: Sebaceomas in a Muir&amp;ndash;Torre-like Phenotype in a Patient with MUTYH-Associated Polyposis</title>
	<link>https://www.mdpi.com/2296-3529/11/1/11</link>
	<description>This case report describes a case of a patient with MUTYH-associated polyposis (MAP), who presented with multiple sebaceomas in a Muir&amp;amp;ndash;Torre-like phenotype. MAP is caused by mutations in MUTYH, a base excision repair gene responsible for detecting and repairing the 8-oxo-G:A transversion caused by reactive oxygen species. MAP is associated with an increased risk of developing adenomatous polyps and colorectal cancer. Muir&amp;amp;ndash;Torre syndrome is a clinical phenotype of Lynch syndrome, which presents with multiple cutaneous sebaceous neoplasms. Lynch syndrome, like MAP, increases the likelihood of developing colorectal cancer but with a different pathogenesis and mode of inheritance. This case demonstrates that in a patient presenting with multiple sebaceous neoplasms, further workup and genetic testing may be indicated, not only for Muir&amp;amp;ndash;Torre and Lynch syndrome but also for MAP.</description>
	<pubDate>2024-03-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 124-128: Sebaceomas in a Muir&amp;ndash;Torre-like Phenotype in a Patient with MUTYH-Associated Polyposis</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/11">doi: 10.3390/dermatopathology11010011</a></p>
	<p>Authors:
		Julia Guarrera
		James C. Prezzano
		Kathleen A. Mannava
		</p>
	<p>This case report describes a case of a patient with MUTYH-associated polyposis (MAP), who presented with multiple sebaceomas in a Muir&amp;amp;ndash;Torre-like phenotype. MAP is caused by mutations in MUTYH, a base excision repair gene responsible for detecting and repairing the 8-oxo-G:A transversion caused by reactive oxygen species. MAP is associated with an increased risk of developing adenomatous polyps and colorectal cancer. Muir&amp;amp;ndash;Torre syndrome is a clinical phenotype of Lynch syndrome, which presents with multiple cutaneous sebaceous neoplasms. Lynch syndrome, like MAP, increases the likelihood of developing colorectal cancer but with a different pathogenesis and mode of inheritance. This case demonstrates that in a patient presenting with multiple sebaceous neoplasms, further workup and genetic testing may be indicated, not only for Muir&amp;amp;ndash;Torre and Lynch syndrome but also for MAP.</p>
	]]></content:encoded>

	<dc:title>Sebaceomas in a Muir&amp;amp;ndash;Torre-like Phenotype in a Patient with MUTYH-Associated Polyposis</dc:title>
			<dc:creator>Julia Guarrera</dc:creator>
			<dc:creator>James C. Prezzano</dc:creator>
			<dc:creator>Kathleen A. Mannava</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010011</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-03-04</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-03-04</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>124</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010011</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/10">

	<title>Dermatopathology, Vol. 11, Pages 112-123: Kinase Fusions in Spitz Melanocytic Tumors: The Past, the Present, and the Future</title>
	<link>https://www.mdpi.com/2296-3529/11/1/10</link>
	<description>In recent years, particular interest has developed in molecular biology applied to the field of dermatopathology, with a focus on nevi of the Spitz spectrum. From 2014 onwards, an increasing number of papers have been published to classify, stratify, and correctly frame molecular alterations, including kinase fusions. In this paper, we try to synthesize the knowledge gained in this area so far. In December 2023, we searched Medline and Scopus for case reports and case series, narrative and systematic reviews, meta-analyses, observational studies&amp;amp;mdash;either longitudinal or historical, case series, and case reports published in English in the last 15 years using the keywords spitzoid neoplasms, kinase fusions, ALK, ROS1, NTRK (1-2-3), MET, RET, MAP3K8, and RAF1. ALK-rearranged Spitz tumors and ROS-1-rearranged tumors are among the most studied and characterized entities in the literature, in an attempt (although not always successful) to correlate histopathological features with the probable molecular driver alteration. NTRK-, RET-, and MET-rearranged Spitz tumors present another studied and characterized entity, with several rearrangements described but as of yet incomplete information about their prognostic significance. Furthermore, although rarer, rearrangements of serine&amp;amp;ndash;threonine kinases such as BRAF, RAF1, and MAP3K8 have also been described, but more cases with more detailed information about possible histopathological alterations, mechanisms of etiopathogenesis, and also prognosis are needed. The knowledge of molecular drivers is of great interest in the field of melanocytic diagnostics, and it is important to consider that in addition to immunohistochemistry, molecular techniques such as FISH, PCR, and/or NGS are essential to confirm and classify the different patterns of mutation. Future studies with large case series and molecular sequencing techniques are needed to allow for a more complete and comprehensive understanding of the role of fusion kinases in the spitzoid tumor family.</description>
	<pubDate>2024-02-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 112-123: Kinase Fusions in Spitz Melanocytic Tumors: The Past, the Present, and the Future</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/10">doi: 10.3390/dermatopathology11010010</a></p>
	<p>Authors:
		Maged Daruish
		Francesca Ambrogio
		Anna Colagrande
		Andrea Marzullo
		Rita Alaggio
		Irma Trilli
		Giuseppe Ingravallo
		Gerardo Cazzato
		</p>
	<p>In recent years, particular interest has developed in molecular biology applied to the field of dermatopathology, with a focus on nevi of the Spitz spectrum. From 2014 onwards, an increasing number of papers have been published to classify, stratify, and correctly frame molecular alterations, including kinase fusions. In this paper, we try to synthesize the knowledge gained in this area so far. In December 2023, we searched Medline and Scopus for case reports and case series, narrative and systematic reviews, meta-analyses, observational studies&amp;amp;mdash;either longitudinal or historical, case series, and case reports published in English in the last 15 years using the keywords spitzoid neoplasms, kinase fusions, ALK, ROS1, NTRK (1-2-3), MET, RET, MAP3K8, and RAF1. ALK-rearranged Spitz tumors and ROS-1-rearranged tumors are among the most studied and characterized entities in the literature, in an attempt (although not always successful) to correlate histopathological features with the probable molecular driver alteration. NTRK-, RET-, and MET-rearranged Spitz tumors present another studied and characterized entity, with several rearrangements described but as of yet incomplete information about their prognostic significance. Furthermore, although rarer, rearrangements of serine&amp;amp;ndash;threonine kinases such as BRAF, RAF1, and MAP3K8 have also been described, but more cases with more detailed information about possible histopathological alterations, mechanisms of etiopathogenesis, and also prognosis are needed. The knowledge of molecular drivers is of great interest in the field of melanocytic diagnostics, and it is important to consider that in addition to immunohistochemistry, molecular techniques such as FISH, PCR, and/or NGS are essential to confirm and classify the different patterns of mutation. Future studies with large case series and molecular sequencing techniques are needed to allow for a more complete and comprehensive understanding of the role of fusion kinases in the spitzoid tumor family.</p>
	]]></content:encoded>

	<dc:title>Kinase Fusions in Spitz Melanocytic Tumors: The Past, the Present, and the Future</dc:title>
			<dc:creator>Maged Daruish</dc:creator>
			<dc:creator>Francesca Ambrogio</dc:creator>
			<dc:creator>Anna Colagrande</dc:creator>
			<dc:creator>Andrea Marzullo</dc:creator>
			<dc:creator>Rita Alaggio</dc:creator>
			<dc:creator>Irma Trilli</dc:creator>
			<dc:creator>Giuseppe Ingravallo</dc:creator>
			<dc:creator>Gerardo Cazzato</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010010</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-02-14</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-02-14</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>112</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010010</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/9">

	<title>Dermatopathology, Vol. 11, Pages 101-111: Skin and Syntax: Large Language Models in Dermatopathology</title>
	<link>https://www.mdpi.com/2296-3529/11/1/9</link>
	<description>This literature review introduces the integration of Large Language Models (LLMs) in the field of dermatopathology, outlining their potential benefits, challenges, and prospects. It discusses the changing landscape of dermatopathology with the emergence of LLMs. The potential advantages of LLMs include a streamlined generation of pathology reports, the ability to learn and provide up-to-date information, and simplified patient education. Existing instances of LLMs encompass diagnostic support, research acceleration, and trainee education. Challenges involve biases, data privacy and quality, and establishing a balance between AI and dermatopathological expertise. Prospects include the integration of LLMs with other AI technologies to improve diagnostics and the improvement of multimodal LLMs that can handle both text and image input. Our implementation guidelines highlight the importance of model transparency and interpretability, data quality, and continuous oversight. The transformative potential of LLMs in dermatopathology is underscored, with an emphasis on a dynamic collaboration between artificial intelligence (AI) experts (technical specialists) and dermatopathologists (clinicians) for improved patient outcomes.</description>
	<pubDate>2024-02-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 101-111: Skin and Syntax: Large Language Models in Dermatopathology</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/9">doi: 10.3390/dermatopathology11010009</a></p>
	<p>Authors:
		Asghar Shah
		Samer Wahood
		Dorra Guermazi
		Candice E. Brem
		Elie Saliba
		</p>
	<p>This literature review introduces the integration of Large Language Models (LLMs) in the field of dermatopathology, outlining their potential benefits, challenges, and prospects. It discusses the changing landscape of dermatopathology with the emergence of LLMs. The potential advantages of LLMs include a streamlined generation of pathology reports, the ability to learn and provide up-to-date information, and simplified patient education. Existing instances of LLMs encompass diagnostic support, research acceleration, and trainee education. Challenges involve biases, data privacy and quality, and establishing a balance between AI and dermatopathological expertise. Prospects include the integration of LLMs with other AI technologies to improve diagnostics and the improvement of multimodal LLMs that can handle both text and image input. Our implementation guidelines highlight the importance of model transparency and interpretability, data quality, and continuous oversight. The transformative potential of LLMs in dermatopathology is underscored, with an emphasis on a dynamic collaboration between artificial intelligence (AI) experts (technical specialists) and dermatopathologists (clinicians) for improved patient outcomes.</p>
	]]></content:encoded>

	<dc:title>Skin and Syntax: Large Language Models in Dermatopathology</dc:title>
			<dc:creator>Asghar Shah</dc:creator>
			<dc:creator>Samer Wahood</dc:creator>
			<dc:creator>Dorra Guermazi</dc:creator>
			<dc:creator>Candice E. Brem</dc:creator>
			<dc:creator>Elie Saliba</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010009</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-02-14</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-02-14</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>101</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010009</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/8">

	<title>Dermatopathology, Vol. 11, Pages 79-100: Galli&amp;ndash;Galli Disease: A Comprehensive Literature Review</title>
	<link>https://www.mdpi.com/2296-3529/11/1/8</link>
	<description>Galli&amp;amp;ndash;Galli disease (GGD) is a rare genodermatosis that exhibits autosomal dominant inheritance with variable penetrance. GGD typically manifests with erythematous macules, papules, and reticulate hyperpigmentation in flexural areas. A distinct atypical variant exists, which features brown macules predominantly on the trunk, lower limbs, and extremities, with a notable absence of the hallmark reticulated hyperpigmentation in flexural areas. This review includes a detailed literature search and examines cases since GGD&amp;amp;rsquo;s first description in 1982. It aims to synthesize the current knowledge on GGD, covering its etiology, clinical presentation, histopathology, diagnosis, and treatment. A significant aspect of this review is the exploration of the genetic, histopathological, and clinical parallels between GGD and Dowling-Degos disease (DDD), which is another rare autosomal dominant genodermatosis, particularly focusing on their shared mutations in the KRT5 and POGLUT1 genes. This supports the hypothesis that GGD and DDD may be different phenotypic expressions of the same pathological condition, although they have traditionally been recognized as separate entities, with suprabasal acantholysis being a distinctive feature of GGD. Lastly, this review discusses the existing treatment approaches, underscoring the absence of established guidelines and the limited effectiveness of various treatments.</description>
	<pubDate>2024-02-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 79-100: Galli&amp;ndash;Galli Disease: A Comprehensive Literature Review</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/8">doi: 10.3390/dermatopathology11010008</a></p>
	<p>Authors:
		Andrea Michelerio
		Antonio Greco
		Dario Tomasini
		Carlo Tomasini
		</p>
	<p>Galli&amp;amp;ndash;Galli disease (GGD) is a rare genodermatosis that exhibits autosomal dominant inheritance with variable penetrance. GGD typically manifests with erythematous macules, papules, and reticulate hyperpigmentation in flexural areas. A distinct atypical variant exists, which features brown macules predominantly on the trunk, lower limbs, and extremities, with a notable absence of the hallmark reticulated hyperpigmentation in flexural areas. This review includes a detailed literature search and examines cases since GGD&amp;amp;rsquo;s first description in 1982. It aims to synthesize the current knowledge on GGD, covering its etiology, clinical presentation, histopathology, diagnosis, and treatment. A significant aspect of this review is the exploration of the genetic, histopathological, and clinical parallels between GGD and Dowling-Degos disease (DDD), which is another rare autosomal dominant genodermatosis, particularly focusing on their shared mutations in the KRT5 and POGLUT1 genes. This supports the hypothesis that GGD and DDD may be different phenotypic expressions of the same pathological condition, although they have traditionally been recognized as separate entities, with suprabasal acantholysis being a distinctive feature of GGD. Lastly, this review discusses the existing treatment approaches, underscoring the absence of established guidelines and the limited effectiveness of various treatments.</p>
	]]></content:encoded>

	<dc:title>Galli&amp;amp;ndash;Galli Disease: A Comprehensive Literature Review</dc:title>
			<dc:creator>Andrea Michelerio</dc:creator>
			<dc:creator>Antonio Greco</dc:creator>
			<dc:creator>Dario Tomasini</dc:creator>
			<dc:creator>Carlo Tomasini</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010008</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-02-07</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-02-07</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>79</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010008</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/7">

	<title>Dermatopathology, Vol. 11, Pages 62-78: The Histopathology of Leg Ulcers</title>
	<link>https://www.mdpi.com/2296-3529/11/1/7</link>
	<description>Ulcerations of the lower extremities are a frequently encountered problem in clinical practice and are of significant interest in public health due to the high prevalence of underlying pathologies, including chronic venous disease, diabetes and peripheral arterial occlusive disease. However, leg ulcers can also present as signs and symptoms of various rare diseases and even as an adverse reaction to drugs. In such cases, correct diagnosis ultimately relies on histopathological examination. Apart from the macroscopic presentation, patient history and anatomic location, which are sometimes indicative, most ulcers have very distinct histopathological features. These features are found in different layers of the skin or even associated vessels. In this narrative review, we discuss and highlight the histopathological differences of several types of leg ulcers that can contribute to efficient and accurate diagnosis.</description>
	<pubDate>2024-01-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 62-78: The Histopathology of Leg Ulcers</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/7">doi: 10.3390/dermatopathology11010007</a></p>
	<p>Authors:
		Amun Georg Hofmann
		Julia Deinsberger
		André Oszwald
		Benedikt Weber
		</p>
	<p>Ulcerations of the lower extremities are a frequently encountered problem in clinical practice and are of significant interest in public health due to the high prevalence of underlying pathologies, including chronic venous disease, diabetes and peripheral arterial occlusive disease. However, leg ulcers can also present as signs and symptoms of various rare diseases and even as an adverse reaction to drugs. In such cases, correct diagnosis ultimately relies on histopathological examination. Apart from the macroscopic presentation, patient history and anatomic location, which are sometimes indicative, most ulcers have very distinct histopathological features. These features are found in different layers of the skin or even associated vessels. In this narrative review, we discuss and highlight the histopathological differences of several types of leg ulcers that can contribute to efficient and accurate diagnosis.</p>
	]]></content:encoded>

	<dc:title>The Histopathology of Leg Ulcers</dc:title>
			<dc:creator>Amun Georg Hofmann</dc:creator>
			<dc:creator>Julia Deinsberger</dc:creator>
			<dc:creator>André Oszwald</dc:creator>
			<dc:creator>Benedikt Weber</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010007</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-01-29</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-01-29</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>62</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010007</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/6">

	<title>Dermatopathology, Vol. 11, Pages 52-61: Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site</title>
	<link>https://www.mdpi.com/2296-3529/11/1/6</link>
	<description>Direct immunofluorescence is a vital diagnostic test for assessing vesiculobullous disorders, vasculitides, and connective tissue diseases. It is a robust and valuable technique that offers essential diagnostic information for many critical dermatoses. Dermatopathologists depend heavily on the data obtained from direct immunofluorescence evaluation to confirm final diagnoses. Selecting the most appropriate biopsy site is necessary for maximizing diagnostic accuracy, and the best site may vary depending on the clinical differential diagnosis. Inaccurate biopsy site selection can significantly impact the accuracy of the results. To optimize the use of direct immunofluorescence studies, this review provides helpful guidelines and some practical tips for selecting the best biopsy site.</description>
	<pubDate>2024-01-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 52-61: Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/6">doi: 10.3390/dermatopathology11010006</a></p>
	<p>Authors:
		Muhammad N. Mahmood
		</p>
	<p>Direct immunofluorescence is a vital diagnostic test for assessing vesiculobullous disorders, vasculitides, and connective tissue diseases. It is a robust and valuable technique that offers essential diagnostic information for many critical dermatoses. Dermatopathologists depend heavily on the data obtained from direct immunofluorescence evaluation to confirm final diagnoses. Selecting the most appropriate biopsy site is necessary for maximizing diagnostic accuracy, and the best site may vary depending on the clinical differential diagnosis. Inaccurate biopsy site selection can significantly impact the accuracy of the results. To optimize the use of direct immunofluorescence studies, this review provides helpful guidelines and some practical tips for selecting the best biopsy site.</p>
	]]></content:encoded>

	<dc:title>Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site</dc:title>
			<dc:creator>Muhammad N. Mahmood</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010006</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-01-19</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-01-19</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>52</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010006</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/5">

	<title>Dermatopathology, Vol. 11, Pages 26-51: Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature</title>
	<link>https://www.mdpi.com/2296-3529/11/1/5</link>
	<description>Over the past decade, molecular and genomic discoveries have experienced unprecedented growth, fundamentally reshaping our comprehension of melanocytic tumors. This review comprises three main sections. The first part gives an overview of the current genomic landscape of cutaneous melanocytic tumors. The second part provides an update on the associated molecular tests and immunohistochemical stains that are helpful for diagnostic purposes. The third section briefly outlines the diverse molecular pathways now utilized for the classification of cutaneous melanomas. The primary goal of this review is to provide a succinct overview of the molecular pathways involved in melanocytic tumors and demonstrate their practical integration into the realm of diagnostic aids. As the molecular and genomic knowledge base continues to expand, this review hopes to serve as a valuable resource for healthcare professionals, offering insight into the evolving molecular landscape of cutaneous melanocytic tumors and its implications for patient care.</description>
	<pubDate>2024-01-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 26-51: Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/5">doi: 10.3390/dermatopathology11010005</a></p>
	<p>Authors:
		Chelsea Huang
		Tiffany Wing-See Lau
		Bruce R. Smoller
		</p>
	<p>Over the past decade, molecular and genomic discoveries have experienced unprecedented growth, fundamentally reshaping our comprehension of melanocytic tumors. This review comprises three main sections. The first part gives an overview of the current genomic landscape of cutaneous melanocytic tumors. The second part provides an update on the associated molecular tests and immunohistochemical stains that are helpful for diagnostic purposes. The third section briefly outlines the diverse molecular pathways now utilized for the classification of cutaneous melanomas. The primary goal of this review is to provide a succinct overview of the molecular pathways involved in melanocytic tumors and demonstrate their practical integration into the realm of diagnostic aids. As the molecular and genomic knowledge base continues to expand, this review hopes to serve as a valuable resource for healthcare professionals, offering insight into the evolving molecular landscape of cutaneous melanocytic tumors and its implications for patient care.</p>
	]]></content:encoded>

	<dc:title>Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature</dc:title>
			<dc:creator>Chelsea Huang</dc:creator>
			<dc:creator>Tiffany Wing-See Lau</dc:creator>
			<dc:creator>Bruce R. Smoller</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010005</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2024-01-18</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2024-01-18</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>26</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010005</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/4">

	<title>Dermatopathology, Vol. 11, Pages 19-25: Giant Folliculosebaceous Cystic Hamartoma of the Face</title>
	<link>https://www.mdpi.com/2296-3529/11/1/4</link>
	<description>Folliculosebaceous cystic hamartoma (FSCH) is a rare and benign form of cutaneous hamartomas. These skin lesions often lead to clinical and histopathological misdiagnosis due to their similarities to cutaneous lesions with overproduction of clustered sebaceous glands. Clinically, the lesions often present as solitary, skin-colored, pedunculated warts to cauliflower-like, exophytic papules and nodules, usually with a diameter ranging 0.5&amp;amp;ndash;1.5 cm that rarely exceed 2 cm in size. Only a small number of giant variants are reported in the literature with a diameter in the range of 5&amp;amp;ndash;23 cm. The vast majority of the lesions appear in the central face and show a striking predilection for the nose, ears, and scalp, but also emerge on the nipples, extremities, and genitals. Histologically, the epithelial components of folliculosebaceous cystic hamartoma comprise dilated infundibular cystic proliferation with surrounding mesenchymal components, which commonly include fibroplasia and vascular and adipose tissue proliferation. These histological characteristics were coined by Kimura and colleagues (1991). To the best of our knowledge, our case represents the biggest variant of giant folliculosebaceous cystic hamartoma.</description>
	<pubDate>2023-12-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 19-25: Giant Folliculosebaceous Cystic Hamartoma of the Face</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/4">doi: 10.3390/dermatopathology11010004</a></p>
	<p>Authors:
		Ramona Tasar
		Melanie Peckruhn
		Jörg Tittelbach
		</p>
	<p>Folliculosebaceous cystic hamartoma (FSCH) is a rare and benign form of cutaneous hamartomas. These skin lesions often lead to clinical and histopathological misdiagnosis due to their similarities to cutaneous lesions with overproduction of clustered sebaceous glands. Clinically, the lesions often present as solitary, skin-colored, pedunculated warts to cauliflower-like, exophytic papules and nodules, usually with a diameter ranging 0.5&amp;amp;ndash;1.5 cm that rarely exceed 2 cm in size. Only a small number of giant variants are reported in the literature with a diameter in the range of 5&amp;amp;ndash;23 cm. The vast majority of the lesions appear in the central face and show a striking predilection for the nose, ears, and scalp, but also emerge on the nipples, extremities, and genitals. Histologically, the epithelial components of folliculosebaceous cystic hamartoma comprise dilated infundibular cystic proliferation with surrounding mesenchymal components, which commonly include fibroplasia and vascular and adipose tissue proliferation. These histological characteristics were coined by Kimura and colleagues (1991). To the best of our knowledge, our case represents the biggest variant of giant folliculosebaceous cystic hamartoma.</p>
	]]></content:encoded>

	<dc:title>Giant Folliculosebaceous Cystic Hamartoma of the Face</dc:title>
			<dc:creator>Ramona Tasar</dc:creator>
			<dc:creator>Melanie Peckruhn</dc:creator>
			<dc:creator>Jörg Tittelbach</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010004</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2023-12-31</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2023-12-31</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>19</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010004</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/3">

	<title>Dermatopathology, Vol. 11, Pages 13-18: A Case of Pleomorphic Dermal Sarcoma: Giant Exophytic Tumor of the Medial Canthus</title>
	<link>https://www.mdpi.com/2296-3529/11/1/3</link>
	<description>We present the case of a 99-year-old Caucasian female who was referred for treatment of a painless, 8.0 cm &amp;amp;times; 7.8 cm exophytic, pedunculated, ulcerated tumor of the left medial canthus. Pathology showed spindled, oval, and polygonal cells with pleomorphic nuclei. Many multinuclear giant cells and mitotic figures were also noted. The tumor was highlighted with CD10, showed focal positivity with actin, desmin, and CD68, and had increased Ki67 immunohistochemical staining. The tumor was negative for pancytokeratin, CK5/6, p63, MART-1/MelanA, S100, Sox10, p40, CD34, and CD23. Based on clinicopathologic correlation, the diagnosis of pleomorphic dermal sarcoma (PDS) was made. Pleomorphic dermal sarcoma (PDS) refers to a deep, histologically high-grade tumor that often resembles other tumors clinically and histologically. As PDS is frequently aggressive and related to adverse outcomes, it is important to recognize its distinguishing features in comparison to other similar entities, including atypical fibroxanthoma (AFX) and pleomorphic leiomyosarcoma (PLMS). To our knowledge, there is only one other reported case in the literature of PDS occurring on the eye. By reviewing and understanding characteristic etiologies, locations of presentation, histopathological features, and management techniques, pathologists can make a more accurate diagnosis and dermatologists can provide more effective patient care in a timely manner.</description>
	<pubDate>2023-12-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 13-18: A Case of Pleomorphic Dermal Sarcoma: Giant Exophytic Tumor of the Medial Canthus</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/3">doi: 10.3390/dermatopathology11010003</a></p>
	<p>Authors:
		Rylee Moody
		Kavita Darji
		Tricia A. Missall
		Peter Chow
		Ramona Behshad
		</p>
	<p>We present the case of a 99-year-old Caucasian female who was referred for treatment of a painless, 8.0 cm &amp;amp;times; 7.8 cm exophytic, pedunculated, ulcerated tumor of the left medial canthus. Pathology showed spindled, oval, and polygonal cells with pleomorphic nuclei. Many multinuclear giant cells and mitotic figures were also noted. The tumor was highlighted with CD10, showed focal positivity with actin, desmin, and CD68, and had increased Ki67 immunohistochemical staining. The tumor was negative for pancytokeratin, CK5/6, p63, MART-1/MelanA, S100, Sox10, p40, CD34, and CD23. Based on clinicopathologic correlation, the diagnosis of pleomorphic dermal sarcoma (PDS) was made. Pleomorphic dermal sarcoma (PDS) refers to a deep, histologically high-grade tumor that often resembles other tumors clinically and histologically. As PDS is frequently aggressive and related to adverse outcomes, it is important to recognize its distinguishing features in comparison to other similar entities, including atypical fibroxanthoma (AFX) and pleomorphic leiomyosarcoma (PLMS). To our knowledge, there is only one other reported case in the literature of PDS occurring on the eye. By reviewing and understanding characteristic etiologies, locations of presentation, histopathological features, and management techniques, pathologists can make a more accurate diagnosis and dermatologists can provide more effective patient care in a timely manner.</p>
	]]></content:encoded>

	<dc:title>A Case of Pleomorphic Dermal Sarcoma: Giant Exophytic Tumor of the Medial Canthus</dc:title>
			<dc:creator>Rylee Moody</dc:creator>
			<dc:creator>Kavita Darji</dc:creator>
			<dc:creator>Tricia A. Missall</dc:creator>
			<dc:creator>Peter Chow</dc:creator>
			<dc:creator>Ramona Behshad</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010003</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2023-12-29</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2023-12-29</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010003</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2296-3529/11/1/2">

	<title>Dermatopathology, Vol. 11, Pages 8-12: Perforating Fibrous Histiocytoma Mimicking Keratoacanthoma: A Case Report</title>
	<link>https://www.mdpi.com/2296-3529/11/1/2</link>
	<description>A 31-year-old male presented with a firm, well-demarcated, erythematous, crateriform, and ulcerated nodule in the left lumbar region, which persisted for 3 months. Clinically, a keratoacanthoma was suspected. The histological analysis was consistent with perforating fibrous histiocytoma, a rare histopathologic variant of fibrous histiocytoma. To our knowledge, this is the third case reported in the literature.</description>
	<pubDate>2023-12-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Dermatopathology, Vol. 11, Pages 8-12: Perforating Fibrous Histiocytoma Mimicking Keratoacanthoma: A Case Report</b></p>
	<p>Dermatopathology <a href="https://www.mdpi.com/2296-3529/11/1/2">doi: 10.3390/dermatopathology11010002</a></p>
	<p>Authors:
		Alina Lungu
		Aurélie Hsieh
		Gürkan Kaya
		Sébastien Menzinger
		</p>
	<p>A 31-year-old male presented with a firm, well-demarcated, erythematous, crateriform, and ulcerated nodule in the left lumbar region, which persisted for 3 months. Clinically, a keratoacanthoma was suspected. The histological analysis was consistent with perforating fibrous histiocytoma, a rare histopathologic variant of fibrous histiocytoma. To our knowledge, this is the third case reported in the literature.</p>
	]]></content:encoded>

	<dc:title>Perforating Fibrous Histiocytoma Mimicking Keratoacanthoma: A Case Report</dc:title>
			<dc:creator>Alina Lungu</dc:creator>
			<dc:creator>Aurélie Hsieh</dc:creator>
			<dc:creator>Gürkan Kaya</dc:creator>
			<dc:creator>Sébastien Menzinger</dc:creator>
		<dc:identifier>doi: 10.3390/dermatopathology11010002</dc:identifier>
	<dc:source>Dermatopathology</dc:source>
	<dc:date>2023-12-25</dc:date>

	<prism:publicationName>Dermatopathology</prism:publicationName>
	<prism:publicationDate>2023-12-25</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/dermatopathology11010002</prism:doi>
	<prism:url>https://www.mdpi.com/2296-3529/11/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
    
<cc:License rdf:about="https://creativecommons.org/licenses/by/4.0/">
	<cc:permits rdf:resource="https://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
